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 I 
ABSTRACT 
GATA proteins are a family of transcription factors that play a crucial role in the 
development of several organs and in the maintenance of their homeostasis. 
Specifically, Gata4 and Gata6 are known to be necessary for murine pancreas 
development and, recently, Gata6 has been described to be an important 
regulator of pancreatic acinar cell differentiation. In addition, a number of 
studies have attributed Gata6 a tumour suppressor role in pancreatic 
carcinogenesis, both in mouse and human. Yet, the role of Gata4 in pancreas 
homeostasis and tumour progression has not been investigated. 
I have characterized Gata4 function in the murine pancreas by specifically 
deleting the gene during embryonic development and have found that, unlike 
Gata6, Gata4 is not required to maintain acinar homeostasis in the adult.  
The study of Gata4 function in tumour initiation and progression by deleting it in 
a mutant Kras-induced model of pancreatic carcinogenesis (Kras*;Gata4P-/- mice) 
has revealed that Gata4-null mice develop pancreatic cancer (PDAC) in the 
absence of PanINs and acino-ductal metaplasia (ADM), which are believed to be 
the most common PDAC precursors. Lineage tracing experiments have shown 
that tumours can arise from adult pancreatic acinar cells. In addition, I 
demonstrate that Gata4 is necessary for PanIN development, as intrapancreatic 
delivery of IL17 in Kras*;Gata4P-/- mice, which is known to promote PanIN 
formation in Kras*;Gata4WT mice, results in the development of ductal lesions but 
not PanIN. I have modelled the lack of ADM/PanIN in vitro by establishing 3D 
cultures of acinar cells: treatment with EGF induces cyst formation -a surrogate 
for ADM- in Gata4WT acini, but fails to completely induce such phenomenon in 
Gata4-/- acini.  IL17 treatment induces cysts both in Gata4WT and Gata4-/- acinar 
cells.  
I show that Gata4 is required for the inflammatory response elicited by Kras* in 
the pancreas. Gata4 regulates expression of secreted factors –among them 
Reg3β- that activate macrophages to further enhance an inflammatory response. 
 I also show that Gata4 is a bona fide tumour suppressor as the combined 
deletion of Gata4 and Trp53 in the mutant Kras-driven model results in 
acceleration of tumour progression and reduced survival.  
Finally, I show that GATA4 expression is lost in a subset of pancreatic cancers in 
humans and that the concomitant loss of GATA4 and GATA6 is associated with 
very poor prognosis.  
These studies support the conclusion that, in the pancreas, GATA4 plays a 
distinct role, different from that of GATA6. 
 III 
RESUMEN 
Las proteínas GATA forman una familia de factores de transcripción que juegan 
un papel crucial en el desarrollo de una variedad de órganos y el mantenimiento 
de su homeostasis. En concreto, Gata4 y Gata6 son necesarios para el desarrollo 
del páncreas de ratón y, recientemente, Gata6 se ha descrito como un regulador 
importante de la diferenciación de las células acinares pancreáticas. Además, 
varios estudios han atribuido a Gata6 un rol de supresor tumoral en la 
carcinogénesis pancreática en ratón y humano.  Aun así, el rol de Gata4 en la 
homeostasis pancreática y la progresión tumoral no ha sido investigado. 
He caracterizado el rol de Gata4 en el páncreas de ratón mediante su deleción 
durante el desarrollo pancreático y he observado que Gata4, contrariamente a 
Gata6, no es necesario para mantener la homeostasis acinar en el adulto.  
El estudio de Gata4 en la iniciación y progresión tumoral mediante su deleción 
en un modelo de carcinogénesis inducida por Kras mutante (ratones Kras*; 
Gata4P-/-) ha desvelado que estos ratones desarrollan cáncer de páncreas (PDAC) 
en ausencia de PanINs y metaplasia acino-ductal (ADM), considerados los 
precursores más comunes del PDAC. Experimentos de rastreo de linaje muestran 
que los tumores en los ratones Kras*;Gata4P-/- pueden formarse a partir de 
células acinares adultas. Además, he demostrado que Gata4 es necesario para el 
desarrollo de PanINs, ya que la administración intrapancreática en ratones 
Kras*;Gata4P-/- de IL17, un potente inductor de PanINs en ratones Kras*;Gata4WT, 
resulta en el desarrollo de lesiones ductales, pero no de PanINs. He modelado la 
ausencia de ADM/PanIN in vitro mediante cultivos 3D de células acinares: EGF 
induce formación de estructuras quísticas -equivalentes a ADM- en acinos 
Gata4WT, pero no logra hacerlo de igual forma en acinos Gata4-/-. En cambio, IL17 
induce estructuras quísticas en ambos genotipos. 
He mostrado que Gata4 es necesario para la respuesta inflamatoria provocada 
por Kras* en el páncreas: Gata4 regula la expresión de factores secretados –como 
Reg3β- que activan macrófagos para inducir una mayor respuesta inflamatoria.  
También muestro que Gata4 es un gen supresor tumoral ya que su deleción junto 
con la de Trp53 en el modelo de Kras* resulta en una aceleración de la 
progresión tumoral y una menor supervivencia.  
Finalmente, muestro que la expresión de GATA4 se pierde en un subtipo de 
cáncer de páncreas en humanos y que la pérdida conjunta de GATA4 y GATA6 se 
asocia con un peor pronóstico.  
En conjunto, estos estudios respaldan la conclusión de que, en el páncreas, 
GATA4 juega un papel distinto al de GATA6.  
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1. THE PANCREAS 
1.1. General considerations and anatomy of the pancreas 
The name pancreas derives from the Greek roots ‘pan’ meaning ‘all’ and ‘creas’ 
meaning ‘flesh’ due to its fleshy consistency (Slack, 1982). The mature 
mammalian pancreas is a compound exocrine-endocrine gland that regulates 
essential physiologic functions such as food digestion and glucose homeostasis, 
respectively.  
In humans, the pancreas forms a well-defined organ of 70-150 grams measuring 
15-25cm in length. The terms head, neck, body and tail are used to designate 
regions of the organ from proximal to distal. In contrast, the shape of the 
pancreas in rodents is less well defined. The organ is localized in the upper 
region of the abdomen, between the spleen, stomach and small intestine, and it is 
connected to the duodenum by the ampulla of Vater, where the main pancreatic 
duct joins with the common bile duct (Slack, 1982) (Fig. I1A). 
1.2. Histology and physiology of the pancreas 
 1.2.1 The exocrine pancreas 
The exocrine pancreas constitutes more than 90% of the whole tissue and is 
composed of three distinguishable epithelial cell types: acinar, ductal, and 
centroacinar cells (Fig. I1B). 
Acinar cells are organized into functional secretory units called acini, which are 
in charge of producing hydrolytic digestive enzymes at a large scale. Acinar cells 
have pyramidal shape with basal nuclei, regular arrays of rough endoplasmic 
reticulum (ER), a prominent Golgi complex and numerous secretory (zymogen) 
granules, containing the digestive enzymes. There are at least 22 of these, 
including proteases, amylases, lipases and nucleases. Most of them are secreted 
as inactive precursors and become activated after they enter the duodenum 
(Slack, 1982). The biology of acinar cells will be further detailed in a subsequent 
chapter. 
Ductal cells form the epithelial lining of the branched tubes that deliver the 
enzymes produced by acinar cells into the duodenum. Ductal cells secrete 
mucins and fluid that flushes the acinar secretions into the intestine, as well as 
bicarbonate to neutralize stomach acidity. The intercalated ducts, which drain 
the acini, are composed of a simple epithelium of ductal cells and are surrounded 
by little connective tissue. As ducts become larger the epithelium becomes either 
cuboidal or columnar and, in the largest branches of the network, goblet cells are 
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intermingled with ductal cells, forming about 2% of its structure. The 
intercalated ducts converge to form interlobular ducts that connect the different 
lobes of the pancreas, merging into the main pancreatic duct, which is formed by 
a columnar epithelium, surrounded by abundant connective tissue (Grapin-
botton, 2005; Slack, 1982). 
 
Figure I1. Anatomy of the pancreas. (A) Gross anatomy of the pancreas (left). H-E staining of 
the pancreas showing the exocrine (Duct and Acini) and the endocrine compartments (Islet of 
Langherhans). (B) Schematic representation of the exocrine tissue showing organization of 
acinar, ductal and centroacinar cells. (C) Schematic representation of the endocrine tissue 
showing an Islet of Langherhans embedded in exocrine tissue. Adapted from Bardeesy & Depinho, 
2002. 
Centroacinar cells (CACs) are located at the junction of acini and the terminal 
ductal epithelium, have a low cuboidal shape and are rich in mitochondria. 
(Slack, 1982). This cell type is poorly characterized and it is uncertain whether 
centroacinar and terminal duct cells represent two different cell types. They 
have been proposed as possible multilineage pancreatic progenitors as they 
rapidly proliferate upon damaging processes such as partial pancreatectomy 
(Hayashi et al., 2003); administration of streptozotocin (a chemical that is 
particularly toxic to the insulin-producing beta cells of the pancreas) (Nagasao, et 
al., 2003); or  administration of caerulein, which induces pancreatic damage at 
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high doses (Gasslandek, et al., 1992). In addition, CACs express high levels of 
Aldh1, which is linked to multipotency in other systems. In the pancreas 
Aldh1high cells have increased progenitor properties, being able to form self-
renewing "pancreatospheres" in suspension and displaying spontaneous 
endocrine and exocrine differentiation capacity (Rovira et al., 2010). 
 1.2.1. The endocrine pancreas 
The endocrine pancreas is composed by compact structures called Islets of 
Langerhans that are embedded in the exocrine tissue. Islets comprise 1-2% of 
the pancreas and have a mean diameter of 130μm in humans (Rorsman & Braun, 
2013). In addition, isolated islet cells may be found dispersed in the acinar 
lobules or in association with ducts (MacDonald et al., 2010). Several hormone-
producing cell types populate the islet, including β-cells (which secrete insulin), 
α-cells (glucagon), δ-cells (somatostatin), ε-cells (ghrelin), and PP-cells 
(pancreatic polypeptide). Finely tuned regulation of hormone release is achieved 
by coordinated interactions between the islet cells and the vascular 
environment, establishing hormonal homeostasis that maintain appropriate 
glucose levels within tissues and blood (Puri & Hebrok, 2010).  
1.3. Development of the mouse pancreas 
  1.3.1. Morphogenesis 
The pancreas originates from the primitive gut tube, which derives from the 
definitive endoderm, and its development is divided in three major periods: a 
primary transition from embryonic day (E) 9.5 to E12.5; a secondary transition 
from E13 to birth; and the postnatal maturation period from birth to weaning 
(Fig. I2).  
During the primary transition, pancreas development begins with thickening of 
the endoderm and proliferation of early pancreatic progenitors that results in 
evagination of a dorsal and two smaller ventral pancreatic buds (Fig. I2-1). 
During bud evagination, transient epithelial stratification results in formation of 
microlumens, which subsequently coalesce and form continuous tubular 
structures (Fig. I2-2). Concomitantly, specification and patterning of early 
pancreatic progenitors results in formation of a bipotent stalk or “trunk” domain 
and multipotent “tip” domain. Cells residing at the "tip" domain are thought to 
include multipotent progenitor cells (MPCs) that will give rise to both endocrine 
and exocrine cells, whereas progeny of cells residing in the trunk will produce 
duct and endocrine cells (panel 3 of Fig. 1). (Benitez, et al., 2012). 
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The secondary transition represents a period of extensive epithelial expansion 
concomitant with differentiation of acinar, ductal and endocrine cells (Fig. I2-4). 
At E13, progenitors of the "tip" domain lose their multipotency and become 
preacinar cells, which begin to synthesize acinar digestive enzymes such as 
amylase, elastase, and trypsinogen. After, about E14.5, acinar cells are mainly 
generated by the duplication of existing acinar cells. Endocrine progenitor cells 
emerge from within the trunk epithelium and, following specification, they 
delaminate from the epithelium and coalesce to form islets. Acinar and endocrine 
cells go through a maturation process lasting into postnatal life (Benitez, et al., 
2012; Gittes et al., 2009; Pan & Wright, 2011). 
 
 Figure I2. Pancreas development. (1) Pancreatic bud formation and epithelial expansion. (2) 
Microlumen formation. (3) Tube formation and establishment of "tip" and "trunk" domains. (4) 
Pancreatic morphogenesis, branching, cell differentiation, and isletogenesis. Adapted from 
Benitez et al., 2012. 
  1.3.2. Master regulators of pancreas and acinar specification 
During pancreas morphogenesis, cell specification is driven by extrinsic signals 
from the surrounding mesenchyme and penetrating blood vessels that crosstalk 
with intrinsic regulation of differentiation conducted by pancreas-specific 
transcription programs (Magenheim et al., 2011; Puri & Hebrok, 2010). The main 
transcription factors involved in pancreas specification are the pancreas and 
duodenal homeobox gene-1 (Pdx1) and the pancreatic transcription factor-1 
(Ptf1a/p48) (Fig. I2-1). 
Pdx1 is a homeodomain transcription factor that is expressed in mouse 
prepancreatic endoderm at E8.5, before the formation of pancreatic buds. Since 
inactivation of Pdx1 results in complete arrest of pancreas formation, it is 
believed to initiate pancreatic development (Offield et al., 1996). In addition, 
lineage tracing experiments determined that Pdx1+ cells contribute to all 
pancreatic cell types in the mature tissue (Gu et al., 2002), supporting the notion 
that Pdx1-expressing cells are the early precursors of all pancreatic cell types. In 
the adult, Pdx1 is mainly expressed in β-cells and δ-cells, and its expression in 
the exocrine remains low. It is required for maintaining β-cell identity and 
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function, and its deletion in this cell type leads to diabetes (Ahlgren et al., 1998; 
Ohlsson et al., 1993). 
Ptf1a (or p48) is a pancreas and neural-specific class B bHLH transcription 
factor (Meredith et al., 2013). In the murine pancreas it is expressed in early 
pancreatic progenitors shortly after Pdx1 expression, around E9-9.5. Ptf1a is 
required for the evagination of the ventral buds and the growth of the dorsal 
bud, and it determines the pancreatic fate of Pdx1-expressing cells, as its deletion 
results in differentiation of progenitor cells towards an intestinal phenotype 
(Kawaguchi et al., 2002; Krapp et al., 1996, 1998).  
  1.3.3. Acinar differentiation and maturation 
During primary transition, MPCs of the "tip" domain express Ptf1a that, together 
with Tcf12 and Rbpj, form a trimeric complex (called PTF1-J) that is required for 
growth and morphogenesis of pancreatic epithelium. Indeed, PTF1-J complex 
plays such a critical role in pancreas organogenesis that inactivation of Ptf1a or 
blocking its interaction with Rbpj leads to pancreas agenesis (Masui, et al., 2007). 
PTF1-J complex directly activates expression of Ptf1a itself (Masui et al., 2007) 
and of some digestive enzymes such as Carboxypeptidase A1 (Cpa1), which is 
considered a marker of MPCs (Q. Zhou et al., 2007). At the same time, cells at the 
"trunk" domain express Nkx6.1 and Nkx6.2 that antagonize Ptf1a, thus inhibiting 
MPC phenotype and directing these cells into a bipotent endocrine-ductal fate 
(Schaffer et al., 2010). 
Acinar specification during the secondary transition implicates a replacement of 
Rbpj by Rbpjl in PTF1 complex (Beres et al., 2006) (FIg. I3). Rbpjl is first 
expressed shortly after MPCs start expressing high levels of Ptf1a (also required 
for acinar specification). Induction of Rbpjl transcription requires binding of the 
PTF1-J complex to its promoter (Masui et al., 2008) and, as Rbpjl accumulates 
during acinar cell maturation, it gradually replaces Rbpj in the complex (now 
termed PTF1-L).  
Expression of Rbpjl as well as Ptf1a is maintained in differentiated acinar cells as 
they are targets of PTF1-L complex (Masui et al., 2008). In addition, PTF1-L 
complex regulates expression of 27 out of 28 major acinar secretory proteins; 
enzymes necessary for mitochondrial carbon, nitrogen and energy metabolism; 
and eight components of the intracellular protein transport apparatus. 
Regulation of genes involved in such processes is in accordance with acinar 
function: enhanced mitochondrial metabolism is necessary for the great amount 
of energy required for massive synthesis of secretory proteins, packaging and 
regulated secretion; and the proteins for intracellular transport increase the 
efficiency of packaging the pancreatic enzymes (MacDonald et al., 2010; Masui et 
al., 2010, 2007).  
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Figure I3. The PTF1 complex. In multipotent pancreatic progenitors, the embryonic form of the 
PTF1 complex (PFT1-J) is constituted by Ptf1a, a ubiquitous bHLH cofactor (i.e. Tcf12) and Rbpj. 
During development, when acinar cell specification occurs, PTF1-J binds to Rbpjl promoter. 
During acinar cells maturation, Rbpjl starts to accumulate, replacing Rbpj in the adult form of 
PTF1 complex (PTF1-L). PTF1-L promotes complete acinar differentiation, enhancing the 
expression of acinar specific genes, such as the digestive enzymes Caboxypeptidase A1 (Cpa1), 
Amylase 2 (Amy2), Carboxyl Ester Lipase (Cel), and others, as well as the machinery necessary for 
high protein synthesis and secretory functions. Adapted from Masui et al, 2007.  
1.3.4. Maintenance of acinar differentiation in the adult murine 
pancreas 
In addition to the PTF1 complex, other important factors regulating pancreas 
development and maintenance of acinar identity include Nr5a2, Gata6, Mist1 and 
Hnf1a.  
Nr5a2 (or Lrh1) is a transcription factor of the orphan nuclear receptor family 
that maintains acinar differentiation, and its deletion leads to destabilisation of 
the mature acinar state, conversion of acinar cells to ductal-like cells, and loss of 
regenerative capacity following acute caerulein pancreatitis. (Flández et al., 
2014; Holmstrom et al., 2011; von Figura et al., 2014). 
Gata6 is a Zn finger transcription factor that is required for pancreas 
development (Carrasco et al., 2012; Decker, et al., 2006; Xuan et al., 2012). 
During post-natal maturation, Gata6 is necessary to complete acinar 
differentiation, to establish cell polarity and to maintain acinar cell identity in the 
adult. Gata6 regulates directly the promoter of genes coding for digestive 
enzymes and the transcription factors Rbpjl and Mist1. Pancreas-specific 
inactivation of Gata6 leads to massive loss of acinar cells and replacement by fat; 
increased acinar apoptosis and proliferation; and acinar-to-ductal metaplasia 
(ADM) (Martinelli et al., 2012). The role of Gata6 in pancreas development, 
homeostasis and carcinogenesis is further discussed in following chapters.  
Mist1/Bhlha15 is a bHLH transcription factor that functions as a homodimer 
and plays an important role in maintaining acinar differentiation (Pin et al., 
2001). Mist1 regulates apical-basal polarity, formation of gap junctions, proper 
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positioning of zymogen granules and their secretion; and its ablation leads to 
depletion of gap juntions, loss of polarity, dedifferentiation and ADM (Direnzo et 
al., 2012; Zhu et al., 2004). 
Hnf1a (or Tcf1) is a homeobox transcription factor whose deletion results in 
reduced expression of Ptf1a and digestive enzymes. Hnf1a-null acini show 
suboptimal secretory responses to cerulein. In silico and ChIP-PCR studies 
revealed that Hnf1a binds to, and regulates, the promoter of Nr5a2 (Molero et al., 
2012). 
1.4. Pancreatic acinar cell biology  
 1.4.1. Acinar cell function in food digestion 
Pancreatic acinar cells produce the majority of the digestive enzymes that are in 
charge of digesting food in the intestine for further absorption. Acinar cells have 
the highest rate of protein synthesis of all mammalian cell types in order to 
generate the different enzymes involved in the hydrolysis of proteins (trypsin, 
chymotrypsin, carboxypeptidase, gelatinase and elastase), lipids (lipases), 
polysaccharides (amylases), and nucleic acids (deoxyribonucleases and 
ribonucleases) (Case, 1978). This massive protein production is achieved due to 
a very high rate of transcription of genes coding for digestive enzymes, a very 
abundant rough ER and an efficient system for storage and secretion. 
Transcripts coding for digestive enzymes constitute around 80% of all mRNAs of 
acinar cells (MacDonald et al., 2010). Upon translation, immature proteins are 
modified in the lumen of the ER and in the Golgi complex, and finally, undergo 
concentration and packaging into highly specialized storage structures called 
zymogen granules (Farquhar & Palade, 1998). In addition to protein synthesis, 
the ER also plays an important role in zymogen granule secretion. Upon 
neurohumoral stimulation of acinar cells receptors, the Ca2+ ions stored in the ER 
flux into the cytosol, resulting in secretion of zymogen granules into the lumen of 
the ducts (Petersen & Tepikin, 2008). 
Among all digestive enzymes produced by acinar cells, proteases are synthesized 
as inactive pro-enzymes that are activated in the duodenum through a cascade of 
enzymatic reactions. First, in the duodenal lumen, enteropeptidase activates 
trypsinogen yielding trypsin, the active enzyme. Trypsin further catalyses the 
activation of other pro-enzymes (including remaining trypsinogen), including 
procarboxypeptidase (to carboxypeptidase), chymotrypsynogen (to 
chymotripsin), proelastase (to elastase), and others (Whitcomb & Lowe, 2007). 
Trypsin also undergoes self-hydrolysis providing a negative regulatory loop to 
the digestive process (Whitcomb et al., 1996). 
INTRODUCTION 
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 1.4.2. Acinar cell plasticity 
Adult pancreatic acinar cells display a wide plasticity and are able to give rise to 
other differentiated cell types, both pancreatic and non-pancreatic. 
The best studied process is the ability of acinar cells to transdifferentiate to 
ductal-like cells in a process known as acinar-to-ductal metaplasia (ADM) (Fig. 
I4), which was first observed in vitro (Hall et al., 1992; Vila, et al., 1994) and later 
shown in vivo to be a true transdifferentiation event through lineage tracing 
experiments (Means et al., 2005).  ADM takes place in the damaged pancreas and 
it plays a crucial role in tissue regeneration. The signalling pathways triggering 
ADM, the process itself, and its consequences will be detailed later in this 
chapter.   
Prior to the establishment of ductal structures during ADM, acinar cells undergo 
a process of dedifferentiation (Fig. I4), in which genes that are hallmark of 
complete differentiation are downregulated (i.e. Ptf1a, digestive enzymes). 
Acinar dedifferentiation occurs in response to pancreatic injury, upon loss of 
cell–cell and cell–matrix contacts, loss of polarity, Kras hyperactivity and 
increased inflammatory signalling. Under these circumstances dedifferentiated 
acinar cells transdifferentiate to a duct-like phenotype and complete the ADM 
process required for pancreatic regeneration (Storz, 2017). In addition, acinar 
cell dedifferentiation is also observed in human cases of pancreatitis and in 
mouse models of acute and chronic pancreatitis, as well as in murine acinar cells 
cultured in suspension (Pinho et al., 2011). 
 
 
Figure I4. Acinar-to-ductal metaplasia. Pancreatic injury, loss of cell–cell and cell–matrix 
contacts, loss of polarity, Kras hyperactivity and increased inflammatory signalling can drive 
acinar cells to undergo dedifferentiation (loosing expression of differentiation markers such as 
Ptf1a or digestive enzymes) and transdifferentiation to a duct-like phenotype (expressing Krt19, 
Sox9 and Hnf1b), which is needed for pancreatic regeneration. Adapted from Storz, 2017. 
 
Acinar cells also have the ability to differentiate to endocrine cells. This process 
has been described to happen in vitro (Baeyens et al., 2009) and, most 
importantly, in vivo generation of β-cells from acinar cells has been achieved in 
mice by re-expressing the developmental transcription factors Ngn3, Pdx1 and 
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Mafa (Zhou et al., 2008). Although the process in mice needs to be completely 
optimized (Akinci et al., 2012), there is evidence that also human acinar cells can 
convert to β-like cells (Lemper et al., 2014). Lately, it has also been demonstrated 
that acinar cells are able to acquire a phenotype similar to to α- and δ-cells (W. Li 
et al., 2014). 
Acinar cells can also transdifferentiate into hepatocytes, which share a common 
endodermal origin with pancreatic cells. It has been shown that foci of hepatic 
cells appear in the pancreas of rats exposed to a low-copper diet (Dabeva et al., 
1995) and in rats treated with ciprofibrate, a peroxisome proliferator (Reddy et 
al., 1984). Transdifferentiation into hepatocytes has been shown to happen in 
vitro when culturing exocrine cells in the presence of the synthetic glucocorticoid 
dexamethasone (Shen et al., 2000; Shen et al., 2003). 
Transdifferentiation of acinar cells into ductal, endocrine or hepatic cells are 
cases of epithelial-to-epithelial transition. However, acinar cells can also lose 
their epithelial characteristics and transdifferentiate into adipocytes, thus 
undergoing an epithelial-to-mesenchymal transition (EMT). This process has 
been reported to occur upon c-Myc inativation (Bonal et al., 2009) or, as already 
mentioned, upon Gata6 deletion in mouse pancreas (Martinelli et al., 2012). This 
event is relevant because it may be occurring in ageing and pancreatitis, 
conditions that are characterized by exocrine pancreas involution and 
replacement with adipose tissue (Bonal et al., 2009). 
   1.4.2.1. Acinar-to-ductal metaplasia (ADM) 
Metaplasia is a broad histological term that is defined by the conversion or 
replacement of one differentiated cell type with another (Slack & Tosh, 2001). In 
the pancreas, the most relevant metaplastic process is the conversion of acinar 
cells to ductal through loss of acinar genes (dedifferentiation) and induction of 
genes typically expressed by ductal cells, such as the intermediate filament Krt19 
(Bouwens, 1998) or the transcription factors Sox9 and Hnf1b (Reichert & Rustgi, 
2011) (Fig. I4). 
While in the normal pancreas the predominant cells are acinar, in the diseased 
pancreas acinar tissue is often replaced by metaplastic ductal lesions (MDL), 
which are the result of ADM. MDL can be observed in cases of pancreatitis as well 
as in pancreatic cancer (Strobel et al., 2007). Depending on the morphological 
features of MDL it is possible to distinguish two types of lesions: (I) tubular 
complexes (TC) and (II) mucinous metaplastic lesions, recently agreed to be 
termed Pancreatic Intraepithelial Neoplasia (PanIN), and considered a precursor 
of pancreatic cancer (Hruban et al., 2001). 
TC are defined as cylindrical tubes with an often wide lumen lined by a 
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monolayer of flattened duct-like cells (Lechene de la Porte et al., 1991; Willemer 
et al., 1989). In humans, TC have been observed in pancreatitis, both acute 
(Willemer & Adler, 1989) and chronic (Bockman et al., 1982). In rodents, TC 
have been also identified in models of pancreatitis (Lechene de la Porte et al., 
1991), in models of pancreatic cancer induced by carcinogens (Bockman et al., 
2003), upon 90% pancreatectomy in a model for pancreatic regeneration 
(Tokoro et al., 2003), and in genetically engineered mouse models (GEMMs) of 
pancreatic carcinogenesis (Kong et al., 2016; Wagner et al., 1998).  
PanINs are defined as microscopic papillary or flat non-invasive neoplasms, 
characterized by columnar to cuboidal cells with varying amounts of mucin and 
increasing degrees of cytological and architectural atypia. They were initially 
thought to arise in the pancreatic duct, but recent studies have attributed them 
an acinar origin (Buchholz et al., 2005; Guerra et al., 2007; Hruban et al., 2001). 
Development of PanIN lesions and their role as putative precursor lesions of 
pancreatic cancer will be discussed in following chapters. 
  1.4.2.2. Signalling leading to ADM 
It is believed that the proliferative duct-like structures resulting from ADM are 
able to regenerate the acinar cell mass that has been lost during damaging 
processes of the pancreas such as pancreatitis (Desai et al., 2007; Fendrich et al., 
2008; Strobel et al., 2007). Upon pancreatic damage/stress, a number of 
transcription factors and signalling pathways that result in ADM are activated in 
order to promote an inflammatory response and subsequent tissue repair.  
Mitogen activated protein kinase (MAPK) pathway has been widely 
implicated in the development of ADM at the ligand, receptor and signalling 
pathway level. Overexpression of ligands that activate epidermal growth factor 
receptor (EGFR), which subsequently activates MAPK pathway, results in acinar 
metaplasia (Means et al., 2003; Sandgren et al., 1990). EGFR itself has also been 
described to be necessary for the development of acinar metaplasia, even when 
the downstream MAPK pathway is manipulated to be constitutively activated by 
mutant Kras (Ardito et al., 2012; Navas et al., 2012). Inhibition of the MAPK 
signalling transducer MEK has also attributed to this kinase a crucial role in ADM 
(Halbrook et al., 2017). 
Notch pathway has also been involved in ADM. Actually, activation of EGFR by 
TGF-α results in upregulation of the Notch signalling pathway (Miyamoto et al., 
2003), linking MAPK and Notch signalling in metaplastic lesions. In addition, the 
metalloproteinase MMP-7 has been found to be necessary and sufficient to 
induce ADM through activation of Notch signalling (Sawey et al., 2007).  
The activation of nuclear factor kappa B (NF-κB) has also been determined to 
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play an important role in ADM. NF-κβ is a key factor in the development of 
inflammatory responses (Tak & Firestein, 2001), a process tightly linked to ADM. 
It has been shown that, upon pancreatic damage, macrophages infiltrate the 
pancreas and secrete inflammatory cytokines, such as Ccl5 and Tumour Necrosis 
Factor (TNF), which drive ADM through activation of NF-κB (Liou et al., 2013). In 
addition, high activity of NF-κB has been linked to a higher incidence of 
metaplastic lesions and an overall increase in pancreatitis severity (Huang, H. et 
al., 2013). 
As said, the metaplastic process converting an acinar cell to a ductal one requires 
expression of different genes, which is achieved by activation of a subset of 
transcription factors. Under inflammatory conditions or upon oncogene 
activation (both promoting ADM) Sox9 expression in acinar cells increases and 
stimulates transcription of genes that lead to ADM. According with these 
findings, SOX9 expression in patient tumour samples is elevated at all stages of 
preneoplastic lesions and in pancreatic cancer, and positevily correlates with 
increased activation of EGFR pathway. Pdx1 is upregulated during pancreatitis, 
in all types of tumour precursor lesions (including PanIN and other neoplasms), 
as well as in pancreatic tumours. Pdx1 regulates ADM through activation of 
Signal Transducer and Activator of Transcription 3 (STAT3), which is also a 
regulator of inflammation. Other factors required for ADM include Hepatocyte 
Nuclear Factor 6 (Hnf6), which represses acinar genes and upregulates ductal 
genes in both mouse and human acinar cells; and cMyc and Klf4, which are 
required to initiate the ADM process in mice (reviewed in Storz, 2017). 
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2. DISEASES OF THE EXOCRINE PANCREAS 
The major exocrine pancreas diseases include pancreatitis (acute and chronic) 
and pancreatic cancer; and acinar cells play a central role in the pathogenesis of 
both conditions. In pancreatitis, injury is initiated in acinar cells probably as a 
consequence of the premature intracellular activation of digestive enzymes 
(Lerch et al., 2000). Repeated attacks of acute pancreatitis have the potential to 
evolve into a chronic disease characterized by loss of pancreatic function and 
fibrosis (Vonlaufen et al., 2008); and chronic pancreatitis is a major risk factor 
for cancer, specially when caused by genetic factors (Raimondi et al., 2010). 
Pancreatic cancer has historically been thought to arise from ductal epithelium, 
yet murine models have revealed that acinar cells are capable of transforming 
into PDAC through a process involving oncogene mutation, deletion of tumour 
suppressors, and activation of developmental pathways (Reichert et al., 2016), 
highlighting the importance of these cells in all forms of panceatic disease. 
2.1. Pancreatitis 
 2.1.1. General considerations and aetiology 
Pancreatitis is a necroinflammatory condition of the pancreas that can present 
with acute and/or chronic manifestations. Acute pancreatitis (AP) is 
characterized histologically by oedema, acinar cell vacuolization/necrosis and 
parenchymal inflammatory infiltrates (Fig. I5A). Although AP is usually a mild 
and self-limiting process, 10–15% of cases are severe and associate with multi-
organ dysfunction and high mortality (Vonlaufen et al., 2008). Chronic 
pancreatitis (CP) is characterized by acinar atrophy, fibrosis (Fig. I5B), and loss 
of endocrine and exocrine function. It is believed to occur as a result of repeated 
episodes of AP and in approximately 50% of cases is associated with alcohol 
abuse (Whitcomb, 2012).  
 Fig I5. Pancreatitis. (A) 
High-magnification 
histology of caerulein-
induced pancreatitis in 
mouse pancreas, showing 
oedema and immune 
infiltrates. (B) Low-
magnification image of 
chronic pancreatitis in 
human, showing the 
prominent fibrotic reaction. 
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Regardless of its aaetiology, pancreatitis is thought to be initiated by premature 
activation of digestive enzymes within the acinar cell leading to autodigestion of 
the gland in the most severe cases. The most common causes of AP are alcohol 
abuse or occlusion of the pancreatic duct by gallstones. Drugs, viruses, venoms, 
hypercalcemia and hyperlipidemia represent rare causes. Some forms of 
pancreatitis that were initially classified with unknown aetiology (idiopathic 
pancreatitis) are now known to be caused by inherited germline mutations. 
These include activating mutations in the trypsinogen gene PRSS1, which 
enhance protein auto-activation and result in proteolysis and activation of other 
digestive enzymes within acinar cells; and inactivating mutations of genes 
encoding proteins that inhibit protease activity, such as SPINK1, or 
chymotrypsinogen C (CTRC) that degrades trypsinogen and trypsin with high 
specificity. Other genetic causes of pancreatitis include mutations in the cystic 
fibrosis transmembrane conductance regular gene (CFTR) and the calcium 
sensing receptor gene (CASR), among others (Whitcomb, 2012). Autoimmune 
and tropical pancreatitis represent less common causes, usually presented as 
chronic manifestations from the beginning (Vonlaufen et al., 2008). 
 2.1.2. Molecular and cellular events during pancreatitis 
Acute pancreatitis results from altered physiological stimuli and cellular 
responses. In normal conditions, both neural (acetylcholine) and humoral 
(cholecystokinin, CCK) pathways stimulate acinar cells to respond to meal, 
inducing digestive enzyme secretion. However, abnormal signalling consisting of 
supraphysiologic concentrations of CCK can initiate pancreatitis. Although there 
is no evidence that levels of CCK necessary to cause pancreatitis (10-fold greater 
than in response to meal) are reached in pathological settings, this concept has 
been widely used to experimentally promote pancreatitis in rodents by 
administrating supramaximal doses of the CCK analog caerulein. (Gorelick & 
Thrower, 2009). 
During the initial phases of AP, zymogens are activated within acinar cells, a 
process that is mediated by cathepsin B upon fusion of zymogen granules and 
lysosomes (Halangk et al., 2000), which leads to trypsin release and subsequent 
proteolysis and activation of other pro-enzymes. There are two mechanisms 
protecting from intracellular activation of trypsinogen: the presence of a trypsin 
inhibitor (SPINK1) that binds trypsin and blocks its activity, and the presence of 
proteases that degrade trypsin. As commented before, mutations in genes coding 
for these proteins predispose to risk of developing pancreatitis (Gorelick & 
Thrower, 2009) 
Acute changes in cytosolic Ca2+ signalling are also associated with several forms 
of AP. Pathological Ca2+ signalling (stimulated mainly by bile and alcohol 
metabolites) is associated to trypsin activation, vacuolization and necrosis. 
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Causes of such cell damage include increased release of Ca2+ from intracellular 
ER stores, and/or increased Ca2+ entry through the plasma membrane (J. Li et al., 
2014). 
In the early stages of pancreatitis, acinar cells produce cytokines such as TNFa, 
IL-6, IL-10 and the chemokine monocyte chemoattractant protein-1 (MCP-1), 
suggesting that the initial inflammatory responses and signals that recruit 
leukocytes can originate in injured acinar cells (Habtezion, 2015). Neutrophils 
play a pathogenic role in the early phase of AP as they are the first cells recruited 
to the injury site and contribute to trypsinogen activation and progression to 
severe pancreatitis through generation of NADPH oxidase products (e.g. 
hydrogen peroxide and superoxide). These reactive oxygen species (ROS) oxidize 
proteins, enhancing their susceptibility to hydroliysis by serine proteases 
(Gukovskaya et al., 2002). Rapid neutrophil infiltration is followed by 
macrophage recruitment, playing both cell populations a key role in 
inflammation and repair. However, when this balance goes awry, permanent 
inflammatory responses can lead to recruitment of proinflammatory 
macrophages that impair regeneration and re-differentiation of acinar cells. In 
addition, continuous episodes of AP (chronic pancreatitis) lead to acinar atrophy 
and fibrosis, the formation of which is mediated by pancreatic stellate cells (PSC) 
that are scattered in the pancreatic parenchyma. In response to chronic injury, 
PSC become activated, acquire myofibroblast features, proliferate and secrete 
extracellular matrix components and growth factors. (Apte & Wilson, 2003; 
Habtezion, 2015). 
 2.1.3. Regeneration of the pancreas after pancreatitis: role of ADM 
Destruction of large amounts of a specific cell type may be compensated by 
proliferation of residual surviving cells, or by neogenesis from a stem cell 
compartment. In the pancreas, regeneration caused by proliferation of surviving 
cells was first demonstrated for endocrine β-cells (Dor et al., 2004) and was later 
extended to acinar cells in models of damage such as caerulein pancreatitis and 
partial pancreatectomy (Desai et al., 2007; Fendrich et al., 2008; Strobel et al., 
2007). However, it is not clear how replacement of acinar tissue occurs: some 
reports argue that proliferation of surviving differentiated acinar cells 
predominates and that metaplastic lesions have a minor role (Desai et al., 2007; 
Strobel et al., 2007); while others claim that mature exocrine cells regenerate 
pancreatic epithelium through formation of metaplastic ductal intermediates 
through activation of Hedgehog (Fendrich et al., 2008), Notch (Siveke et al., 
2008) and Wnt signalling (Morris et al.,2010).  
It is believed that loss of acinar identity (dedifferentiation) and reactivation of 
developmental signalling pathways might provide protective mechanisms by 
which the acinar cells can undergo regeneration and repair. Since acinar cells 
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produce enormous amounts of digestive enzymes, reduced protein synthesis 
might provide cells with the opportunity to repair injury-related damage 
(Stanger & Hebrok, 2013). While transient metaplasia resulting from activation 
of developmental pathways allows proper cell regeneration, it has been 
demonstrated that mutations in the Kras oncogene promote permanent ADM 
and establishment of putative cancerous lesions (PanINs) by blocking acinar 
regeneration. Upon acute pancreatitis in wild-type mice, the Wnt target β-
catenin is activated (through protein stabilization) allowing acinar regeneration. 
However, β-catenin stabilization does not occur upon pancreatitis in cells 
carrying Kras mutations, therefore blocking acinar regeneration and resulting in 
the formation of permanent metaplastic lesions. Interestingly, forcing β-catenin 
signalling antagonizes the ability of Kras to reprogram acini into preneoplastic 
precursors (Morris et al., 2010). 
 2.1.4. Pancreatitis as a major risk factor for pancreatic cancer 
development 
Chronic pancreatitis is a major risk for pancreatic cancer development in 
humans. A meta-analysis including 22 studies demonstrated a relative risk of 
13.3 for developing pancreatic cancer in those patients with chronic pancreatitis, 
with a 10-20 year lag between the incidences of pancreatitis and malignancy. In 
addition, it was found that the relative risk for PDAC development in cases of 
hereditary chronic pancreatitis raised to 69.0 (Raimondi et al., 2010). Likewise, 
chronic pancreatitis induced by repeated injections of caerulein has been 
broadly used as a model to accelerate carcinogenesis in mice (Guerra et al., 2007, 
2011). Similarly, a single episode of acute pancreatitis increases the incidence of 
neoplastic lesions and pancreatic cancer in models of Kras-induced 
carcinogenesis (Carrière et al., 2009; 2011; Flandez et al., 2014). 
2.2. Pancreatic cancer 
 2.2.1. Incidence and mortality  
Pancreatic cancer (or Pancreatic Ductal Adenocarcinoma, PDAC) is a highly lethal 
disease, for which mortality rates are similar to incidence, and a 5-year survival 
as low as 6% in the USA. The poor survival can be attributed to several factors, 
the major problem being the late stage at which patients are diagnosed. The 
majority of patients with PDAC are asymptomatic until the disease is in an 
advanced stage. Only 20% of patients are eligible for surgery, and even after 
potentially curative resection, most will eventually recur, the 5-year survival 
being only 25%. Other factors that worsen survival include high incidence of 
metastasis, with about 90% of cases presenting distant metastasis, as well as the 
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fact that pancreatic tumours are highly resistant to chemotherapy and 
radiotherapy (Kamisawa et al., 2016). In addition, PDAC is generally diagnosed at 
an advanced age and patients often present with cachexia. For 2017, the 
American Cancer Society estimates that 53,670 people will be diagnosed with 
pancreatic cancer in the USA and 43,090 will die of the disease (R. L. Siegel, 
Miller, & Jemal, 2017). 
 2.2.2. Risk factors 
The risk factors associated with the development of pancreatic cancer are 
classified into modifiable -related to environment and lifestyle- and genetic 
(reviewed in Becker et al., 2014), and are listed below: 
 2.2.2.1 Modifiable risk factors 
Smoking is the most important modifiable risk factor for PDAC, contributing to 
20-35% of the cases. A pooled analysis performed in 2012 found the risk of 
cigarette use to be 2.2-fold and, even after 10 years of smoking cessation, a 
modestly elevated risk of 1.48 remains, which disappears after 20 years of 
cessation (Bosetti et al., 2012). It is likely that PDAC develops from exposure to 
tobacco-related carcinogens such as nitrosamines and polycyclic aromatic 
hydrocarbons, as well as their metabolites, which reach the pancreas through 
circulating blood and cause mutations in both protoncogenes and tumour 
suppressors. However, recent studies have shown that additional effects from 
other tobacco smoke components such as nicotine can also contribute (Hermann 
et al., 2014). 
Alcohol ingestion has been found to be associated with PDAC, but the current 
evidence indicates that only heavy alcohol usage (three or more drinks per day) 
associates with 1.22 to 1.36-fold increase risk of developing PDAC, with a dose 
response relationship (Genkinger et al., 2009; Tramacere et al., 2010). High 
alcohol consumption contributes to pancreatitis, which may be an intermediate 
mechanism contributing to the increased risk of PDAC. In addition, carcinogens 
such as acetaldehyde (an ethanol metabolite) can contribute directly to 
carcinogenesis (Duell, 2012). 
As discussed previously, chronic pancreatitis is a major factor for developing 
pancreatic cancer with a 13.3-fold increase risk. However, only 5% of patients 
with PDAC have a medical history of chronic pancreatitis (Raimondi et al., 2010). 
Diet and obesity can also increase the risk of developing PDAC. Specifically, diet 
including red meat (1.29 risk) and processed meat (1.19 risk) (Larsson et al., 
2012); or increase in body mass index (relative risk of 1.12 for each 5kg/m2) 
(Larsson et al., 2007) are thought to induce pancreatic hypertrophy and 
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hyperplasia in response to abundant cholecystokinin secretion, which may 
favour the carcinogenic process (Jarosz et al., 2012). 
Meta-analysis have demonstrated an association between diabetes mellitus, 
both type 1 and 2, and pancreatic cancer, with odds ratios of approximately 2.0 
and 1.8, respectively (Huxley et al., 2005; Stevens et al., 2007). There is much 
debate about the molecular mechanisms accounting for such an association as 
well as the possible confounding by the presence of the tumour. Insulin is growth 
promoting and, thus, chronic insulinemia may result in increased cellular 
proliferation and decreased apoptosis, a mechanism that might contribute to 
PDAC. Additionally, the oxidative stress from hyperglycemia may be the cause of 
cell damage that could contribute to the development of neoplasm (Larsson et 
al., 2007; Stocks et al., 2009; Stolzenberg-Solomon et al., 2005). 
Other factors that have been associated with the risk for developing pancreatic 
cancer include have undergone surgeries such as cholecystectomy (1.23, risk) 
(Lin et al., 2012) or gastrectomy (1.54 risk) (Y. Gong et al., 2012); and infections 
with H. Pylori (1.38 risk) (Raderer et al., 1998). There is also some evidence for a 
link between hepatitis B and pancreatic cancer (Hassan et al., 2008), as well as 
hepatitis C (El-serag et al., 2010). Exposure to hydrocarbons such as chlorinated 
hydrocarbons and polycyclic aromatic hydrocarbons positively correlate with 
increased risk to develop PDAC, yet consistently statistically significant results 
have not been found with either of these two occupational exposures (Andreotti 
et al., 2012). 
Concentrations of trace elements (metals) can also affect the risk of developing 
PDAC. Interestingly, it has been reported that individuals with high 
concentrations of cadmium, arsenic and lead have an increased risk of PDAC 
(3.58, 2.02, and 6.26-fold increased risk, respectively), while high levels of 
selenium and nickel are inversely associated with risk of PDAC (0.05 and 0.27, 
respectively) (Amaral et al., 2013).  
Although the majority of studies have reported conditions that increase PDAC 
risk, it has also been found that asthma and nasal allergies have an opposite 
effect and protect against PDAC development. Concretely, asthma is associated 
with lower risk of PDAC (OR 0.64), and the effect is even greater in long-standing 
asthma (>=17 years) (OR 0.39). Similarly, nasal allergies and related symptoms 
are associated with lower risk of PDAC (OR 0.66) (Gomez-rubio et al., 2015). 
 2.2.2.2 Genetic risk factors 
In regard to genetic susceptibility, PDAC can be classified as hereditary or 
sporadic. In the first group, there is a strong inherited predisposition to 
pancreatic cancer in three distinct clinical settings: hereditary tumour 
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predisposition syndromes, syndromes associated with chronic inflammation of 
the pancreas and familial pancreatic cancer (FPC). In the second group, although 
environmental factors are the main drivers of pancreatic carcinogenesis, the 
presence of certain genetic variants (SNPs) has also been shown to modulate the 
risk of developing PDAC.  
Hereditary pancreatic cancer 
The first setting of hereditary pancreatic cancer comprises familial cancer 
syndromes known to be associated with an increased risk of pancreatic cancer, 
including Peutz–Jeghers syndrome, familial atypical multiple mole melanoma 
(FAMMM), hereditary breast–ovarian cancer (HBOC), hereditary non-polyposis 
colorectal carcinoma (HNPCC or Lynch syndrome), and familial adenomatous 
polyposis (FAP). It was estimated that these cancer syndromes account for 15–
20% of hereditary pancreatic cancer cases (Hruban et al., 2010).  The genes 
typically mutated in each syndrome as well as the relative risk (RR) of 
developing PDAC are summarized in Table I1. 
Syndrome Genes affected Risk References 
Peutz-Jeghers STK11 132 Giardiello et al., 1987; Jenne et al., 1998 
FAMMM p16INK4A 13-22 Lynch et al., 2008; Vasen et al., 2000 
HBOC 
BRCA1, BRCA2, 
PALB2 
3.5-10 
Consortium, 1999; Lynch et al., 2005; 
Murphy et al., 2002 
HNPCC 
MLH1, MSH2, MSH6, 
PMS2, EPCAM 
8.6 Kastrinos et al., 2009 
FAP APC 4.5-6 Giardiello et al., 1993 
Ataxia 
telangiectasia 
ATM 2 Morrell et al., 1990; Swift et al., 1987 
Table I1. Familial cancer syndromes associated with increased risk of PDAC development. 
Risk column expresses the relative risk of developing PDAC expressed as fold increase over 
general population. Abbreviations: FAMM, familial atypical multiple mole melanoma; HBOC, 
hereditary breast-ovarian cancer; HNPCC, hereditary non-polyposis colorectal carcinoma; FAP, 
familial adenomatous polyposis. 
The second setting for an inherited predisposition to pancreatic cancer includes 
hereditary pancreatitis and cystic fibrosis. As described earlier, hereditary 
pancreatitis is caused by mutations in genes that result in premature and 
persistent activation, or reduced deactivation of pancreatic proteases, leading to 
pancreatic injury (PRSS1, SPINK1). A 2010 meta-analysis found a relative risk of 
69 for PDAC in patients with hereditary pancreatitis compared to the general 
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population (Raimondi et al., 2010). Cystic fibrosis is caused by homozygous 
mutations in CFTR gene, and predisposes with 5.3-fold greater risk of PDAC 
development (Maisonneuve et al., 2007). However, CFTR mutations inherited in 
a heterozygous fashion also confer a 4-fold greater chance of developing chronic 
pancreatitis, and therefore, increase risk for PDAC development (Weiss et al., 
2005) 
The third setting is familial pancreatic cancer (FPC) syndrome, which accounts 
for the majority of hereditary pancreatic cancer, around 80% of cases (Hruban et 
al., 2010). FPC is defined as having 2 or more first-degree relatives (FDRs) with 
PDAC with no known genetic cause, and accounts for 4-10% of all PDAC cases. It 
has been described a nine-fold greater risk of developing PDAC among 
individuals with an FDR with PDAC in the setting of FPC, compared to a 1.8-fold 
greater risk for those with an FDR with sporadic PDAC (Klein et al., 2004). 
Additionally, among FPC kindreds, having two or three FDRs with PDAC was 
associated with a 6.4-fold and 32-fold greater risk of developing PDAC, 
respectively (Klein et al., 2004). FPC has several epidemiological features that 
distinguish it from sporadic PDAC. Similarly to other familial cancers, FPC shows 
a trend towards a younger onset (FPC: age 58-68; compared to sporadic PDAC: 
age 61-74). Similar to the sporadic cases, smoking and diabetes also increase the 
risk for FPC (Matsubayashi et al., 2017). Although linkage analysis have 
determined that mutations in PALLD, BRCA2, PALB2, ATM are the cause of FPC in 
some families, the genetic basis of FPC still remains to be established in the 
majority of cases (Bartsch et al., 2012). 
Sporadic pancreatic cancer 
Genetic predisposition to sporadic pancreatic cancer has been assessed through 
genome wide association studies (GWAS). These studies have provided with 
relevant information on allelic variants that predispose to or protect from PDAC 
development, and the gene to which the variant is associated. Some of these 
genes are listed in Table I2.  
 2.2.3. Histopathology of PDAC 
Among all the different cancer types that can arise from the exocrine pancreas, 
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common pancreatic 
neoplasm and accounts for >85% of pancreatic tumour cases (Hezel et al., 2006). 
It receives this name as a result of the histological resemblance to normal ductal 
cells. Although other uncommon tumours of the exocrine pancreas have been 
described, including Signet-ring cell carcinoma, undifferentiated anaplastic 
carcinoma, mixed ductal-endocrine carcinoma, osteoclast-like giant cell tumour, 
serous cystadenocarcinoma, mucinous cystadenocarcinoma, acinar cell 
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carcinoma or pancreatoblastoma, among others (reviewed in Klöppel et al., 
1996), pancreatic cancer and PDAC are used as synonyms in the present work.  
 
Gene identified Study Gene identified Study 
CEL Dalva et al., 2017 NR5A2 Petersen et al., 2010 
LINC-PINT Wolpin et al., 2014 CLPTM1L- TERT Petersen et al., 2010 
BCAR1/CTRB1/CTRB2 Wolpin et al., 2014 LINC00673 Childs et al., 2015 
PDX1 Wolpin et al., 2014 SUGCT Childs et al., 2015 
ZNRF3 Wolpin et al., 2014 TP63 Childs et al., 2015 
TERT Wolpin et al., 2014 ETAA1 Childs et al., 2015 
PVT1 Wolpin et al., 2014 ABO Amundadottir et al., 2009 
BRCA2 L. Huang et al., 2013 TERT Bao et al., 2017 
MAP2K4 L. Huang et al., 2013   
Table I2. Genes presenting genetic variants that modulate predisposition to PDAC development. 
 
Among all the low-penetrance variants that influence predisposition to PDAC 
development, the ones affecting the AB0 system are well defined. Non-0 blood 
groups have been associated with a 1.3 higher risk of PDAC (Amundadottir et al., 
2009; Egawa et al., 2013; Risch et al., 2010). In addition, a meta-analysis found 
that having an O blood group was associated with a relative risk of 0.79 for the 
development of PDAC, indicating that this variant is protective (Amundadottir et 
al., 2009; Iodice et al., 2010).   
At the macroscopic level, PDAC usually consists of a firm, highly sclerotic mass, 
with poorly defined edges and long tongues of carcinoma extending beyond the 
main tumour (Fig. I6A). Microscopically, pancreatic cancer is composed of an 
infiltrating gland-forming neoplastic epithelium displaying variable 
differentiation features, ranging from a glandular appearance (differentiated) to 
a mesenchymal (less differentiated) aspect (Maitra & Hruban, 2008). However, 
the majority of tumours are reported by pathologists as being “moderately 
differentiated”. Neoplastic cells upregulate the expression of mucins (especially 
MUC1 and MUC4), a feature that has contributed to establish a progression 
model to PDAC from non-invasive lesions that also produce mucins (Balagué et 
al., 1994; Jonckheere et al., 2010). A hallmark of PDAC is that epithelial 
compartment of the tumour is surrounded with a dense stroma of fibroblasts 
and inflammatory cells, called desmoplastic reaction, which can comprise as 
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much as 90% of the total tumour (Fig. I6B, C). Pancreatic cancers are extremely 
infiltrative neoplasms: vascular and perineural invasion are present in the 
majority of surgically resected cancers, and metastases to regional lymph nodes, 
the liver, and distant sites are also common (Maitra & Hruban, 2008).  
Figure I6. Pathology of PDAC. (A) Gross photograph of an infiltrating adenocarcinoma. Note the 
dramatic narrowing (arrowhead) of the pancreatic duct (d) associated with the poorly defined 
white neoplasm (dashed line). (B) Low-magnification image of a differentiated infiltrating 
adenocarcinoma. Note the irregular arrangement of the glands and the extensive associated non-
neoplastic desmoplastic stroma. (C) High-magnification image of a differentiated 
adenocarcinoma. Note the desmoplastic stroma and the marked pleomorphism in the cancer (*) 
relative to the trapped non-neoplastic duct (d). Adapted from Maitra & Hruban, 2008. 
 2.2.4. Precursor lesions of PDAC 
The high aggressiveness and invasiveness that characterize PDAC has led to 
intensive research in an attempt to identify morphologically the precursor 
lesions whose biology and genetics should be understood in order to improve 
early diagnosis. The best studied precursor lesions are Pancreatic Intraepithelial 
Neoplasia (PanIN), Intraductal Papillary Mucinous Neoplasms (IPMN), and 
Mucinous Cystic Neoplasm (MCN) (Distler et al., 2014); being PanINs by far the 
most common of all precursor lesions. However, atypical flat lesions (AFL) have 
been lately postulated as an additional PDAC precursor (Aichler et al., 2012). 
  2.2.4.1. Pancreatic intraepithelial neoplasia - PanIN 
Lesions known now as PanINs have been recognized for over a century and have 
been termed with a variety of names including duct hyperplasia, hypertrophy, 
metaplasia, and dysplasia. Recently, their significance as PDAC precursors has 
led to establish a universal nomenclature and histopathological classification (R. 
Hruban et al., 2001). PanINs are microscopic non-invasive epithelial neoplasms 
(<0.5mm) that had historically been considered to arise in the smaller pancreatic 
ducts, yet recent evidences points to acinar cells as the putative cell of origin 
based mainly on the use of GEMMs. They are characterized by mucin-containing 
cuboidal to columnar cells, and can be classified morphologically into three 
grades. PanIN-1 lesions are composed of columnar epithelial cells lacking 
dysplasia, with basally oriented uniform and round nuclei. PanIN-1 lesions can 
be flat (PanIN-1A) or papillary (PanIN-1B). PanIN-2 lesions are architecturally 
   INTRODUCTION 
 25 
more complex and they have more nuclear changes including loss of nuclear 
polarity, nuclear crowding, variation in nuclear size (pleomorphism), nuclear 
hyperchromasia, and nuclear pseudostratification. PanIN-3 lesions show high-
grade dysplasia. These lesions are architecturally complex, forming papillae and 
cribriform structures, and in some instances clusters of cells bud off of the 
epithelium into the lumen of the duct. Cytologically, the nuclei in PanIN-3 lesions 
are enlarged, pleomorphic, and poorly oriented. Nucleoli are often prominent 
and mitotic figures (and even abnormal mitoses) can be seen (Hong et al., 2011; 
Hruban et al., 2008) (Fig. I4A).  
Although PanINs are considered PDAC precursors, PanIN1 are generally 
regarded as benign lesions because of their ubiquitous presence in the aged 
population.  In a recent study it has found that PanIN1 were present in 77% of 
the analysed cases, while PanIN2 and PanIN3 were found in lower frequencies, 
28% and 4% respectively (Matsuda et al., 2017). Indeed, expression analysis of 
PanINs of different grades has shown that the expression profile of PanIN1 
differs from normal ductal cells by few genes, while PanIN2, PanIN3 and PDAC 
gene expression is largely deregulated, suggesting that PanIN2 is the actual 
precursor of PDAC (Buchholz et al., 2005) 
As expected for a precursor lesion, some proteins expressed in pancreatic cancer 
are also expressed in PanINs. This is the case for some mucins, particularly 
MUC1, MUC4, MUC5AC, and MUC6, which are expressed by PanINs (Nagata et al., 
2007). These mucins can be used to distinguish PanINs from IPMNs, because 
PanINs do not display intestinal differentiation and, therefore, do not express 
MUC2. In addition, global analyses of gene expression have shown that a number 
of markers of gastric epithelial differentiation, such as pepsinogen C, MUC6, KLF4 
and TFF1, are expressed in PanINs (Buchholz et al., 2005; Prasad et al., 2005). 
  2.2.4.2. Intraductal papillary mucinous neoplasia - IPMN 
IPMNs are mucin-producing epithelial neoplasms that, by definition, involve the 
main and/or branch pancreatic ducts. These neoplasms are larger than PanINs 
(≥1 cm) and therefore can be detected by imaging. The neoplastic epithelium is 
usually composed of tall columnar cells with abundant apical mucin droplets. 
IPMNs present a papillary morphology and the degree of architectural and 
nuclear atypia can be dramatically heterogeneous, sometimes presenting areas 
of focal invasive cancer. Most common subtype of IPMN shows intestinal 
differentiation and is characterized by expression of MUC2 and CDX2, but not 
MUC1; by contrast, IPMNs with pancreato-biliary differentiation are less 
common, usually express MUC1 (but not MUC2 or CDX2), and are frequently 
associated with the presence of a carcinoma in situ (Grützmann et al., 2011; 
Maitra et al., 2005). 
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  2.2.4.3. Mucinous cystic neoplasms  - MCN 
MCNs are distinctive mucin-producing epithelial neoplasms that are 
characterized by presenting an ovarian-type stroma and, in 90% of the cases, 
arise in women. The epithelial component of MCNs consists of columnar mucin-
producing cells with varying degrees of architectural and nuclear atypia. An 
invasive component is present in one-third of MCNs. In contrast to IPMNs, MCNs 
do not communicate with the larger pancreatic ducts and differ from both IPMNs 
and PanINs by the presence of the ovarian-type stroma (Fernández-del Castillo, 
2008). 
  2.2.4.4. Atypical flat lesion - AFL 
In addition to the mucin-producing lesions described above, AFL have been 
lately described as PDAC precursors by the group of I. Esposito, as well. These 
consist of tubular structures lined by cuboidal cells with cytological atypia, 
namely enlarged nuclei with prominent nucleoli, a high nuclear–cytoplasmic 
ratio, and the presence of mitoses. AFLs are observed in areas of ADM and are 
characterized by the presence of a peculiar stroma surrounding the lesions, 
which is loose but highly cellular, with whorls of spindle cells that surround the 
tubular structures (Aichler et al., 2012). In the only study describing these 
lesions, AFLs were found to be the ones predominantly proliferative active, with 
22% of them showing a Ki-67 rate between 10% and 80%, while all other 
lesions, including mPanIN, showed predominantly low (<10%) proliferation 
rates. They were found both in patients with sporadic PDAC and Familiar 
pancreatic cancer, as well as in the pancreas of the mutant Kras GEMMs.   
Figure I7. Precursor lesions of PDAC. Representative images of: (A) Pancreatic intraepithelial 
neoplasia (PanIN). (B) Intrapapillary mucinous neoplasia (IPMN). (C) Mucinous Cystic Neoplasia 
(MCN).  (D) Atypical flat lesion (AFL). A, B and C images were extracted from Distler et al., 2014; 
and D from Aichler et al., 2012. 
 2.2.5. Mutational genomic landscape of PDAC 
Progression from precursor lesions to invasive PDAC occurs through acquisition 
of mutations, epigenetic changes, and non-genetic events, including changes in 
the microenvironment. Although IPMN and MCN harbour their own specific 
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mutational features, we will focus on the mutational landscape of PanINs and 
how it is thought they evolve to PDAC, as it is the most relevant road to cancer in 
this work. 
Mutational progression from PanIN to PDAC  
The notion that histological progression from early neoplastic lesions to invasive 
cancer is related to genetic progression was first established for colon cancer 
(Vogelstein et al., 1988). By aligning specific driver mutations to cancer 
precursors stages, this group posited the first genetic model of tumourigenesis. 
Years later, a genetic model for pancreatic cancer progression was established 
following the same rationale (Hruban et al., 2000). In this model, acquisition of 
mutations drives the progression from preneoplastic lesions (PanINs) to invasive 
PDAC.  
The first genetic event taking place in pancreatic carcinogenesis is an activating 
point mutation in the KRAS oncogene. Initially, it was shown that activating point 
mutations of KRAS occur in 90-95% of PDAC as well as in approximately 36%, 
44%, and 87% of PanIN-1A, 1B, and 2-3 lesions, respectively (Hruban et al., 
2008; Tada et al., 1996). Lately, using a more sensitive KRAS mutation detection 
technique it was shown that indeed all PanINs share a high frequency of KRAS 
mutations (>90%) (Kanda et al., 2012). In addition, telomere shortening was 
found in approximately 90% of PanIN-1 as well as in PanIN-2 and -3 and PDAC, 
which may contribute to global chromosomal abnormalities (Matsuda et al., 
2015; Van Heek et al., 2002).  
Following the progression model, PanIN-1 evolves to PanIN-2 through mutations 
of p16/CDKN2A (Moskaluk, Hruban, & Kern, 1997), while inactivation of the 
tumour suppressors TP53, SMAD4, and BRCA2 are generally associated with 
progression to high-grade PanIN lesions (PanIN-3) and PDAC (Goggins et al., 
2000; Hruban et al., 2008; Lüttges et al., 2001; Wilentz et al., 2002). The 
incidence, characterization and implications of these mutations are discussed in 
the following section.  
Genetic alterations in PDAC 
As commented, KRAS mutations are thought to be the earliest genetic event to 
occur during PDAC development, being found in 90%–95% of cancer cases as 
well as in PanINs (Kanda et al., 2012; Maitra & Hruban, 2008). Recent studies 
directed by the International Cancer Genome Consortium (ICGC), in which a 
large number of PDAC were subjected to integrated genomic analysis, confirmed 
a high prevalence of activating KRAS mutations, which were found in more than 
90% of the analysed cases (P. Bailey et al., 2016; Biankin et al., 2012; Waddell et 
al., 2015; Witkiewicz et al., 2015). The relevance of KRAS in pancreatic cancer 
initiation has been underscored by the development of genetically engineered 
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mouse models (GEMMs) in which an activating Kras mutation is expressed from 
the endogenous locus under the control of a Cre recombinase driven from a 
pancreas-specific promoter, such as Pdx1 or Ptf1a. These mice develop the full 
spectrum of the human disease (Hingorani et al., 2003). The murine models to 
study pancreatic cancer will be discussed in detail in a following chapter. 
KRAS belongs to a group of small guanine triphosphate (GTP) binding proteins, 
which oscillate between an active (GTP-bound) and an inactive (GDP-bound) 
state. KRAS is activated by a number of stimuli such as growth factor binding to 
tyrosine kinase receptors, among others. Upon ceasing of the activating stimulus, 
guanine-triphosphatase-activating proteins promote GTP hydrolysis to GDP and 
attenuate KRAS signalling (Malumbres & Barbacid, 2003). More than 90% of 
PDAC harbor KRAS activating mutations, located predominantly in codon 12, 
which inhibit the protein's ability to hydrolyze GTP, resulting in a constitutively 
activated molecule that signals independently of growth factor stimulation 
(Maitra & Hruban, 2008). Activated KRAS signals through multiple effector 
pathways that promote proliferation, cell survival, cytoskeletal remodeling, 
motility and differentiation. The best established KRAS downstream targets are 
the RAF-mitogen activated protein kinase (MAPK), the phosphoinositide-3-
kinase (PI3K) and RAL-GDS pathways (Malumbres & Barbacid, 2003) (Fig. I8). 
The important role of RAF-MAPK pathway in cancer has been established with 
the identification of activating mutations in B-RAF in many malignancies (H. 
Davies et al., 2002). Although they are not very common in PDAC, it was found 
that B-RAF mutations are present in one third of pancreatic cancers harbouring 
unaltered KRAS, thereby resulting in the activation of RAF-MAPK signalling in 
cases with wild-type KRAS (Calhoun et al., 2003). In addition, abrogation of RAS-
MAPK signalling through small molecule inhibitors or with antisense technology 
results in growth inhibition of pancreatic cancer xenografts (Xing et al., 2003). 
Indeed, RAF-MAPK pathway has been targeted with small molecules to treat 
pancreatic cancer with positive results in vitro (Xing et al., 2003), yet clinical 
studies have shown no efficacy in patients (Infante et al., 2014).  
The PI3K-AKT pathway is an essential cell survival pathway with diverse roles 
in tumourigenesis across multiple malignancies. The PI3K pathway is 
constitutively activated in most pancreatic cancers and targeting this pathway 
with small molecule inhibitors or genetic strategies results in growth inhibition 
in vitro and in vivo (Maitra & Hruban, 2008). Although RAS certainly contributes 
to PI3K-AKT signalling in pancreatic cancer, independent genomic events can 
also activate this pathway, including amplification of the AKT2 gene in 10-20% of 
PDAC cases (Cheng et al., 1996). In addition, activating mutations and 
amplifications in PIK3CA have also been found by exome sequencing 
experiments (Waddell et al., 2015; Witkiewicz et al., 2015). Interestingly, 
combined therapies using inhibitors of the PI3K-AKT and RAF-MAPK have been 
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proved to be effective in vitro, leading to cell cycle arrest and apoptosis of cancer 
cells (Roy et al., 2010). 
 
Figure I8. RAS 
signalling network. Ras 
uses a multitude of 
downstream effectors. 
Depicted are the three 
major signalling cascades 
that have been implicated 
in PDAC progression and 
mainte-nance: the 
Raf/Map Kinase (ERK) 
pathway, the PI3K 
pathway, and the Ral GDS 
pathway. Adapted from 
Ying et al., 2016. 
 
The gene coding for p16 (INK4A/CDKN2A) is the most commonly inactivated 
tumour suppressor gene in pancreatic cancers. Loss of p16 function has been 
described to occur in more than 90% of pancreatic cancers through several 
mechanisms, including homozygous deletions (40%), intragenic mutation with 
loss of the second allele (40%), and epigenetic silencing by promoter 
methylation (10%–15%) (Maitra & Hruban, 2008). Recent data coming from the 
ICGC has confirmed the presence of CDKN2A inactivating mutations in 35% of 
PDAC cases, including structural variants and point mutations (P. Bailey et al., 
2016; Biankin et al., 2012; Waddell et al., 2015). p16/INK4A belongs to the 
cyclin-dependent kinase (CDK) inhibitor family and inhibits cell cycle 
progression by inhibiting CDK4/6-mediated phosphorylation of RB (Kim & 
Sharpless, 2006).  
Inactivation of the TP53 gene has been described in approximately 50%–75% of 
pancreatic cancers through intragenic mutation combined with loss of the 
second allele. TP53 loss occurs almost exclusively in the most advanced lesions 
(PanIN-3 or carcinoma in situ) (Hruban, 2000; Maitra & Hruban, 2008). TP53 
inactivating events including mutations and structural variants has been recently 
confirmed by the ICGC in 74% of PDAC cases (P. Bailey et al., 2016; Biankin et al., 
2012; Waddell et al., 2015). P53 is a major regulator of responses to stress: 
under normal conditions it is functionally inactive due to its rapid degradation 
by the ubiquitin ligase MDM2; upon stress (including DNA damage or oncogenic 
signalling) MDM2-driven degradation is impaired and p53 accumulates, gaining 
full competence in transcriptional activation. p53 targets include cell cycle 
inhibitors and pro-apoptotic proteins, which results in cell-cycle arrest, 
senescence or apoptosis. Loss of p53 function allows cells to survive and divide 
despite the presence of damaged DNA, leading to the accumulation of additional 
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genetic abnormalities (Vousden & Lane, 2007). In murine models of PDAC, the 
point mutation R172H in Trp53 gene confers gain-of-function properties to p53 
that result in chromosomal instability and widely metastatic cancer (Hingorani 
et al., 2005). Recently, it has been described that sustained expression of 
p53R172H mediates PDAC pro-metastatic potential through the platelet-derived 
growth factor receptor b (PDGFRb), which is both necessary and sufficient to 
mediate these effects (Weissmueller et al., 2014). 
The SMAD4 gene was initially found to be inactivated in approximately 55% of 
pancreatic cancers, either by homozygous deletion (30%) or by intragenic 
mutations and loss of the second allele (25%). As commented earlier, this gene 
as well as TP53 are usually inactivated in high-grade PanINs, and therefore these 
two events are considered to occur late in the linear progression model for PDAC 
(Hruban et al., 2000; Maitra & Hruban, 2008). Again, recent data from ICGC has 
confirmed that 31% of PDAC harbour SMAD4 genetic alterations (P. Bailey et al., 
2016; Waddell et al., 2015). SMAD4 is a transcriptional regulator that plays a 
critical role in the transforming growth factor-β (TGF-β) pathway. TGF-β is a 
cytokine that binds to serine/threonine kinase receptors, which propagate the 
signal by phosphorylating SMAD transcription factors (i.e. SMAD2 and 3) that 
shuttle to the nucleus where they form a complex with Smad4, activating a 
variety of downstream targets (Massagué, 2008). The TGF-β pathway has 
profound growth-inhibitory effects by regulating the expression of specific target 
genes; therefore, loss of Smad4 in pancreatic cancer cells, which abrogates Smad-
dependent TGF-β signalling, provides a selective growth advantage (P. M. Siegel 
& Massagué, 2003).  
In addition to the genetic alterations of these "classic" genes (KRAS, TP53, 
CDKN2A and SMAD4), which have been widely studied and characterized, next 
generation sequencing (NGS) has facilitated the study of additional genetic 
players. Jones et al. were the first to interrogate the PDAC genome globally (Jones 
et al., 2008), and they found that nearly all tumours harboured mutations in 
Hedgehog/Wnt/Notch signalling components. Another study analysing more 
than 100 PDAC determined that one fifth of PDAC genomes harbour mutations 
and copy number aberrations in genes involved in axon guidance a signalling 
pathway that provides attractive and repulsive cues in axon development 
(Biankin et al., 2012). In addition, this study identified several new genetic 
players that are mutated at low frequency (generally below 5%) in PDAC, 
including MLL3, TGFBR2, ARID1A, EPC1, ARID2, SF3B1, ATM and RNF43.  
The resolution of the first genomic analyses was limited by the fact that PDAC 
are often highly desmoplastic. By needle microdissection to enrich for epithelial 
tumour cells prior to exome sequencing, Witkiewicz et al. actually found 
mutation rates of PDAC were higher compared to Biakin et al. Their increased 
detection limit allowed identifying novel recurrent mutations (still at or below 
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5%) in BCLAF1, IRF6, FLG, AXIN1, GLI3, PIK3CA, and RBM10 (Witkiewicz et al., 
2015). More recent genomic studies analysing more than 450 PDAC cases have 
characterized novel mutations, being able to define 10 pathways -some already 
known to be altered and some new ones- that are commonly affected in PDAC, 
including KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, 
SWI-SNF, chromatin modification, DNA repair and RNA processing (P. Bailey et 
al., 2016). Overall, these studies have revealed a striking mutational 
heterogeneity in PDAC and have confirmed that beyond the “classic four” genetic 
players, recurrent mutations in PDA generally occur in rare subsets.  
In addition to mutations activating oncogenes or deletion of tumour suppressors, 
telomere erosion also plays an important role in PDAC initiation and 
progression. Indeed, it is one of the earliest demonstrable genetic aberrations in 
pancreatic cancer, with >90% of PanIN lesions presenting it compared to normal 
ducts (Matsuda et al., 2015; Van Heek et al., 2002). Telomeres consist of 
repetitive DNA sequences that associate with shelterins, proteins that confer 
stability to chromosomes during cell division. Loss of telomeres renders 
chromosome ends highly recombinogenic, which may result in amplifications 
and deletions (Shay & Wright, 2010). Cells with critically short telomeres 
activate a p53-dependent DNA damage response that prevents from 
immortalization and transformation of these cells. However, p53 is lost only in 
50-75% of PDAC cases which raises the possibility that other p53 pathway 
components involved in the telomere-induced checkpoint responses are 
neutralized in a subset of pancreatic cancers (Hezel et al., 2006). 
 2.2.6. Progression models of PDAC development 
   2.2.6.1. The “classical” model  
The “classical model” for pancreatic cancer progression states that tumours arise 
from histologically well-defined precursor lesions through the accumulation of 
multi-step genetic alterations (Hruban et al., 2000; Maitra & Hruban, 2008). In 
this regard, PanINs are considered to be the most common precursor lesion as 
they are frequently found in biopsies from patients presenting PDAC. Classically, 
the model has proposed that PanINs arise in small ducts through mutations that 
initiate the neoplastic process (Maitra & Hruban, 2008). However, several 
studies in mice have shown that acinar and centroacinar cells could rather be the 
cell of origin of PanINs (Aichler et al., 2012; Bailey et al., 2014; Carrière et al., 
2007; De La O et al., 2008; Esposito et al., 2007; Guerra et al., 2007, 2011; Habbe 
et al., 2008; Kopp et al., 2012; Morris IV et al., 2010). Regardless of the 
compartment where they originate, PanINs are proposed to progress in a linear 
fashion through the sequential stepwise accumulation of mutations as already 
discussed: KRAS mutations would initiate transformation and loss of 
p16/INK4A/CDKN2A, TP53 and SMAD4 would be the cause of progression first to 
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more dysplastic lesions (PanIN2 and PanIN3) and eventually to invasive cancer. 
The major evidence that led to the development of the linear progression model 
for PDAC is the observation that PanINs harbor many of the genetic alterations 
that are found in invasive pancreatic cancer (Fig. I9A). 
  2.2.6.2. The "alternative" model 
The linear progression model initially proposed (Hruban et al., 2000) has been 
questioned given a number of limitations that may not have been appropriately 
taken into account by the scientific community, leading to a rapid establishment 
of a "dogma" model. These limitations have been described elsewhere (Notta et 
al., unpublished; Real, 2003; Real et al., 2008)..The existing evidence supporting 
PanIN-1 to PDAC progression considering the prevalence of genetic changes does 
not allow concluding about the sequence in which a given genetic alteration 
occurs, and could actually be interpreted differently. Therefore, the alternative 
model suggests that KRAS mutations might favour the appearance of dysplasia 
and tumour progression only when occurring in cells harbouring loss of 
heterozygosity (LOH) in a crucial tumour suppressor gene, such as INK4A or 
TP53. On the other hand, KRAS mutations occurring in normal cells might lead to 
growth arrest by activation of senescence. This would mean that only PanIN-2/3 
would progress into PDAC while PanIN-1, presenting only KRAS mutations, 
would undergo cell cycle arrest (Real et al., 2008). The proposed model is 
supported by results obtained using global transcriptome analysis of human 
PanINs, showing that the expression profiles of PanIN-1 lesions were similar to 
those of normal ducts, while PanIN-2 and 3 cluster together with PDAC samples 
(Buchholz et al., 2005). Moreover, it has been firmly established using in vitro 
and in vivo studies the existence of oncogene-induced senescence, which would 
function as a protective mechanism against tumour progression in cells that are 
subjected to oncogenic stress (Collado et al., 2005). In fact, in a mouse model of 
PDAC expressing oncogenic Kras in the pancreas, it has been shown that PanINs 
were positive for senescence markers while PDAC was negative (Caldwell et al., 
2012; Collado et al., 2005) (Fig. I9B). 
The alternative model is in agreement with a recent study analysing mutations, 
DNA copy number changes, and genomic rearrangements of human PDAC 
genomes using whole genome sequencing (Notta et al., 2016). This study has 
revealed that: first, pancreatic carcinogenesis does not necessarily develop 
through a particular sequence of genetic alterations (KRAS followed by CDKN2A, 
then TP53 and SMAD4); and second, that the evolutionary trajectory of 
pancreatic cancer progression is not gradual, or in other words, that each 
alteration is not acquired independently as initially proposed. The study shows 
that 45% of PDAC displays changes in copy number consistent with 
polyploidization. In addition, two thirds of analysed PDAC carry complex 
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rearrangement patterns associated with mitotic errors, pointing to genomic 
instability as the principal cause of malignant progression. The study also shows 
that a single event of chromothripsis can inactivate en bloc the tumour 
suppressors CDKN2A, TP53 and SMAD4, being this a major transforming event 
contributing to malignancy. This rare event could confer a cell both invasive and 
metastatic properties, thus accounting for the very short latency between the 
birth of the invasive clone and the acquisition of its ability to metastasize (Notta 
et al., 2016).  
 
Figure I9. Model of PDAC progression. (A) Classical model showing the linear progression 
from low to high-grade PanIN to carcinoma with the mutations associated in each step. (B) 
Alternative model showing that PDAC may arise from advanced lesions and that low-grade PanIN 
act as tumour suppressor events that allow growth arrest of neoplastic cells. Adapted from Pinho, 
2011. 
 
 
2.2.7. Genetically engineered mouse models to study pancreatic cancer  
The first approaches to generate mouse models of pancreatic cancer started in 
the late 1980s and they were based on the transgenic expression of oncogenes 
that resulted in neoplastic processes different from the ones observed in the 
human setting (Ornitz et al., 1987; Quaife et al., 1987). The first GEMM closely 
resembling the human disease was established in 2003 (Hingorani et al., 2003). 
This model is based on a strain of mice expressing a conditional KrasG12D mutant 
allele silenced by a floxed transcriptional STOP cassette (Lox-Stop-Lox or LSL) 
inserted upstream of the targeted Exon1 (LSL-KrasG12D mice). Removal of the LSL 
cassette by expression of Cre recombinase allows expression of oncogenic 
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KrasG12D. When these mice are crossed with those expressing Cre recombinase 
under the control of the Pdx1 or Ptf1a regulatory sequences, mice develop PDAC 
(Hingorani et al., 2003). Such compound mutant mice (Pdx1+/Cre;LSL-KrasG12D and 
Ptf1a+/Cre;LSL-KrasG12D) develop PanIN with complete penetrance and a subset of 
older mice develop PDAC (Fig. I10). The PanINs that develop in these mice 
resemble those of patients in that they express mucins, cytokeratin-19, 
Cyclooxygenase (Cox)-2, MMP-7, and Hes1 (Hingorani et al., 2003). This GEMM 
supported the PanIN-to-PDAC model of pancreatic cancer progression described 
by  Hruban et al., 2000. 
As discussed earlier, human PanINs are believed to progress to PDAC following 
inactivation or point mutation of p16/CDKN2A, TP53, and SMAD4 and other 
regulators of TGFb pathway (Maitra & Hruban, 2008). Studies of GEMMs 
incorporating these additional mutant alleles to the expression of mutant Kras in 
the pancreatic compartment have supported the proposed model of progression 
to PDAC. Specifically, mice harbouring monoallelic and biallelic loss of the 
p16Ink4a/p19Arf and Trp53 genes (Aguirre et al., 2003; Bardeesy et al., 2006), the 
concomitant expression of dominant-negative forms of p53 (Hingorani et al., 
2005), or the ablation of the type II TGF-β  receptor (Ijichi et al., 2006) develop 
invasive and metastatic PDAC (Fig. I10).  
In the above described mice, mutant Kras expression is activated in progenitor 
cells during pancreas organogenesis and, therefore, all cells in the adult pancreas 
express the mutant allele, not allowing to determine the cell of origin of 
preneoplastic lesions and PDAC. In this regard, attempts to induce PanINs from 
ductal cells by regulating expression of Kras with the promoters of the ductal 
markers cytokeratin-19 (Brembeck et al., 2003), Hnf1b (Diersch et al., 2015), or 
Sox9 (Kopp et al., 2012) did not lead to PanINs or PDA. In contrast, a GEMM 
harbouring an active Kras carrying a G12V mutation expressed under the 
Elastase promoter during late embryonic development, and therefore expressed 
in the acinar compartment, reproduced the development of PanIN lesions as well 
as invasive PDAC with an incidence and latency similar to those observed in mice 
expressing KrasG12D from pancreatic progenitors (Guerra et al., 2007). These 
observations, together with other studies, provided evidence that PanINs and 
PDAC can originate from acinar cells (De La O et al., 2008; Guerra et al., 2007; 
Habbe et al., 2008) and that ductal cells appear to be more resistant to mutant 
KRas-induced transformation. Indeed, these results support the model described 
above where acinar-to-ductal metaplasia might be the earliest pancreatic lesion 
and, as such, the precursor of low-grade PanINs (Storz, 2017). 
As commented, pancreatitis is a risk factor for PDAC development and this 
observation has been harnessed in mouse models to accelerate pancreatic 
carcinogenesis. Actually, when Kras is activated in acinar cells in the post-natal 
pancreas of 8-week-old mice, cells are refractory to the development of PanINs 
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and PDAC (Guerra et al., 2007). Only when mice are subjected to chronic 
pancreatitis neoplastic events, both PanIN and PDAC, are observed (Guerra et al., 
2007, 2011). In addition, carcinogenesis is enhanced in mice with embryonic 
expression of mutant Kras when subjected to even a single episode of acute 
pancreatitis (Carrière, et al., 2009; Carrière, et al., 2011; Flandez et al., 2014).  
 
Figure I10. GEMMs for PDAC study. Expression of Cre recombinase, regulated by pancreas-
specific promoters (PSP), leads to conditional activation of mutant Kras allele in the pancreas; 
which induce development of PanINs. PanINs can progress to PDAC in cooperation with loss of 
tumour suppressor genes, including p53, p16Ink4a/p19Arf, Smad4, and Tgfbr2. Nongenetic 
events, such as induction of pancreatitis by cerulein, cooperate with oncogenic Kras in PanINs to 
promote progression to PDAC. Adapted from Pérez-Mancera, et al., 2012 
 
In addition to the known genes whose mutation contributes to PDAC 
progression, it is very likely that PDAC can progress through alterations in other 
genes whose role in PDAC progression has not been described yet. The use of 
transposons has allowed uncovering those genes through an agnostic approach. 
Transposons are DNA transposable elements that are recognized by 
transposases, which can mobilize the transposons along the genome in an “excise 
and jump” mechanism. There are 2 well-described transposition systems that 
can promote the development of solid tumours: Sleeping Beauty and PiggyBac. 
They have gene-trapping features that capture upstream exons to inactivate 
potential tumour suppressor genes (loss-of-function activity). The transposons 
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can also include a strong promoter element to ectopically activate the expression 
of potential proto-oncogenes or dominant-negative forms of tumour suppressor 
genes (gain-of-function activity). The tropism of insertional mutagenesis is 
controlled by tissue-specific transposase alleles. Although this biallelic system 
can promote neoplasms in certain tissues by itself (such as in colon), in the 
pancreas it was observed that the KrasG12D allele was required to sensitize the 
mice for the development of PDAC. A study using Sleeping Beauty system 
showed that this technology promoted early lethality from PDAC, and analyses of 
common insertion sites in this screen revealed that the TGF-β and Rb/p16Ink4a 
pathways were affected, confirming the relevance of this approach (Pérez-
Mancera et al., 2012). In addition, this study identified the deubiquitinase USP9X 
as a major tumour suppressor in pancreatic carcinogenesis.  
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3. GATA TRANSCRIPTION FACTORS 
3.1. The origin and molecular structure of the GATA family 
 GATA proteins are a family of transcription factors that are involved in a 
variety of physiological and pathological processes. All GATA members contain a 
highly conserved DNA binding domain consisting of two zinc fingers of the motif 
Cys-X2-Cys-X17- Cys-X2-Cys (Tsai et al., 1989) that directs binding to the 
nucleotide sequence element (A/T)GATA(A/G) (Ko & Engel, 1993). Although all 
GATA proteins contain two Zn finger domains, a number of reports have 
demonstrated that only the C-terminal zinc finger and an adjacent basic domain 
are necessary for specific DNA binding in vitro (Omichinski et al., 1993; Visvader 
et al., 1995). 
GATA-like transcription factors have been studied in invertebrates such as D. 
melanogater and six different GATA members have been identified in vertebrates 
displaying  more than 70% conserved in the Zn finger domain, while the 
sequences of the amino-terminal and carboxyl-terminal domains exhibit lower 
similarity  (Morrisey et al., 1997). According to traditional phylogenetic analysis 
and tissue expression profiles, GATA proteins can be divided into two 
subfamilies: GATA1/2/3 are expressed in hematopoietic cell lineages and are 
essential for differentiation of erythrocytes and megakaryocytes, proliferation of 
hematopoietic stem cells and development of T lymphocytes (Shimizu & 
Yamamoto, 2016). However, their expression is not limited to hematopoietic 
lineages, as they also play an important role in the development of brain, spinal 
cord and inner ear (George et al., 1994; Lilleväli, et al., 2004; Nardelli, et al., 
1999). In contrast, GATA4/5/6 are considered the mesodermal-endodermal 
group as these proteins were initially found to be expressed in tissues with this 
embryonic origin, such as heart, gut, liver and gonads (Lavemiere et al., 1994; 
Molkentin, 2000). However, such histotypic classification is no longer supported 
by the fact that both "hematopoietic" and "endodermal" GATAs are involved in 
the development of tissues with a different embryonic origin than originally 
described (i.e. GATA4 and GAT6 in central nervous system or GATA1 in testis, 
Fig. I11). Yet, a study analysing the phylogenetic relationship between GATA 
proteins revealed that the two subfamilies cluster separately, indicating that this 
classification is consistent with their initially described functions (He et al., 
2007). 
3.2. Gata4 and Gata6 as main factors controlling pancreatic organogenesis 
The first evidence of GATA4 and GATA6 being expressed in the pancreas 
appeared in a study where mRNA expression was assessed in all human tissues 
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by northern blotting (E. Suzuki et al., 1996). It was found that in adult, GATA6 
was expressed at high levels in heart, ovary, lung and pancreas. Conversely, 
GATA4 was expressed at highest levels in testes, pancreas, ovary and heart, 
showing that both GATA members are expressed in pancreas, ovary and heart. 
Although GATA4 and GATA6 transcripts could not be detected in human 
embryonic pancreas (E. Suzuki et al., 1996), many reports subsequently showed 
that these transcription factors play a key role in mouse pancreas development. 
Figure I11. GATA factors in tissue development. Schematic representation showing which 
GATA factors are required for the development of a variety of tissues. As depicted, the hystotypic 
classification dividing them as "hematopoietic" (GATA1/2/3) or "endodermal-mesodermal" 
(GATA4/5/6) is no longer supported as GATA4/6 play a role in the development of the central 
nervous system (ectoderm), and GATA1 is needed for the development of testis (endoderm). 
Extracted from Lentjes et al., 2016. 
The specific functions of Gata4 and Gata6 in murine pancreas development have 
not been precisely determined since embryos lacking Gata4 or Gata6 are lethal 
before pancreas formation. Gata4-null mouse embryos are arrested in 
development between E7.0 and E9.5 due to severe developmental abnormalities, 
including lack of a primitive heart tube, lack of foregut and a development 
partially outside the yolk sac (Kuo et al., 1997; Molkentin et al., 1997). Gata6-null 
embryos are lethal shortly after implantation (E5.5) due to a defect in 
extraembryonic tissues that, in turn, affect epiblast development (Koutsourakis 
et al., 1999). Experiments of tetraploid embryo complementation to avoid early 
lethality showed a complete absence of the ventral but not the dorsal pancreas in 
Gata4-/- embryos. Likewise, Gata6-/- embryos displayed a similar, although less 
dramatic phenotype, suggesting a critical role for multiple Gata factors at the 
earliest stages of ventral pancreas development (Watt et al. 2007).  
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Pancreas-specific deletion of Gata4 and Gata6 mediated by Pdx1-driven 
expression of Cre recombinase showed that both genes control pancreas 
organogenesis. Deletion of either Gata4 or Gata6 results in mild pancreatic 
defects that resolve postnatally. However, simultaneous deletion causes severe 
pancreatic agenesis that is attributed to disruption of pancreatic cell 
proliferation, defects in branching morphogenesis and a subsequent failure to 
induce differentiation of progenitor cells. Interestingly, deletion of a single Gata6 
allele in a Gata4-null background severely reduces pancreatic mass, while one 
functional Gata4 allele in a Gata6-null background is sufficient for normal 
pancreatic development, indicating differential contributions of Gata factors to 
pancreas formation. These studies placed Gata factors at the top of the 
transcriptional network hierarchy controlling pancreas organogenesis (Carrasco 
et al., 2012; Xuan et al., 2012). 
Despite these studies unequivocally showing that Gata factors are crucial for 
pancreas development (Rodríguez-Seguí et al., 2012), their specific roles in the 
exocrine and endocrine components have been a matter of discussion and 
controversy. Studies performed in human tissue describing that both GATAs are 
expressed in the pancreas did not address whether expression was in endocrine 
or exocrine compartment (E. Suzuki et al., 1996). In mice, Gata4 was found to be 
expressed in the exocrine pancreas (Decker, et al., 2006; Ketola et al., 2004; 
Nemer, et al., 2003; Ritz-Laser et al., 2005). In addition, some reports using 
RIN1046-38 and glucagonoma and insulinoma cell lines also attributed Gata4 a 
role in the endocrine lineage (Swift et al., 1994), with the ability of activating 
Glucagon expression (Ritz-Laser et al., 2005). Similar results were described for 
Gata6, with some reports describing that it is expressed in the exocrine pancreas 
(Nemer et al., 2003; Ritz-Laser et al., 2005), and others proposing that Gata6 is 
restricted to the endocrine compartment (Decker et al., 2006; Ketola et al., 
2004). However, the conclusions drawn from the later studies may not be 
adequated as they were based on: 
1) In situ hybridisation experiments showing that Gata6 mRNA was expressed at 
E12.5 in the pancreatic epithelium in the same regions as the endocrine 
transcription factor Nkx2.2 and the marker of endocrine progenitors Ngn3 
(Decker et al., 2006). However, detection of Gata6, Nkx2.2 and Ngn3 transcripts 
in similar regions at E12.5 does not imply that Gata6 cannot be expressed in the 
adult exocrine pancreas.  
2) IHC stainings showing that Gata6 was  exclusively expressed in the Islets of 
Langerhans in the adult murine pancreas (Ketola et al., 2004). However, the 
Gata6 antibody they used was considered to be not reliable in subsequent 
studies, including the one from Decker et al. 2006. 
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A recent study performed by Martinelli et al.  in our laboratory clarified the role 
of Gata6 in adult pancreas. In this study, it was shown by IHC that Gata6 is 
expressed in the adult pancreas in acinar, ductal and endocrine cells. Although 
antibody reliability had been a controversial issue, the fact that Gata6 signal was 
lost in Gata6-null pancreas indicated high specificity of the antibody.  
In this study, the role of Gata6 in the adult pancreas was investigated by deleting 
the gene specifically in the pancreas during embryo development through Cre 
Recombinase expressed under the promoter of Ptf1a, which is active starting 
around E9.5. Histology of Gata6-null pancreata of 8-week-old mice looked 
normal. However, transcripts coding for digestive enzymes and regulators of the 
acinar programme -such as Ptf1a, Rbpjl or Mist1- were largely downregulated, 
indicating that Gata6 is required for complete acinar differentiation. 
Mislocalization of the apical marker Muc1 in Gata6-/- pancreata indicated that 
Gata6 is also necessary for establishment of acinar cell polarity. In addition, 
Gata6-null pancreata of 30-week-old mice presented with massive loss of acinar 
cells and replacement by fat, increased acinar apoptosis and proliferation, ADM 
and adipocyte transdifferentiation, indicating that Gata6 is necessary to maintain 
acinar cell identity in the adult pancreas. 
The deleterious effect of Gata6 deletion in acinar cells and the fact that neither 
mouse weight nor response to glucose administration were different in Gata6-
null mice indicated that Gata6 plays a crucial role in the exocrine, but not the 
endocrine, pancreas.  
The role of GATA4 and GATA6 in human pancreas development is evidenced by 
the fact that inactivating mutations in these genes result in pancreas agenesis. 
Regarding GATA6, there are several reports showing that damaging mutations 
cause pancreatic defficiencies. The study with the largest number of cases 
analysed determined that 15/27 cases presenting pancreatic agenesis where due 
to heterozygous mutations in GATA6 (Allen et al., 2012). In addition, other 
studies (most of them case-report studies) have shown that GATA6 mutations 
can lead to a broad spectrum of phenotypes, ranging from adult-onset diabetes 
without exocrine insufficiency, to pancreatic malformations/hypoplasia (causing 
neonatal diabetes), as well as pancreatic agenesis(Bonnefond et al., 2012; Chao 
et al., 2015; De Franco et al., 2013; Eifes et al., 2013; M. Gong et al., 2013; 
Stanescu et al., 2015; Suzuki et al., 2014; Yau et al., 2017; Yorifuji et al., 2012). In 
the case of GATA4, it has been found that inactivating mutations and deletions 
cause neonatal or childhood-onset diabetes, with different degrees of exocrine 
insufficiency (Shaw-Smith et al., 2014). Although one report has also attributed a 
mutation in GATA4 causing heart defects together with pancreas agenesis, the 
presence of the same mutations in other individuals was only associated to 
cardiac defects with no signs of pancreas affectation, indicating that the two 
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pathologies were attributable to two independent events, and that mutation of 
GATA4 might not be the cause for the pancreas affectation (D’Amato et al., 2010). 
In addition to the already referred study, mutations in GATA4 may cause cardiac 
developmental defects (Garg et al., 2003; Pehlivan et al., 1999). Actually, many 
studies have attributed a crucial role of GATA4 in heart development both in 
human and mouse (Borok & Papaioannou, 2015; Holtzinger & Evans, 2005; Kuo 
et al., 1997; Molkentin et al., 1997; Pu et al., 2004; Watt et al., 2004; Zhao et al., 
2008). In the case of GATA6, although it is not necessary for early heart 
development (Zhao et al., 2005), it also plays a role in cardiogenesis as some 
mutations -also causing pancreatic defects- result in alterations in heart 
development (Eifes et al., 2013; M. Gong et al., 2013). Altogether, these studies 
highlight the importance of these transcription factors in the development of 
multiple organs. 
3.3. GATA6 in PDAC 
The role of GATA6 in pancreatic carcinogenesis has also been a field of 
discussion and controversy. Based on the occurrence of GATA6 
gains/amplifications in some tumours, an oncogenic role was proposed for 
GATA6 in PDAC (Fu, et al., 2008; Kwei et al., 2008). This notion was supported by 
in vitro assays showing that siRNA-mediated knockdown of GATA6 in pancreatic 
cancer cell lines with amplification led to reduced cell proliferation, cell cycle 
progression, and colony formation (Kwei et al., 2008); and that forced 
overexpression of GATA6 in MiaPaca2 cells resulted in increased proliferation 
and growth in soft-agar (Fu et al.. 2008). However, the number of tumours 
studied was relatively small in both studies, and in vitro assays did not provide 
mechanistic insights on the putative role of GATA6 as an oncogene. In addition, 
another study showed that high GATA6 levels were found in well-differentiated 
tumours and were associated with better patient outcome (Zhong et al., 2011), 
suggesting that GATA6 function in pancreatic cancer progression could be more 
complex than originally proposed.  
Recently, and contrary to what had been published earlier, studies using mouse 
models of pancreatic cancer have attributed Gata6 a tumour suppressor role. It 
has been shown that Gata6 deletion renders acinar cells more sensitive to 
KrasG12V, thereby accelerating tumour progression. In addition, Gata6 
expression is lost in KrasG12V-driven PDAC, specifically in poorly differentiated 
tumours. Mechanistically, it was proposed that Gata6 exerts its tumour-
suppressive effect through the promotion of cell differentiation, the suppression 
of inflammatory pathways, and the direct repression of the cancer-related EGFR 
pathway, which is upregulated in the normal and preneoplastic Gata6-null 
pancreas as well as in GATA6-silenced human PDAC cells (Martinelli et al., 2015). 
Other reports have also linked loss of Gata6 activity to dedifferentiation of acinar 
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cells and enhanced tumourigenesis in the KrasG12D mouse model, in this case 
through nicotine administration (Hermann et al., 2014). The mechanisms 
through which GATA6 promotes differentiation of tumour cells were further 
dissected by Martinelli et al., 2016. They found that GATA6 inhibits the 
epithelial–mesenchymal transition (EMT) in vitro and cell dissemination in vivo 
through a unique pro-epithelial and anti-mesenchymal function. Furthermore, 
they observed that GATA6 is commonly lost in tumours with altered 
differentiation, which have acquired a basal-like molecular phenotype. In 
humans, presenting with a basal-like GATA6-low tumour is linked to shorter 
survival and a distinctly poor response to adjuvant 5-fluorouracil (5-
FU)/leucovorin (Martinelli et al., 2016). 
Experiments where PDAC genomes have been analysed by next generation 
sequencing (NGS) technology have confirmed that GATA6 is amplified in a subset 
of tumours, and in some studies this amplification has been linked to tumours 
with better outcome (P. Bailey et al., 2016; Murphy et al., 2016; Waddell et al., 
2015). Interestingly, GATA6 has also been found to be hypermethylated in 
another subset of tumours with basal-like features presenting the poorest 
survival (P. Bailey et al., 2016), supporting its tumour suppressor role in human 
PDAC. 
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During embryo development, Gata4 and Gata6 play a crucial role in pancreas 
organogenesis. In the adult pancreas Gata6 is required for acinar cell 
hoemostasis and acts as a tumour suppressor in pancreatic carcinogenesis, yet 
the role of Gata4 has not been studied.  
 
We hypothesize that Gata4 might also be an important regulator of pancreas 
homeostasis and we aim to investigate whether it also plays a role in pancreatic 
tumourigenesis. Therefore, in this work we set the following objectives: 
 
1. To define the role of Gata4 in pancreas homeostasis.  
 
2. To define the role of Gata4 during pancreatic damage and recovery. 
 
3. To dissect the function of Gata4 during pancreatic carcinogenesis in a mouse 
model of pancreatic cancer. 
 
4. To analyse whether Gata4 plays a role in human pancreatic carcinogenesis and 
whether it functions as a tumour suppressor or an oncogene. 
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1. MOUSE STRAINS  
Mouse strains used in the experiments were in a predominant C57BL/6 
background with the following genetic modifications (alone or in combination): 
Ptf1a+/Cre (Chris Wright, Vanderbilt University; Kawaguchi et al., 2002), 
Gata4lox/lox (Jackson Laboratory; Watt, et al., 2004), Kras+/LSL-G12Vgeo (Mariano 
Barbacid, CNIO; Guerra et al., 2003), Ptf1a+/CreERT2 (Chris Wright, Vanderbilt 
University; Pan et al., 2013), Reg3b-/- (Juan Iovanna, Centre de Recherche en 
Cancérologie de Marseille; Lieu et al., 2006), Trp53lox/lox (Jackson Laboratory; 
Donehower et al., 1992), Rosa26YFP/YFP (Philippe Soriano, Icahn School of 
Medicine at Mount Sinai; Soriano, 1999). Mice were bred to generate the 
different strains used in the study (Table M1) and maintained under sterile and 
pathogen-free conditions at the animal room of CNIO. Experiments were 
approved by the Animal Ethical Committee of Instituto de Salud Carlos III and 
performed following guidelines for Ethical Conduct in the Care and Use of 
Animals.  
 
Strain Short name Procedures/Experiments 
Wild-Type WT Acini culture (IHC), Pancreatic Duct Ligation 
Ptf1a+/Cre; Gata4lox/lox Gata4P-/- 
IHC, RT-qPCR, RNAseq, glucose tolerance 
test, mild acute pancreatitis, in vitro ADM, 
conditioned medium. 
Ptf1a+/Cre; Kras+/LSL-G12Vgeo; 
Gata4lox/lox 
Kras*;Gata4P-/- 
IHC, histopathological analysis, severe acute 
pancreatitis, RNAseq, acini culture (RT-
qPCR), in vitro ADM, conditioned medium. 
Ptf1a+/CreERT2; Kras+/LSL-G12Vgeo; 
Rosa26YFP/YFP; Gata4lox/lox 
i-Kras*;Gata4P-/- 
TMX administration, chronic pancreatitis (2 
and 6 months), histopathological analysis. 
Ptf1a+/Cre; Kras+/LSL-G12Vgeo; 
Trp53lox/lox; Gata4lox/lox 
Kras*;Trp53-/-
;Gata4-/- 
Histopathological analysis, survival. 
Ptf1a+/Cre; Kras+/LSL-G12Vgeo; 
Trp53+/lox; Gata4lox/lox 
Kras*;Trp53+/-; 
Gata4-/- 
Survival 
Reg3b-/- Reg3b-/- In vitro ADM 
Table M1. Strains generated for this work and corresponding procedures/experiments. In all 
experiments, we included control mice harbouring wild-type alleles of those represented in bold.  
2. IN VIVO PROCEDURES 
2.1. Recombination in i-Kras*;Gata4P-/- mice 
Recombination was achieved by administrating 3 doses of 4-Hydroxytamoxifen 
(TMX) via gavage to 8-10 week old mice. On days 1 and 3, mice received 10mg  
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TMX diluted in 100μl of a solution containing 10% EtOH, 90% Saline; and at day 
5, mice received 5mg of TMX in 50 μl of the same solution. After the last dose of 
TMX, mice were free of treatment at least for 1 week before proceeding with 
further experimental manipulation. 
2.2. Caerulein-induced acute pancreatitis 
Induction of a mild acute pancreatitis  
Acute pancreatitis was induced by seven hourly intraperitoneal injections of 
caerulein (50μg/kg); saline-treated mice were used as experimental controls. 
Mice were sacrificed by cervical dislocation at 24 hours, 48 hours, 7 days and 14 
days after the treatment. The pancreas was quickly collected: one piece was flash 
frozen and stored at -80 ºC for subsequent RNA analysis, and the rest of the 
pancreas was fixed for subsequent histological analysis. A minimum of 3 
mice/group were included as saline controls and 6 mice/group were used in 
each pancreatitis timepoint.   
Induction of a severe acute pancreatitis  
A severe acute pancreatitis was induced by seven hourly intraperitoneal 
injections of caerulein (50μg/kg) during two non-consecutive days, with 24 
hours intermission. Pancreatitis was induced at "early" and "late" timepoints in 
cohorts of 20-week-old and 40-week-old mice, respectively. The "early" cohort 
included Kras* (n=4) and Kras*;Gata4P-/- (n=8) mice; and the "late" cohort 
included Kras* (n=7) and Kras*;Gata4P-/- (n=6) mice. All mice were sacrificed at 1 
year of age by cervical dislocation, and the pancreas was collected for 
histological analysis. 
2.3. Caerulein-induced chronic pancreatitis  
Chronic pancreatitis was induced by daily injection of one dose of caerulein 
(5μg/mouse in 100μl of saline). In order to test whether chronic administration 
of caerulein could accelerate PDAC formation, a cohort of 10-12 week-old mice 
including i-Kras* (n=6) and i-Kras*;Gata4P-/- (n=9) was treated during 6 months  
and allowed to further age for 3 months until reaching 1 year of age. In order to 
test whether chronic administration of caerulein could accelerate PanIN 
development, a cohort of 10-12 week-old mice including i-Kras* (n=4) and i-
Kras*;Gata4P-/- (n=6) was treated for 2 months. At the end of the protocol, mice 
were culled by cervical dislocation and the pancreas was collected for 
histological analysis. 
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2.4. Intrapancreatic adenoviral administration  
Mice were appropriately anesthetized and a small incision was performed in the 
skin and peritoneum at the upper left quadrant to expose the pancreas. 
Adenovirus (1x109 plaque-forming units [pfu] in 50 μl of saline) encoding either 
GFP (Ad-EGFP) or IL-17A (Ad-IL-17A) (Schwarzenberger et al., 1998) were 
injected directly into multiple sites of the pancreas of 10 week-old mice. A cohort 
of Kras* (n=5) and Kras*;Gata4P-/- (n=5) mice were injected with Ad-EGFP, and 
another cohort with the same number of mice was injected with Ad-IL-17A. 
Mouse serum was collected prior to virus infection, 2 weeks post-infection, and 6 
weeks post-infection, before sacrifice. Mice were sacrificed by cervical 
dislocation and pancreas was quickly processed: a piece of tissue was snap-
frozen for RNA analysis and the remaining tissue was collected for histological 
analysis.  
2.5. Glucose Tolerance Test 
Male mice were fasted overnight and basal glycaemia was measured from tail 
blood. Mice were administered a glucose solution of 2g/kg intraperitoneally, and 
glycaemia was measured at indicated timepoints using an automated glucose 
monitor. A minimum of 13 mice was used in each group. 
2.6. Pancreatic Duct Ligation  
A laparatomy was performed in 8-10-week-old wild type mice through a midline 
abdominal incision. The pancreatic ducts of the gastric and the splenic segments 
were ligated as described in Wang, et al., 1995. A double ligature was performed 
around the pancreas, just next to the blood vessels, in a region close to the great 
curvature of the stomach marked by the cranial mesenteric lymph nodes. The 
ligation totally obstructed exocrine flow from the gastrosplenic portion of the 
pancreas, which accounts for 50-60% of the entire pancreas. 
 
3. EX VIVO PROCEDURES  
3.1. Acinar cell isolation 
Mice were sacrificed by cervical dislocation, and the skin and peritoneum were 
excised to expose viscera. A solution of Collagenase P (Roche) in HBSS at 
1.33mg/ml was injected into different sites of the pancreas. After removal and 
placement in Collagenase P solution, the pancreas was cut into small pieces, and 
digested at 37 ºC for 20min in a shaking water bath. The resulting cell 
suspension was washed with HBSS 5% FBS, filtered through 105μm mesh to get 
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rid of islets and non-digested tissue. Finally, isolated acinar cells were placed on 
top of an HBSS 30% FBS solution and centrifuged to get rid of dead cells. Acinar 
cells were cultured in all cases in the following complete medium: RPMI 
supplemented with 1x sodium pyruvate, 1x Penicillin/Streptomycin, and 
Soybean Trypsin Inhibitor (STI) at 0.1mg/ml, and FBS at different 
concentrations depending on the experiment. 
3.2. Acinar culture for RNA and IHC analysis 
Isolated acinar cells were resuspended in complete medium with 10% FBS and 
cultured in suspension in anti-adherent Petri dishes at 37 ºC, 5% CO2. After 48h, 
cells were collected, centrifuged, and the pellet was resuspended in fresh 
medium. Cells were cultured in the same conditions for an additional 48h. 
For RNA extraction, an aliquot of cell suspension was taken 24h after seeding 
cells, washed with PBS, and RNA was isolated using Mammalian Total RNA 
Miniprep Kit (Sigma) according to manufacturer’s indications. 
For IHC analysis, freshly isolated acini and acinar cells cultured for 72h were 
taken, washed with PBS, fixed in PBS-buffered 4% formalin for 2h and 
resuspended in 2% low melting point Agarose. Acini embedded in agarose were 
included in paraffin to make blocks. Sections of 3μm were cut and 
immunohistochemical stainings were performed as described in section 4.2. 
3.3. Medium conditioned by acinar cells and macrophage treatment 
Isolated acinar cells were resuspended in RPMI supplemented with 1% FBS for 
48h. The medium was collected, filtered through 45μm filters to remove debris 
and stored at -80 ºC.  
Immortalized RAW264.7 macrophages were cultured in DMEM supplemented 
with 10% FBS until reaching 50-60% confluence. Then, medium was removed 
and medium conditioned by acini was added for 24h. Finally, cells were lysed 
and RNA was isolated using Mammalian Total RNA Miniprep Kit (Sigma) 
according to manufacturer’s indications. 
3.4. In vitro ADM induction 
Isolated acinar cells were resuspended in complete medium supplemented with 
1% FBS and growth factor-reduced matrigel at proportion 1:1. Acini were plated 
at appropriate concentration in wells of a 96-well plate previously coated with a 
thin layer of matrigel. After polymerization of matrigel-acini suspension, medium 
containing the indicated factors was added at the indicated concentrations: 
EGF (50ng/ml), IL17 (50ng/ml), IL6 (50ng/ml), IL1b (50ng/ml), IL2 (50ng/ml), 
IL4 (50ng/ml), IL10 (2ng/ml), Reg3b (500nM), Ccl5 (50ng/ml), Cxcl12 
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(50ng/ml). Medium was changed after 48h culture (day 3), and 48h later (day 5) 
number of cysts/well was quantified under the microscope. 
4. HISTOLOGICAL ANALYSIS 
4.1. Tissue preparation and histopathological analysis 
Mouse pancreata were placed in 4% PBS-buffered formaldehyde and fixed 
overnight. After fixation, they were embedded in paraffin and serially sectioned 
(3μm). Sections from at least 3 representative areas of the whole tissue (150-
200μm separation in thickness) were deparaffinized, stained with hematoxylin-
eosin (H-E) and subjected to histopathological analysis. Evaluation of all 
carcinogenesis experiments was performed by Dr. Irene Espósito (Institute of 
Pathology, Heinrich-Heine-University, Düsseldorf). Quantification of the area 
affected by ADM/PanIN or by lipomatosis (and its degree) was assessed through 
visual inspection of pancreas sections and not through computerized analysis. 
Evaluation of the pancreatitis experiments in Gata4P-/- and control mice was 
performed by Dr. Mar Iglesias (Departament de Patologia, Hospital del Mar, 
Barcelona).  
In order to quantify the area affected by PanIN and ADM in i-Kras*;Gata4P-/- and 
control mice induced with a chronic pancreatitis for 2 months, sections were 
digitally scanned (Mirax Scan, Zeiss) and processed according to pixel intensity. 
We took advantage of the fact that areas of PanIN and ADM have lumina that 
appear light-coloured in the H-E histology. We therefore trained the analysis 
software (AxioVision 4.6 software package, Zeiss) to distinguish areas of tissue 
including light-coloured pixels (damaged) from areas presenting darker pixels 
(not damaged). The software quantified the two types of areas and the total area, 
so that we were able to calculate percentage of damaged tissue. 
Images from stained tissue sections were acquired with a Nikon Eclipse Ti 
microscope and managed with NIS-Elements BR3.2 software.  
4.2 Immunohistochemical analysis 
Paraffin-embedded tissue sections were deparaffinized in xylol, rehydrated with 
solutions of absolute, 96% and 70% EtOH, and distilled water. Sections were 
then boiled in 10mM sodium citrate buffer (pH 6.0) for 10 min to retrieve the 
antigens. Next, sections were incubated for 30 min with 3% H2O2 in methanol to 
block endogenous peroxidase and permeabilize cell membrane. Sections were 
washed with distilled water and blocked for 30 min with 2% BSA in PBS at room 
temperature. After blocking, the sections were incubated with primary 
antibodies, diluted in PBS with 2% BSA, for 1h at room temperature or overnight 
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at 4ºC. Next, sections were washed in PBS three times for 10min and incubated 
for 45min with EnVision+ HRP labeled secondary anti-rabbit antibodies (Dako). 
After this, sections were washed again and the signal was obtained using DAB+ 
Chromogen system (Dako). Finally, sections were rinsed with water, 
counterstained for 2min with Carazzi´s Hematoxylin solution DC (Panreac), 
dehydrated with increasing concentrations of alcohol, then with Xylol, and 
mounted using DePeX mounting medium (Gurr). The primary antibodies used 
are listed in Table M2.  
Images from stained tissue sections were acquired with a Nikon Eclipse Ti 
microscope and managed with NIS-Elements BR3.2 software. Quantification of 
Mcm4+ and Ki67+ cells in control and Gata4-/- pancreata was performed by 
counting the proportion of positive cells in 5 random fields in the pancreas of >4 
mice/genotype.  
 
Antibody Company, reference Dilution 
Goat α-Gata4 Santa Cruz, SC-1237 1:1000 
Rabbit α-Ki67 Novocastra, NCL-Ki67p 1:1000 
Rabbit α-Mcm4  Polyclonal sera provided by Dr. Juan Méndez, CNIO 1:400 
Rat α-Krt19 Developmental Studies Hybridoma Bank, Troma III 1:1000 
Rabbit α-cleaved Caspase-3  Cell Signaling, 9661 1:1000 
Mouse α-gH2Ax Ser139  Upstate, 05-636,  1:2000 
Rabbit α-p65 Santa Cruz, SC-372 1:500 
Rabbit α-phospho-Stat3 Tyr705  Cell Signaling, 9145  1:200 
Rabbit α-P53 Leica Byosistems NCL-L-p53-CM5p 1:500 
Rabbit α-phospho-Gata4 Ser105 Abcam, ab5245  1:100 
Mouse α-GFP (also for eYFP) Roche, 11814460001  1:250 
Goat α-Hnf1b  Santa Cruz, SC-7411 1:500 
Rabbit α-Sox9  Millipore, AB5535  1:500 
Mouse α-Glucagon Sigma, G2654 1:500 
Rat α-F4/80 ABD Serotec, MCA497 clone CI:A3-1 * 
Rabbit α-Myeloperoxidase Dako, A0398 * 
Goat α-Cd3e Santa Cruz, SC-1127 M-20 * 
Goat α-Pax5 Santa Cruz, SC-1974 C-20 * 
Rabbit α-Reg3b Provided by Dr. Juan Iovanna, CRCM 1:400 
Guinea pig anti-Insulin Dako, A0564  1:500 
Table M2. Antibodies used in immunohistochemical analyses. For some antibodies, the 
dilution is indicated with (*) as it was performed in CNIO histopathology unit. 
4.3. Immunofluorescence analysis 
Tissue sections were processed as described in the previous paragraph, but 
skipping the blocking step with hydrogen peroxide. After incubation with the 
primary antibody (Table 3), sections were washed with PBS and incubated with 
a fluorescently-labeled secondary antibody at 1:200 dilution (Table M3). Next, 
sections were washed with PBS twice and with distilled H2O once, and incubated 
with DAPI (0.5μg/ml in dH2O). Finally, tissues were mounted using ProLong® 
Gold Antifade Reagent (Life Technologies). Images were acquired using a 
confocal microscope (TCS SP5, Leica). 
Comentario [M1]: Revisando los 
anticuerpos que mencionas en 
resultados faltan: Muc1, E-cad, YPF, 
Glucagon. 
Muc1: tabla IF 
E-cad: tabla IF 
YFP: el mismo que GFP. indicado 
Glucagon: OK, need to check in the 
notebook 
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1ary Ab (dilution) Company, reference 2ary Ab, spectra Company, reference 
Rabbit anti-Muc1 
CT-1 (1:100) 
Provided by (Ref) Goat anti-rabbit,  
Alexa Fluor 555 
Thermofisher,  
A-21428 
Mouse anti-               
E-cadherin (1:200) 
BD Transduction 
laboratories, #610182 
Goat anti-Mouse, 
Alexa Fluor 488 
Thermofisher,  
A-11001 
Table M3. Antibodies (Ab) used in immunofluorescence analysis. Ref: Pemberton L, et al. 
Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout 
mammals. Biochem Biophys Res Commun 1992;185:167–75 
4.4. Alcian Blue + P.A.S. staining 
Sections were deparaffinized as described in section 2.2 and placed in distilled 
water. Alcian blue/Periodic acid-Schiff/Hematoxylin stain was performed using 
an automated staining platform (ArtisanLink Pro, Dako). In this procedure, slides 
were incubated in Alcian Blue solution for 5 minutes at 35ºC, in Periodic acid-
Schiff for 13 minutes at room temperature, and in Mayer hematoxylin for 1 
minute at room temperature; washing the slides between each step. The acidic 
mucins and neutral mucins vary in color (blue and magenta). The colour of the 
resulting staining in mixtures of acidic and neutral mucins depends on the 
dominant entity, and will range from blue-purple to violet or mauve. 
Hematoxylin provides nuclear counterstain. Finally, the slides were dehydrated, 
cleared and mounted with a permanent mounting medium for microscopic 
evaluation. 
4.5. Evaluation of human TMA 
A series of 23 evaluable cases was analysed. Only cases presenting one core with 
areas of normal pancreas with strong positivity in acinar cells were considered 
valid. A total of 18 different cases of normal pancreas as well as 27 low-grade 
PanIN, 2 high-grade PanIN, and 20 PDAC were scored for staining intensity. 
To determine histoscore (HS), we assigned a value for the intensity of staining, 
ranging from 0 (null) to 3 (strong). If the lesion was heterogeneous, we 
estimated the proportion of reactive cells showing a given intensity. We then 
multiplied percentage of cells to degree of staining and obtained a value ranging 
from 0-300. For lesions in different cores belonging to the same case, we did the 
average of the HS. We then classified HS values as follows: negative (0-49), low 
(50-99), intermediate (100-199), high (200-300).  
 
Comentario [PR2]: source fo 
samples, informed consent, study, all 
that... Aquesta info no sé molt bé 
d'on treure-la, ho veiem junts 
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5. RNA ANALYSIS  
5.1. RNA isolation 
Pieces of mouse pancreas were homogenized using T10 basic ULTRA-TURRAX 
homogenizer (IKA) in GTC buffer (4M Guanidine thiocyanate, 0.1M Tris-HCl, 1% 
2-Mercaptoethanol, pH 7.5, prepared in DEPC treated water) and total RNA was 
extracted using Phenol-Chloroform method (Chirgwin et al., 1979).  
5.2. Reverse transcriptase and quantitative PCR (RT-qPCR)  
RNA was treated with DNase (DNA-free™ DNase Treatment & Removal Reagents, 
Ambion). mRNA was retro-transcribed with TaqMan® Reverse Transcription 
Reagents kit (Invitrogen). Quantitative PCR was performed using SYBR® Green 
PCR Master Mix in the 7500 Fast Real-Time PCR System for PCRs<96 samples 
and the QuantStudio 6 Flex system for PCRs >96 samples (both reagents and PCR 
machines from Thermofisher). mRNA expression was normalized with Hprt 
levels and calculated as fold-change over control samples. Primers used in this 
study are listed in Table M4. 
 
Transcript Forward primer Reverse primer 
Hprt GGCCAGACTTTGTTGGATTTG TGCGCTCATCTTAGGCTTTGT 
Ptf1a ACAAGCCGCTAATGTGCGAGA TTGGAGAGGCGCTTTTCGT 
Mist1 CCTTCAACTCTCCAGGGAAA GCCACCACACATGCAATT 
Cpa1 TACACCCACAAAACGAATCGC GCCACGGTAAGTTTCTTGAGCA 
Amy2a5 TGGCGTCAAATCAGGAACATG AAAGTGGCTGACAAAGCCCAG 
Pnlip ACAGATCAACACCCGCTTTC CGGGTTTTTCTGTTTGTTCG 
Cela1 TGTGTCACACCCCTACTGGA TTGTTAGCCAGGATGGTTCC 
Cel AAGTTGCCCGTGAAAAAGCAG ATGGTAGCAAATAGGTGGCCG 
Pdx1 AAATCCACCAAAGCTCACGC CGGTCAAGTTCAACATCACTGC 
Hnf1a TAATAGGGCGGAGTGCAT GGTCCGTTATAGGTGTCCAT 
Gata6 GGTGCTCCACAGCTTACAGG CACAGTGGCGTCTGGATG 
Nr5a2 ATGTCCTGTGTGTGGCGATA TCTGCGTTTTGTCAATTTGG 
Cd3e CGTCTACTGCTTTGCAGGACAT CGATCTCGAAGAGGCTGATACA 
Ccl5 GCCTCACCATATGGCTCGGACA CCTTGACGTGGGCACGAGGC 
Ccl19 GAAAGCCTTCCGCTACCTTC CTGGTCTGGAGGTGCACAG 
Icam1 CGCTGTGCTTTGAGAACTGTG ATACACGGTGATGGTAGCGGA 
Cxcl12 TGCATCAGTGACGGTAAACCA CACAGTTTGGAGTGTTGAGGAT 
Cxcr4 TGGAACCGATCAGTGTGAGT GGTGGGCAGGAAGATCCTAT 
Reg3b GGCTTCATTCTTGTCCTCCA AGATGGGTTCCTCTCCCAGT 
Cxcl10 GCTGCCGTCATTTTCTGC TCTCACTGGCCCGTCATC 
Cxcl11 GGCTGCGACAAAGTTGAAGTGA TCCTGGCACAGAGTTCTTATTGGAG 
Nfkb TGTCTGCTGCTGCTGGTGGC CCACGTGGGCATCACCCTCC 
RelA TCTGGCGAATGGCTTTACTT CTCCACATAAGGCCCAGAAG 
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Mmp9 GCAGAGGCATACTTGTACCG TGATGTTATGATGGTCCCACTTG 
Cxcl16 TTGGCACGGATCAGCGCCTTC CCATCGCCTGGCAGGGTCAGC 
Table M4. Sequences of primers used to detect the specified target genes mRNA. All sequences 
are expressed as 5'-3'. 
5.3. RNAseq of mouse pancreata 
Kras* and Kras*;Gata4P-/- mice  
Pancreata from 6 Kras* and 6 Kras*;Gata4P-/- mice were collected and flash-
frozen in liquid nitrogen. Tissue was mashed using a lab mortar and RNA from a 
portion of the whole tissue was extracted as described in section 4.1. Quality of 
RNA was assessed by determining RNA Integrity Number (RIN), and the 3 
samples with higher values (above 8) were sent for library generation and next 
generation sequencing. Total number of reads/sample ranged from 33 to 40 
million reads.  
Control and Gata4P-/- mice 
A piece of pancreas from a number of control (Ptf1a+/Cre) and Gata4P-/- mice was 
processed and RNA was extracted following the protocol described in section 
4.1. RIN was determined and samples with highest values (above 8) were mixed 
to generate pools of 3 different pancreata. A total of 3 pools were sent for library 
generation and deep sequencing. Total number of reads/sample ranged from 35 
to 39 million reads.  
In order to process the data we used Nextpresso v1.4 (Graña, et al., 2016), which 
allowed us to evaluate read quality, align reads to a mouse reference genome, 
and process the alignment to finally obtain a list of Diferentially Expressed Genes 
(DEG) between samples. Lists of DEG were then ordered according to the value 
of the test statistic used to compute significance of the observed change in FPKM 
(test_stat column in output file) and subjected to GSEA using KEGG library and 
an acinar-specific signature extracted from Masui et al., 2010 (Table M5).  
Statistical significance was set at False Discovery Rate (FDR)<0.05. 
 
Acinar-specific gene signature 
Cpa1 Ctrb Rnase1 Ela1 Pnliprp2 Prss3 Cpb1 Ela3b 
Amy2a1 Cpa2 Reg1 Pnliprp1 Ela2a Prss2 Ctrl1  
Klk1 Clps Pnlip Cel Try4 Prss1 Ctrc  
Table M5. Digestive enzyme signature extracted from Masui et al., 2010. 
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5.4. Analysis of transcriptomic data from Bailey, et al. 2016 
Data was extracted from Bailey, et al. 2016 supplementary data (GEO accession 
number GSE36924). Cases were stratified according to GATA4 expression, and 
the ones above the median value were considered GATA4-high, and conversely, 
the ones under the median value were considered GATA4-low. Kaplan-Meier 
plots were performed according to the survival of each patient. The same 
procedure was applied to analyse the cases according to both GATA4 and GATA6 
expression 
For the GSEA analysis, gene expression data of cases on the top and bottom 
quartile according to GATA4 expression was extracted (using the Comparative 
Markers Selection tool from Genepattern). Pre-ranked GSEA analysis was run on 
the list of the indicated genes.  
 
6. CHROMATIN IMMUNOPRECIPITATION + QUANTITATIVE PCR 
(ChIP-qPCR)  
Pancreas from wild-type mice was collected and cut into small pieces. Chromatin 
was cross-linked to proteins with 1% formaldehyde for 10min at room 
temperature. Fixation was stopped by adding glycine (to 0.125 M) for 5min.  
Next, tissue pieces were homogenized in ChIP SDS buffer (100 mM NaCl, 50 mM 
Tris [pH 8], 5 mM EDTA pH 8, 1% SDS) using a Dounce homogenizer. Lysates 
were sonicated at 8 ºC for 30min using a Covaris S2 Focused Ultrasonicator, 
(conditions: 10 Intensity, 10 duty cycle, 200 cycles/burst) yelding DNA 
fragments of 300-500bp.  Lysates were diluted in Triton dilution buffer (100 mM 
Tris [pH=8.6], 100 mM NaCl, 5 mM EDTA, 5% Triton X-100) to reduce SDS 
concentration and allow protein-protein interactions. Chromatin in the lysates 
was pre-cleared by incubating with A/G beads and non-specific IgG for 2h at 4 
ºC. After removing beads from pre-clearing, specific antibodies or non-related 
IgG, together with A/G beads, were added for immunoprecipitation of complexes 
overnight at 4 ºC. For each immunoprecipitation, 1ug of antibody was used (Goat 
anti-Gata4 SC-1237 (Santa Cruz); and same amount of goat IgG were used as 
non-related antibody. Next, beads were washed with Triton dilution buffer, 
mixed micelle buffer (150mM NaCl, 20mM Tris, 5 mM EDTA, 5% sucrose, 1% 
Triton X-100 and 0.2% SDS), buffer 500 (0.1% deoxycholic acid, 1mM EDTA, 
50mM HEPES, 1% Triton X-100 and 500 mM NaCl), LiCl buffer (0.5% deoxycholic 
acid, 1mM EDTA, 250mM LiCl, 0.5% NP-40, 10mM Tris) and Tris-EDTA (TE). 
DNA was eluted in elution buffer (0.1M NaHCO3, 1% SDS) and crosslinks were 
reversed by incubating overnight at 65ºC. RNA and protein were digested using 
RNase A and Proteinase K and DNA was purified by phenol–chloroform 
extraction and ethanol precipitation. Abundance of target DNA in material 
Comentario [M3]: you can include 
sonication conditions (duty 
cycle,etc). Done! 
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subject to ChIP was assessed by qPCR using the following primers (sequences 
are written 5' to 3'): Reg3b Fw: GGTAGTGCTTGGCACAGGTT; Reg3b Rv: 
AGCAGGAGACTGCCTGTGAT; ChIP Negative Fw: TTGGGTGTTGGGAACTGAAT; 
ChIP Negative Rv: CCCTTCTCTGCCTTCTGATG.  
 
7. MULTIPLE SEQUENCE ANALYSIS 
Analysis of protein sequences to determine the relevance of Serine 105 of Gata4 
was performed using the online tool T-COFFEE with the default settings 
(available at http://tcoffee.crg.cat/apps/tcoffee/do:regular). Protein sequences 
of all murine Gata members and Gata4 sequences from different species were 
obtained from the genome browser Ensembl 
(http://www.ensembl.org/index.html) 
 
8. STATISTICAL ANALYSIS 
Statistical analyses of quantitative variables were performed using Mann-
Whitney test in experiments where n<5 and data did not follow a normal 
distribution, and two-tailed Student’s test when n≥5. Data are provided as 
mean±SEM. and P<0.05 was considered significant. Statistical analyses were 
performed using the software GraphPad PRISM version 6.0e.  
Statistics for qualitative variables (presence/absence of PanIN, PDAC, etc.; 
degree of lipomatosis; degree of affectation in pancreatitis) was performed using 
Chi square test except for cases where frequencies<5, that we used Fisher's exact 
test. P<0.05 was considered significant. Statistical analyses were performed 
using the software GraphPad PRISM version 6.0e. 
Statistical analysis of RNAseq data was performed by nextpresso v1.4 software. 
Significance threshold was set at P<0.05 after correcting for multiple testing.  
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1. GATA4 IN PANCREAS PHYSIOLOGY                                         
AND RESPONSE TO DAMAGE 
1.1. Gata4 inactivation in the pancreas does not lead to major alterations in 
exocrine pancreas architecture or function 
GATA4 and GATA6 are the main GATA factors expressed in the normal human 
pancreas (Fig. 1A). To analyse the role of Gata4 in murine pancreatic 
development/homeostasis and compare it to the role of Gata6, we used a mouse 
strain in which exon 3, 4 and 5 of Gata4 are floxed by two LoxP sites and are 
deleted upon Cre recombinase-mediated (Cre) inactivation. Exon 3 and 4 contain 
the Zn finger domains that are necessary for Gata4 binding to DNA, and its 
deletion results in the generation of a null allele (Fig. 1B). In order to achieve 
pancreas-specific deletion we have used a strain in which Cre is expressed under 
the control of Ptf1a (Ptf1a-Cre) at Embrionic stage (E)9-E9.5 in multipotent 
pancreatic progenitors, therefore resulting in Gata4 deletion in all cells of the 
adult pancreas (Fig. 1B). This model will hereafter be referred to as Gata4P−/− 
mouse (P stands for pancreas-specific); the pancreas from these mice will be 
designated as Gata4−/− pancreas. As control for these mice, we used Ptf1a-Cre+/KI 
mice in all experiments. 
Figure 1. Gata4 is expressed 
in the pancreas at high levels 
as well as Gata6. (A) mRNA 
expression of GATA1-6 in 
normal human pancreas, 
showing that GATA4 and 
GATA6 are the GATA factors 
expressed at highest levels. 
Data was extracted from 
www.GTExportal.org. (B) 
Schematic representation of the 
strategy used to delete Gata4 in 
the mouse pancreas. The Gata4 
locus contains 2 loxP sites 
(black circles) flanking exons 3, 
4 and 5 (numbered boxes), 
which contain the Zn finger domains through which Gata4 binds to DNA. Expression of Cre 
Recombinase under the promoter of Ptf1a results in the formation of a null allele. 
 
 
We first assessed Gata4 expression in normal adult pancreas using 
immunohistochemistry (IHC): Gata4 is expressed in all acinar cells, but is 
undetectable in ductal and endocrine cells (Fig. 2A).  The specificity of the 
antibody used was demonstrated using Gata4−/− pancreas, where we did not 
detect any reactivity, also indicating that recombination takes place effectively 
(Fig. 2A). Accordingly, wild-type (WT) Gata4 mRNA was undetectable in Gata4−/− 
pancreas (P=0.036) (Fig. 2B). 
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Figure 2. Gata4 inactivation does not lead to major alterations in pancreas architecture or 
function. (A) IHC showing that Gata4 is expressed in acinar but not in endocrine or ductal cells 
(left panel). Upon recombination, Gata4 expression is efficiently lost in acinar cells in Gata4P-/- 
mice. (B) Normalized mRNA expression of Gata4 mRNA in control (Ctl, n=3) and Gata4P-/- mice 
(G4-/-, n=5) assessed by RT-qPCR (P=0.0357). P>0.05 (ns); P<0.05 (*); P<0.01 (**); P<0.001 (***). 
(C) H&E staining showing that the pancreas of Gata4P-/- mice is histologically similar to control 
mice except for a mild increase in lipomatosis and a weaker eosinophilic staining. (D) 
Histopathological quantification of lipomatosis in Gata4-/- pancreas showing a non-statistically 
significant increase both at <40weeks (P=0.315) and >1 year (P=0.143). (E) Representative 
images and quantification of IHC stainings for markers of proliferation (Ki67) and DNA 
replication machinery (Mcm4), showing no significant differences. IHC stainings for DNA damage 
(gH2aX), apoptosis (cleaved-Caspase 3) and cell polarity (E-cadherin, Muc1) show no differences 
between Gata4P-/- and control mice. Expression of the ductal marker Krt19 is increased in     
Gata4-/- pancreas, both at protein (IHC) and mRNA level (RNA-seq data).  
 
At the histological level, Gata4−/− pancreata of 30-week-old mice did not reveal 
any major abnormalities (Fig. 2C), except for a slightly weaker eosinophilic 
cytoplasm in acinar cells (Fig. 2C) and a non-statistically significant increase in 
lipomatosis both at early (<40 weeks) and late (≥1 year) timepoints (Fig. 2C, 2D). 
These findings might be indicative of a mild compromise in acinar function (Fig.2 
C). 
To further characterize the exocrine pancreas of Gata4−/− pancreata, we analysed 
the expression of markers of specific cell lineages, proliferation, apoptosis, DNA 
damage, and cell polarity. We found an increased expression of Krt19 in the 
cytoplasm of acinar cells, with no differences in expression in ductal cells, 
suggesting an incipient acinar-to-ductal metaplasia (ADM) (Fig. 2E). Accordingly, 
RNA-seq data of Gata4-/- and control pancreata (8 weeks) showed a significant 
increase of Krt19 levels (Fig. 2E). Muc1 and E-cadherin were detected in 
mutually exclusive cell membrane domains, indicating the maintenance of acinar 
cell polarity. We did not find significant differences in the proportion of Ki67 and 
Mcm4-positive cells in control and Gata4−/− pancreata (Fig. 2E). These results are 
unlike those found in 8-week-old Gata6P−/− mice where increased proliferation 
(Ki67, Mcm4), DNA damage (gH2aX), apoptosis (cleaved-Caspase3), and altered 
cell polarity (data not shown) were observed (Martinelli et al., 2012). Even more, 
pancreata of 30-week old Gata4-/- mice looked similar to controls except for a 
higher degree of lipomatosis (Fig. 2D), while Gata6-/- pancreata presented with 
extensive lipomatosis, acinar atrophy and acinar-to-ductal metaplasia (ADM) 
(Martinelli et al., 2012). 
To identify subtle changes in cell differentiation, we performed transcriptomic 
analysis using RNA-seq from whole pancreas of control and Gata4P−/− mice (n=3 
for each group). Principal Component Analysis (PCA) showed that the two 
groups clustered separately, indicating the existence of global transcriptomic 
differences (Fig. 3A). Visual inspection of the data revealed that the top 15 
differentially expressed genes downregulated in Gata4-/- pancreata included a 
number of digestive enzymes such as Trypsin (Try10, Prss3), Lipase (Lpl) and 
RNAse (Rnase1); as well as some members of the Reg family genes (Reg3a, 
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Reg3b, Reg3g, Reg3d). By contrast, the list of top genes upregulated in Gata4-/- 
pancreata was very diverse, including a serine protease (Klk1b4), a 
neuroendocrine peptide (Gal) or angiotensinogen (Atg), which is typically 
expressed in the liver (Table 1). 
We then performed Gene Set Enrichment Analysis (GSEA) comparing both 
transcriptomes in order to identify the pathways that were deregulated in each 
condition. We ran the analyses applying the KEGG library so that a set of gene 
signatures representing the majority of biological processes was assessed.  We 
did not find any statistically significant upregulated pathways in Gata4−/− 
pancreata (Fig. 3B). We only found two pathways that were significantly 
downregulated in Gata4−/− pancreata (FDR<0.05), "PPAR signalling pathway" 
and "Hematopoietic cell lineage". In addition, "Complement and coagulation 
cascades" (FDR=0.08), "Systemic lupus erythematosus" (FDR=0.257) and 
"Primary immunodeficiency” (FDR=0.276) pathways appeared downregulated in 
Gata4P−/− pancreata albeit with a lower statistical significance (Fig. 3B). These 
results suggest that Gata4 might play a role in the regulation of 
inflammatory/immune processes in basal conditions. We also interrogated a 
customized signature that includes an acinar geneset containing genes coding for 
digestive enzymes (extracted from Masui et al., 2010) (Fig. 3C). We found a 
significant downregulated of this signature in Gata4−/− pancreata (FDR=0.002), 
indicating a dysfunction in enzyme production upon Gata4 loss. 
To validate these findings, we used RT-qPCR to analyse the expression of specific 
genes that are important for acinar cell function, including enzymes (Pnlip, 
Amy2a5, Cpa1, Cela1, Cel) and regulators of the acinar programme (Mist1, Pdx1, 
Hnf1a, Ptf1a, Gata6, Nr5a2) (Fig. 3D). According to the results obtained in the 
GSEA analysis applying the Masui et al. signature, we found that the majority of 
digestive enzymes checked by RT-qPCR (Pnlip, Amy2a5, Cpa) were significantly 
downregulated in Gata4−/− pancreata.  However, we also observed enzymes with 
unaltered (Cela1) or even upregulated expression (Cel) in the Gata4-/- pancreas. 
Regarding the acinar-related transcription factors, there was also not a 
consistent pattern as some showed similar expression levels (Mist1, Pdx1, Hnf1a) 
but others were upregulated in the Gata4-/- pancreas (Ptf1a, Gata6, Nr5a2). 
Similar results were found in the RNA-seq data for these genes (data not shown). 
These results are unlike those found in Gata6−/− pancreata, where a more severe, 
consistent and uniformly reduced expression of acinar genes and their 
transcriptional regulators was observed (Martinelli et al., 2012).  
Altogether, we conclude that Gata4 is largely dispensable for the development 
and differentiation of the exocrine pancreas after E9.5 and that Gata6 plays a  
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more prominent role in acinar differentiation. Of note, these results are opposite 
to what had been proposed in the literature in the last decade (Decker et al., 
2006; Ketola et al., 2004; Ritz-Laser et al., 2005). 
 
 
   
Figure 3. Gata4 inactivation perturbs pancreatic gene expression.  (A) Principal Component 
Analysis (PCA) of the RNA-Seq data from 3 control (dark blue) and 3 Gata4-/- (light blue) 
pancreata. Principal Component 2 (PC2) separates the two groups, evidencing the effect of Gata4 
loss in pancreatic gene expression. (B) Gene Set Enrichment Analysis (GSEA) comparing the 
transcriptome of Gata4-/- and control pancreas. Significance threshold was set at FDR<0.05, 
although pathways with FDR<0.25 were considered of interest as well. The table shows the lack 
of significantly up-regulated pathways in Gata4-/- pancreata and the few pathways significantly 
down-regulated in Gata4-/- pancreas (NES: normalized enrichment score; FDR: False Discovery 
Rate). (C) GSEA showing positive enrichment (FDR=0.0019) of a signature from Masui, et al. that 
includes the main acinar genes whose expression depends on a functional PTF1 transcriptional 
complex. (D) Relative mRNA expression, assessed by RT-qPCR, of genes related to acinar 
function, including those coding for digestive enzymes (Pnlip, Amy2a5, Cpa1, Cela1, Cel) and 
transcription factors (Mist1, Pdx1, Hnf1a, Ptf1a, Nr5a2, Gata6). P>0.05 (ns); P<0.05 (*); P<0.01 
(**); P<0.001 (***).  
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1.2. Gata4 inactivation in the pancreas leads to a mild perturbation of 
glucose metabolism  
We then characterized the role of Gata4 in the endocrine compartment. Gata4 
was undetectable in the normal islets of Langerhans using IHC (Fig. 2A). 
However, fasting basal glycaemia was slightly lower in Gata4P−/− mice (P<0.001). 
Upon intraperitoneal glucose administration, Gata4P−/− mice showed lower 
glycaemia at all time points of analysis until 2h post-glucose administration (Fig. 
4A). Immunostaining for glucagon and insulin did not reveal any clear-cut 
differences in intensity or distribution in both mouse strains (Fig. 4C).  
We next analysed expression levels of endocrine regulators by interrogating the 
RNA-seq data for endocrine-related genes, including transcription factors 
(Hnf4a, Neurod1, Mafa, Nkx6-2) and hormones (Gcg and Ins1) and did not find 
any significant differences in expression (Fig. 3B). Altogether, these results 
suggest that lack of Gata4 has a mild impact on the regulation of glucose 
homeostasis; the analysis of the mechanisms involved therein was not pursued 
as it is beyond the scope of my aims. Further studies will be necessary to 
determine the mechanisms through which Gata4 is plays a role in endocrine 
pancreas homeostasis. 
 
Figure 4. Analysis of endocrine gene expression and function in Gata4P-/- mice shows a 
mild alteration in glucose metabolism. (A) Glycaemia upon IP glucose administration.     
Gata4P-/- mice present a significantly lower basal glycaemia (after an overnight fasting, P<0.001) 
and maintain the same trend at 15 minutes (P<0.001), 30 minutes (P=0.0014), 60 minutes 
(P<0.001), and 120 minutes (P=0.018) post-injection. P>0.05 (ns); P<0.05 (*); P<0.01 (**); 
P<0.001 (***). (B) Expression of genes related to endocrine function, including transcription 
factors (Hnf4a, Neurod1, Mafa, Nkx6.2), and the hormones glucagon (Gcg) and insulin (Ins1), 
assessed by RNA-seq. (C) Representative images of IHC stainings of glucagon and insulin in 
control and Gata4P-/- mice showing no overt differences in intensity or distribution of the 
hormones within the islet of Langerhans.  
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1.3. Gata4 is phosphorylated in acinar cells upon stress 
Gata4 is known to play an important role in cardiogenesis (Pu et al., 2004; Watt 
et al., 2004) and in the response to cardiac stress (Oka et al., 2006). Studies 
performed in this field have shed light on how Gata4-mediated transcriptional 
regulation is modulated by post-translational modifications. Specifically, Gata4 
S105 phosphorylation has been reported to be required for optimal 
transcriptional activity during cardiac hypertrophy after tissue injury, suggesting 
that Gata4 is activated in response to stress (Van Berlo et al., 2011). The 
relevance of S105 phosphorylation of Gata4 was underlined by the fact that, 
among all Gata proteins, only Gata4 has a Serine at position 105, suggesting that 
phosphorylation at this residue contributes to Gata4-specific functions (Fig. 5A).  
 
Figure 5. Gata4 is phosphorylated in acinar cells under stress conditions. (A) Alignment of 
the amino acid sequence of the 6 mouse Gata members using T-COFFEE multiple sequence 
alignment (MSA). Red arrow indicates the residue S105 that undergoes phosphorylation and is 
absent in other Gata members, supporting that it contributes to Gata4-specific functions. (B) 
Alignment of the amino acid sequence of Gata4 from mouse, human, rat, Xenopus, chicken and 
dog using MSA. Red arrow shows that the S105 residue is conserved across all analysed species, 
suggesting an important role of this residue for Gata4 function. (C) IHC analysis of phospho-
S105-Gata4 in basal conditions and upon induction of pancreatic damage or challenge. Ducts and 
islets are delimited with a dashed line. From left to right, representative images (low and high 
magnification) of wild-type pancreas (unless specified) in the following conditions: I. Basal state 
(no challenge). II. Caerulein-induced acute pancreatitis (24 h time point, inflammatory stage). III. 
Caerulein-induced acute pancreatitis (7 day time point, recovery stage). IV. Obstructive 
pancreatitis induced by Pancreatic Duct Ligation (PDL), (5 days after surgery, inflammatory 
stage). V. Freshly isolated acinar cells, analysed immediately after isolation (upper image) or 
after culture for 5 days in suspension (lower). VI. Kras*-induced acinar-to-ductal metaplasia. VII. 
The specificity of the antibody used is demonstrated by the lack of immunostaining in the 
pancreas of Gata4P-/- mice 24h after the induction of acute caerulein pancreatitis.  
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In addition, we aligned Gata4 amino acid sequences of a number of species 
(mouse, human, rat, Xenopus, chicken and dog) and found that the residue S105 
is conserved across species, supporting the idea that it plays an important role in 
Gata4 activity (Fig. 5B).  
To determine whether Gata4 is phosphorylated in the pancreas in basal 
conditions or upon damage/stress, we stained for phospho-Gata4 at S105 
(pGata4) in different conditions in which the pancreas is challenged (Fig. 5C).  
The specificity of the antibody used was assessed using samples from Gata4-/- 
mice 24h post-caerulein administration; no phospho-Gata4-expressing cells 
were identified (Fig. 5C). 
Phospho-Gata4+ cells were nearly undetectable in basal conditions in all cellular 
compartments of normal pancreas. According to Gata4 expression pattern 
described previously, we did not find any cell from normal ducts or from the 
endocrine compartment positive for phospho-Gata4. However, upon induction of 
a caerulein acute pancreatitis, the majority of acinar cells stained for phospho-
Gata4 at the 24h time point (inflammatory stage), while only residual acinar cells 
were phospho-Gata4+ at day 7 (recovery stage), suggesting a transient 
phosphorylation that is dissipated when tissue is recovered. 
Similarly, we observed phopho-Gata4 staining in acinar cells in other models in 
which acinar cells undergo damage/stress, such as in obstructive pancreatitis 
induced by pancreatic duct ligation (PDL), in isolated acinar cells cultured in 
suspension –displaying an embryonic precursor phenotype that shares features 
with chronic pancreatitis (Pinho et al., 2011), and in Kras*-induced acinar-to-
ductal metaplasia (Fig. 5C). 
We conclude that Gata4 is phosphorylated in the pancreas upon stress 
conditions, which may be indicative of enhanced DNA binding and 
transcriptional activity as reported in other systems (Li et al., 2012). Therefore, 
Gata4 might play an important role in conditions where acinar cells respond to 
damage/stress rather than in basal conditions. 
1.4. Gata4P-/- mice recover normally from acute pancreatitis 
To determine whether the mild exocrine defect identified in Gata4P-/- mice 
compromises their response to damage, we induced a mild acute pancreatitis by 
administering 7 hourly injections of a supramaximal dose of caerulein to Gata4P-
/- mice and controls (Ptf1a-Cre+/KI mice); we included additional control mice of 
both genotypes receiving saline. We analysed signs of damage and inflammation 
[edema, inflammatory cell infiltration, vacuolization, and acinar-ductal 
metaplasia (ADM)] during the inflammatory phase (24h and 48h after caerulein 
administration) and during the recovery phase (7 and 14 days after caerulein 
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administration) (Fig. 6A). Gata4P-/- mice presented with a slight increase in 
edema, acute inflammation and vacuolization, suggesting that the pancreatitis in 
a Gata4-/- context is slightly more severe, but the differences were not 
statistically significant. Two out of 6 Gata4P-/- mice presented moderate, focal, 
ADM at 48h, indicating that ADM occurs in the absence of Gata4 (Fig. 6B), a 
concept that will be important when discussing coming results. Altogether, these 
data suggest that while Gata4 may play a role during pancreatic regeneration 
upon acute pancreatitis, its absence does not compromise the ability of the tissue 
to recover. 
 
 
Figure 6. Gata4P-/- and control mice display a similar response to the induction of an acute 
pancreatitis.  An acute pancreatitis was induced by 7 hourly injections of a supramaximal dose 
of Caerulein. Pancreata were harvested at 24h and 48h post-administration (inflammatory 
stage), and at day 7 and 14 post-administration (recovery stage). For each timepoint, 6 mice 
were analysed. Mice receiving a saline solution are included as basal state (n=3 for controls; n=4 
for Gata4P-/-). (A) Inflammation in the acinar parenchyma was scored according to the presence 
of oedema, leukocyte infiltration, acinar vacuolization, and ADM and categorized as: 1=minimum; 
2=mild; 3=moderate. P>0.05 (ns); P<0.05 (*); P<0.01 (**); P<0.001 (***). (B) Representative 
images at 48h post-Caerulein of mild and moderate ADM in Gata4P-/- and control mice, 
respectively.  
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2. ROLE OF GATA4 IN MOUSE PANCREATIC CARCINOGENESIS 
2.1. Gata4P-/- mice develop PDAC, but not PanIN, in mutant Kras-driven 
carcinogenesis 
Given the prominent role of Gata6 as a tumour suppressor during pancreatic 
carcinogenesis, we asked whether Gata4 could also be involved in tumour 
initiation and progression in a model of mutant Kras-driven pancreatic 
tumourigenesis. For this purpose, we crossed Gata4P−/− mice with LSL-
KRasG12V+/KI to generate Ptf1a-Cre+/KI; Gata4lox/lox; LSL-KRasG12V+/KI (termed 
Kras*;Gata4P-/-).  We analysed the histology of the pancreas at three different 
timepoints: in mice younger than 40 weeks (<40w), representing a pre-tumoural 
stage; in 1 year-old mice and in mice that were 1.5 years of age (1.5y), when 
many Kras* mice have already developed tumours (Guerra et al., 2007). We 
quantified the prevalence of known pre-neoplastic lesions such as Atypical Flat 
Lesions (AFL) and Pancreatic Intraetpithelial Neoplasia (PanIN), and Pancreatic 
Ductal Adenocarcinoma (PDAC), as well as the percentage of remodelled area. All 
histological analyses were performed blindly by an internationally recognized 
pathologist with extensive expertise in both human and mouse pancreatic 
pathology. At least 3 different areas of the tissue with a minimum of 150μm 
distance in thickness between them were analysed.  
Pre-neoplastic lesions 
We found that most Kras* mice presented at least one focus of low-grade PanIN 
at <40w (5/7 cases), while none of the Kras*;Gata4-/- (0/10 cases) of the same 
age showed any PanINs (P=0.003). The differences were even more drastic at 1y 
and 1.5y, where all (14/14 and 14/14, respectively) Kras* mice presented low-
grade PanIN and only 1/23 Kras*;Gata4-/- cases at 1y (P<0.001) and 1/6 cases at 
1.5y (P<0.001) presented one focus of PanIN. In addition to the number of cases 
presenting PanIN, we quantified the area of acinar tissue that had undergone 
remodelling, which includes formation of ADM and PanIN lesions (Fig. 7B), and 
found a dramatic decrease -or absence- in Kras*;Gata4P-/- mice at <40w 
(P=0.027), at ≥1y (P<0.001), and at 1.5y (P=0.009). 
At <40w we found 2/7 Kras* mice with AFL, and similarly to PanIN 
quantification, we did not observe any AFL in Kras*;Gata4P-/- (0/10 cases) 
(P=0.154). Similar results were observed at 1y, with 10/14 Kras* mice 
presenting AFL and only 1/23 Kras*;Gata4-/- case presenting one focus of AFL 
(P<0.001). Similarly, at 1.5y we observed AFL in 7/14 Kras* and in 1/6 
Kras*;Gata4P-/- (P=0.325). Differences at <40w and 1.5y were not significant 
probably due to the lower number of cases analysed. Interestingly, the 1-year-
old Kras*;Gata4-/- case presenting one focus of PanIN was the same mouse 
presenting an AFL, and both lesions were in the vicinity of an early carcinoma,                                 
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Figure 7. Gata4 is necessary for the development of PanIN lesions, but not for PDAC. (A) 
Representative histological findings in 2 Kras* and 2 Kras*;Gata4-/-  pancreata from 1-year-old 
mice. The low-magnification view shows representative areas of ADM/PanIN (dotted square), 
and areas of PDAC (normal square), which are magnified below. (B) Quantification of tissue 
remodelling and incidence of low-grade PanIN, Atypical Flat Lesions (AFL), high-grade PanIN and 
PDAC, including tumour grade. The analysis was stratified according to age (<40 weeks; 1 year; 
and 1.5 years). Tissue remodelling, presence of low-grade PanIN and AFL was almost absent in 
the pancreas of Gata4P-/-. By contrast, the incidence of PDAC was similar in the two groups. 
P>0.05 (ns); P<0.05 (*); P<0.01 (**); P<0.001 (***). Number of Kras* mice analysed: 
N(<40w)=10; N(1y)=14; N(1.5y)=14. Number of Kras*;Gata4P-/- mice analysed: N(<40w)=7; 
N(1y)=23; N(1.5y)=6. For tumour grade, only mice bearing tumours were analysed, and the 
number of cases is displayed within the bar. For Kras* mice at <40weeks, PDAC incidence was 
analysed in an extended series of 17 cases. (C) Quantification of lipomatosis, which is 
significantly increased in Kras*;Gata4-/-  pancreas both at <40w and 1y (P<0.001), and maintains 
the trend at 1.5y (P=0.06) (D) Quantification of islet hyperplasia incidence, which is significantly 
increased in Kras*;Gata4-/-  pancreata at 1y (P<0.001) and at 1.5y (P<0.05). 
   RESULTS 
 77 
therefore they might be part of the developing tumour and not isolated lesions. 
Accordingly, the 1.5-year-old   Kras*;Gata4P-/- cases with either a PanIN or an AFL 
were both presenting PDAC as well. 
High-grade PanIN lesions and PDAC 
High-grade PanINs were absent in both Kras* and Kras*;Gata4P-/- mice at <40w 
and 1.5y. For the largest timepoint dataset (1y) we observed 2/14 Kras* cases 
presenting high-grade PanIN and 0/23 Kras*;Gata4P-/-, this difference being 
statistically non-significant (P=0.137) (Fig. 7B). Low incidence of high-grade 
PanIN may be attributed to the fact that these lesions are frequently considered 
in situ carcinomas, therefore classified as PDAC. Strikingly, despite the lack of 
ADM, PanIN or AFL, tumours did develop in Kras*;Gata4P-/- mice. At <40w we 
found that 2/17 Kras* and 1/10 Kras*;Gata4P-/- mice had developed tumours 
(P=1.00). At 1y of age 5/14 Kras* and 9/23 Kras*;Gata4P-/- presented PDAC 
(P=1.00). Finally, at 1.5 years old we found 7/14 Kras* with PDAC, and 3/6 
Kras*;Gata4-/- with tumour (P=1.00) (Fig. 7B). Notably, the incidence of PDAC 
was not statistically different between the two groups, neither at <40w, 1y or 
1.5y of age, indicating that tumours can arise in Kras*;Gata4P-/- mice at similar 
frequencies than Kras* despite the absence of lesions typically described as 
tumour precursors. Analysis of tumour grading by the pathologist revealed no 
major differences between genotypes. 
Additional histological findings 
During the histopathological analyses, two more observations called our 
attention. The first was the high degree of lipomatosis in Kras*;Gata4P-/- mice 
(Fig. 7C), already present at <40w (P<0.001) and more prominent at 1y of age 
(P<0.001) and, although not significant due to few cases, also at 1.5y (P=0.06). 
The second observation was the presence of islet hyperplasia (Fig. 7D), specially 
in mice >1y of age, where 17/23 Kras*;Gata4P-/- mice presented hyperplasia 
compared to 1/14 Kras* (P<0.001); and also at 1.5y of age, where 3/6 
Kras*;Gata4P-/- mice presented prominent islets and none of the Kras* did 
(P=0.004). 
2.2. Acute pancreatitis does not promote PanIN development in Gata4P-/- 
mice 
Several groups, including ours, have reported that a single episode of acute 
pancreatitis is able to increase PanIN incidence in mice carrying a mutant Kras 
allele (Carrière, et al., 2009, 2011; Flandez et al., 2014). To determine whether 
Kras*;Gata4P-/- mice are able to develop PanIN lesions, we induced a two-day 
caerulein acute pancreatitis consisting in 7 hourly injections of supramaximal 
dose of cerulein the first day, one day intermission, and repeated the same 
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procedure the following day. We treated two cohorts of mice at "early" and "late" 
timepoints, 20 and 40 weeks respectively, and histological analyses were 
performed at age 1 year. The frequency of low-grade PanIN, high-grade PanIN, 
AFL, PDAC, tumour grading, lipomatosis and islet hyperplasia were assessed as 
described in previous sections in "early" and (Fig. 8A) and "late" mice (Fig. 8B). 
As expected, we observed that all "early" and "late" Kras* mice presented low-
grade PanINs, several of them with many foci of lesions (more than 20 foci). In 
agreement with other reports, we found an increase in the proportion of mice 
presenting PDAC, from 35.71% (5/14) in non-challenged mice (Fig. 7B) to 75% 
(3/4) in "early" and 57.14% (4/7) in "late" mice (Fig. 8A,B), indicating that 
pancreatitis is a tumour-accelerating event. Regarding AFL incidence, we found 
no differences comparing non-challenged mice (71.43% cases; 10/14) (Fig. 7B) 
to mice induced with pancreatitis at "early" (75% cases; 3/4) or "late" (85.71% 
cases; 6/7) timepoints (Fig. 8A, 8B).  
 
 
Figure 8. Acute pancreatitis does not result in increased PanIN formation in Kras*;Gata4-/- 
pancreas. (A) Top: experimental design. An acute pancreatitis was induced in 20 week-old Kras* 
and Kras*;Gata4P-/- (K*;G4-/-) mice; analysis was performed at 1 year of age. Bottom: 
Histopathological scoring of low-grade PanIN (LG PanIN), AFL, PDAC and its grading, lipomatosis 
and islet hyperplasia (n=5 for Kras*; n=7 for Kras*;Gata4P-/-). For tumour grade, only mice 
bearing tumours were analysed, and the number of cases is displayed within the bar. P>0.05 (ns); 
P<0.05 (*); P<0.01 (**); P<0.001 (***). (B) Top: experimental design. An acute pancreatitis was 
induced in 40 week-old Kras* and Kras*; Gata4P-/- mice; analysis was performed at 1 year of age. 
Bottom: same histopathological analysis as in panel A (n=7 for Kras*; n=6 for Kras*;Gata4P-/-). 
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However, in none of these settings did we observe an increased incidence of 
PanIN in Gata4-null context, with only 2/8 "early" and 1/6 "late" mice presenting 
1 focus of PanIN. Surprisingly, PDAC incidence in Kras*;Gata4P-/- mice was lower 
than in control mice: in the "early" pancreatitis experiment we did not observe 
any tumour (0/8), and in "late" pancreatitis we observed reduced frequency 
(33.33% cases; 2/6) compared to Kras* mice of the same experiment (85.71% 
cases; 6/7), but a similar frequency compared to non-challenged 1-yer-old mice 
(35.71% cases; 5/14)  (Fig. 7B, Fig. 8A, 8B).  
For the rest of the analyses, the results followed the same trend as in Fig. 7: we 
did not observe AFL in Kras*;Gata4P-/- mice; and lipomatosis was increased in the 
absence of Gata4, as described earlier. Of note, the low number of mice used in 
these experiments (4 Kras*; 8 Kras*;Gata4P-/- mice in "early" settings; 7 Kras*; 6 
Kras*;Gata4P-/- mice in "late" settings) hampers a definitive interpretation of the 
results, and the only solid conclusion we draw is that an episode of acute 
pancreatitis does not increase PanIN formation in Kras*;Gata4P-/- mice.  
2.3. PDAC initiation from adult acinar cells results in a similar phenotype 
upon Gata4 inactivation 
 
Previous studies have shown that PanINs and PDAC can arise in mice in which 
Kras* activation takes place in adult acinar cells provided that there is 
pancreatitis-induced damage. To determine whether PDAC can be initiated from 
acinar cells in Kras*;Gata4-/- mice , we induced Kras* activation and Gata4 
deletion in acinar cells of LSL-KrasG12V+/KI; Gata4lox/lox; Ptf1a-CreERT2+/KI; 
Rosa26-YFPKI/KI mice at 8 weeks of age, when Ptf1a is only expressed in acinar 
cells (termed i-Kras*;Gata4-/- and i-Kras* as controls, where "i" stands for 
inducible). 
In order to promote carcinogenesis, we induced chronic damage by 
administering one supramaximal dose of caerulein daily for 6 months and 
further allowing mice to age until 1 year, when we analysed the histology (Fig. 
9A). Tumours from both i-Kras* and i-Kras*;Gata4P-/- mice showed ductal 
morphology and YFP positive staining, demonstrating that acinar cells are 
indeed the cell of origin of the PDACs (Fig. 9B). These tumours appeared to be 
proliferative as shown by enhanced Ki67 staining within the tumoural cells. 
Again, we observed multiple PanIN foci in i-Kras* mice but not in i-Kras*;Gata4-/- 
pancreata that appeared to be YFP+, also indicating an acinar origin, which 
presented a low rate of Ki67+ cells (Fig. 9B). Importantly, we found that PDAC 
incidence in both strains was not significantly different (P=0.622) (Fig. 9C).  
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Figure 9. Acinar cells give rise to PDAC in i-Kras* and i-Kras*;Gata4P-/- mice. (A) 
Experimental design: two weeks after inducing recombination, a chronic pancreatitis was 
induced by injecting one supramaximal dose of caerulein daily for 6 months. Three months later 
mice were sacrificed for histological analysis. (B) Low-magnification representative images of i-
Kras* (left) and i-Kras*;Gata4P-/- mice (right) pancreata. Dotted square includes non-tumoural 
areas, while normal square includes a region with PDAC, which are magnified below. Detection of 
YFP by IHC in PanINs and the epithelial compartment of the tumour indicates an acinar origin. 
Ki67 staining shows low proliferation in non-tumoural areas and high proliferation in cancer. (C) 
Quantification of tumour incidence in i-Kras* and i-Kras*;Gata4P-/- mice showing no significant 
differences between the two groups (P=0.622). 
 
To specifically study PanIN formation upon loss of Gata4 in adult acinar cells, we 
induced recombination in i-Kras*;Gata4P-/- mice and controls at 8 weeks of age 
and administered caerulein over 2 months to induce a chronic pancreatitis. Mice 
where sacrificed at 20w of age and the pancreas was analysed (Fig. 10A). We 
observed an extensive presence of PanIN in i-Kras* mice, affecting entire lobules 
in some cases (Fig. 10B). In contrast, we did not observe any PanIN in i-
Kras*;Gata4P-/- mice (Fig. 10B). Regarding remodelling, we observed areas of 
ADM similar to the ones observed in Gata4P-/- mice upon acute pancreatitis (Fig. 
6B). We used image analysis to quantify the proportion of the pancreatic 
parenchyma undergoing remodelling/metaplasia and found involvement of 
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55.6% ±26.11 vs. 13.9% ±4.9 in i-Kras*; Gata4P-/- of the area in i-Kras* vs. i-
Kras*; Gata4P-/- mice, respectively (P=0.009) (Fig. 10C). Altogether, these results 
indicate that Gata4 is required for adult acinar cells to form PanINs but not to 
develop PDAC. 
 
 
Figure 10. i-Kras*;Gata4-/- adult acinar cells are refractory to ADM/PanIN induction. (A) 
Schematic representation of experimental design. Kras* activation and Gata4 deletion were 
achieved in 8-week old mice by TMX administration using the Ptf1a-CreERT2 allele, resulting in 
acinar-specific recombination. Recombined i-Kras* and i-Kras*;Gata4-/- mice underwent a 
chronic caerulein pancreatitis for two months and sacrificed for histological analysis. (B) 
Representative H&E staining showing a higher percentage of affected area in i-Kras* mice 
compared to i-Kras*;Gata4-/-  upon induction of chronic pancreatitis.  Affected area includes ADM 
and PanIN lesions. (C) Quantification of affected area in each genotype (P=0.009). 
2.4. IL17 rescues Gata4-/- defect to undergo ADM in vitro, but it induces 
abnormal metaplasia and lipomatosis instead of PanINs in vivo. 
The in vivo experiments described above clearly show that Gata4 is necessary for 
pancreatic cells to undergo Kras*-driven metaplasia and form PanINs.  
ADM can be largely recapitulated in vitro using primary acinar cell preparations 
cultured in 3D. To determine whether Gata4 is also required for in vitro ADM, we 
isolated acinar cells from Gata4-/- and control pancreata and embedded them in 
matrigel. As has been previously described (Means et al., 2005), control cells 
spontaneously underwent ADM and formed cystic structures that could be 
visualized under the microscope, albeit at low frequency. The ability of Gata4-/- 
acinar cells to form cysts was dramatically reduced (P<0.001) (Fig. 11A). 
EGF and several other cytokines such as IL17, IL6, IL1b have been shown to 
promote ADM (Ardito et al., 2012; Ma et al., 2009; Mcallister et al., 2014; Zhang 
et al., 2013); therefore, we analysed their effect on control and Gata4-/- acinar 
cells in vitro. We prioritized cytokines that are induced upon activation of Kras* 
in the pancreas (upregulated in an RNAseq data comparing Kras* vs control 
pancreas) since they are candidates to play a role in neoplastic transformation 
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(Fig. 11A). As expected, EGF significantly increased 3.5-fold the number of cysts 
with respect to the non-treated controls (P<0.0001). EGF also induced cyst 
formation in Gata4-/- acinar cells compared with non-treated Gata4-/- acini (6.25-
fold, P=0.053), yet the number of cysts remained significantly lower than in EGF-
treated controls (P<0.0001). As expected, IL17 significantly increased the 
number of cysts (P<0.0001) and, in addition, it rescued almost completely the 
defect observed in Gata4-/- acinar cells to levels similar to control (P=0.307). IL6 
slightly increased the number of cysts in control acinar cell preparations 
(P=0.033) but it had no effect on the number of cysts formed by Gata4-/- cells. 
The remaining cytokines tested, including IL1b, IL2, IL4, IL10, Ccl5, Cxcl12, and 
Reg3b, did not have any significant effect on cyst formation in control or Gata4-/- 
cells (Fig. 11A). Altogether, these results support the in vivo observations that 
Gata4 plays a crucial role in regulating ADM and show that IL17 can rescue this 
defect. Furthermore, these findings establish that Gata4-null cells can undergo 
ADM under certain circumstances. 
 
 
Figure 11. Gata4-/- acinar cells do not undergo ADM in vitro spontaneously and this defect 
is rescued upon IL17 treatment (A) Acinar cells from control and Gata4P-/- mice were 
embedded in matrigel and the ability of a panel of cytokines to rescue the lack of ADM in Gata4-/- 
cells was tested. After 5 days of culture, only EGF, IL17 and IL6 significantly increased the 
number of cysts compared to non-treated acinar cells. Specially, EGF and IL17 induced the 
formation of big, rounded cystic structures. Experiments/condition: n=13 for NT, EGF, IL17; n=7 
for IL6, IL1b; n=3-5 for IL2, IL4, IL10, Reg3b, Ccl5, Cxcl12. P>0.05 (ns); P<0.05 (*); P<0.01 (**); 
P<0.001 (***); P<0.0001 (****). (B) Kras* and Kras*;Gata4-/- acinar cells were embedded in 
matrigel and treated with EGF and IL17. Left panel, representative images of the cells after 5 days 
of culture. Right panel, quantification of number of cysts, showing that in basal conditions, and 
when treated with EGF, Gata4-/- cells ability to undergo ADM is dramatically reduced (P<0.001). 
In contrast, IL17 efficiently rescues cyst formation although their size is smaller. N=5 
experiments for each condition. 
 
The lack of PanINs described above was identified in a Kras* background. 
Therefore, we also conducted the in vitro ADM assay with Kras* acinar cells. 
Kras* acini spontaneously formed a nearly 4-fold higher number of cysts 
compared to KrasWT cells (Fig. 11A, 11B). Similar to KrasWT;Gata4-/- counterparts, 
Kras*;Gata4-/- cells showed very reduced ability to form cysts in basal conditions 
(P=0.008 compared to non-treated Kras* acini). Upon EGF treatment, a modest 
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increase was observed both in control and KrasWT;Gata4-/-  cells (P=0.031 
compared to EGF-treated Kras* acini). Again, IL17 was able to increase the 
number of cysts formed by Kras*;Gata4-/- cells to the levels of control cells 
(P=0.309), as observed in KrasWT background (Fig. 11B).  
Interestingly, IL17 has been described to induce PanIN formation when 
expressed from adenoviruses coding for IL17 injected orthotopically in Kras* 
pancreas (Mcallister et al., 2014). To determine whether adenoviral delivery of 
IL17 in vivo would be able to induce PanINs in Kras*;Gata4P-/- mice, we injected 
adenovirus preparations expressing either IL17 or control GFP into the pancreas 
of 10-week-old control Kras* and Kras*;Gata4P-/- mice and performed 
histopathological analysis 6 weeks after inoculation. Mice injected with adeno-
GFP showed a slight increase in lipomatosis in Kras*;Gata4-/-, in accordance with 
previous analyses (Fig. 12A). As described in McAllister, et al., we observed that 
Kras* mice injected with adeno-IL17 presented classical PanIN lesions 
expressing intestinal and gastric mucins (Fig. 12B).  
 
 
 
Figure 12. IL17 induces abnormal metaplasia and lipomatosis instead of PanINs in 
Kras*;Gata4-/- pancreas. Kras* and Kras*;Gata4P-/- mice were orthotopically injected with 10^9 
PFU adenoviruses expressing either Il17 or GFP (n=5 for each condition). Mice were sacrificed 6 
weeks after surgery and the histology was analysed for the presence of low-grade PanIN using 
Alcian Blue/PAS staining to reveal the presence of mucins. (A) Upper images show pancreata 
injected with control adeno-GFP. Lower images show extended areas with PanIN lesions in Kras* 
(left), and lack of PanIN in Kras*;Gata4P-/-, with an increase of lipomatosis instead (right). (B) 
High-magnification images showing PanIN lesions stained for mucins in Kras*, and the presence 
of ductal-like structures -which are not PanIN due to lack of mucin production- in Kras*;Gata4P-/- 
pancreas. In both cases the presence of Krt19+ staining indicate a ductal nature of the cells. (C) 
Quantification of PanINs assessed by presence of mucins within the lesions, showing a significant 
increase in Kras* mice injected with Ad-IL17 compared to Ad-GFP (P=0.0015). Kras*;Gata4P-/- 
mice did not present any mucinous lesion both when injected with Ad-GFP (P=0.04 compared to 
Kras*) and Ad-IL17 (P<0.001 compared to Kras*). 
 
Quantification of PanIN foci determined a significant increase in Ad-IL17 treated 
Kras* mice compared to Ad-GFP (P=0.0015) (Fig. 12C). In contrast, Kras*;Gata4-/- 
pancreata completely lacked PanINs in both conditions (compared to Kras* mice, 
P=0.04 for Ad-GFP, and P<0.001 for Ad-IL17 inoculation) (Fig. 12C). Instead they 
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presented with areas of abnormal non-mucinous metaplasia and extensive 
lipomatosis (Fig. 12A,B).  The atypical lesions identified in Gata4-/- pancreata 
expressed Krt19 (Fig. 12B), suggesting that IL17 induces formation of ductal-like 
structures in vivo as well as in vitro. However, the lack of mucins indicates that 
these are not classical PanINs (Fig.12B) and formally demonstrates that Gata4 is 
necessary to establish and maintain the PanIN phenotype. 
2.5. Kras*;Gata4-/- pancreata harbour unconventional metaplastic lesions 
lacking phospho-Stat3 signalling 
The lack of PanIN lesions in mice developing PDAC suggests that an alternative 
type of preneoplastic lesion develops in Kras*;Gata4-/- mice that may not have 
been recognized previously. Pathological analysis of the pancreas of Kras*;Gata4-
/- mice at 1 year of age revealed focal regions of acinar cell clusters characterized 
by paleness, reduced eosinophilia, and a certain degree of hyperplasia with or 
without enlarged lumina, suggesting altered differentiation (Fig. 13). We 
designate these lesions “PALes” for “Pale Acinar Lesions”, and we hypothesize 
that PALes are clusters of acinar cells initiating Kras*-induced metaplastic 
process, which normally progress into ADM/PanIN in a context of Gata4+/+, but 
in a context of Gata4-/- form unconventional metaplastic lesions -or undergo 
adipocyte transdifferentiation. A thorough pathological analysis of Kras* 
pancreata also disclosed the occurrence of PALes, as well as well-recognized 
ductal lesions (ADM and PanIN) (Fig. 13). Indeed, other reports have previously 
noticed the presence of hyperplastic clusters of acini in Kras* pancreata (Guerra 
et al., 2007, supplemental data). To identify and characterize PALes at the 
molecular level, we used immunohistochemistry with a panel of antibodies. 
Results are summarized in Table 2. 
 
 
Acini PALe Ductal-like 
  Kras* K*;G4-/- Kras* K*;G4-/- Kras* (PanIN) K*;G4-/- (D-PALe) 
Krt19 - + ++ - +++ +++ 
Sox9 - - + ++ +++ +++ 
Hnf1b - - - - +++ + 
p65 - - +++ ++ + + 
phospho-STAT3 - - +++ - + - 
Table 2. Comparative analysis of epithelial and signalling markers assessed in lesions from 
1-year-old Kras* and Kras*;Gata4-/- (K*;G4-/-) mice. D-PALe: ductal PALe. 
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Figure 13. Kras*;Gata4P-/- mice develop unconventional metaplastic lesions that display 
differential activation of signalling pathways. Representative images of serial sections of 
pancreata from Kras* and Kras*;Gata4P-/- mice, showing acinar and ductal features. ADM was 
assessed using Krt19, Sox9 and Hnf1b. Signalling pathways important during transformation, 
including NF-kB and Jak-Stat-, were assessed using phospho-Stat3 (pStat3) and p65, respectively. 
 
ADM markers  
We first analysed expression of Sox9 and Krt19, proteins that are expressed 
“early” in the metaplastic process. In addition, we analysed Hnf1b, which is 
expressed in established ductal structures. In Kras* mice, PALes showed slightly 
increased expression of Krt19 compared to normal acinar cells. In lesions where 
complete ductal reprogramming has occurred (ADM, PanIN) expression of Krt19 
was further enhanced. In contrast, PALes in Kras*;Gata4-/- did not display 
marked Krt19 up-regulation, and only when Gata4-null lesions had acquired a 
ductal morphology did they show Krt19 levels similar to those of in PanINs (Fig. 
13). In Kras* mice, Sox9 was expressed in PALes as well as in all ductal lesions. 
Similarly, Sox9 was expressed in PALes in Kras*;Gata4-/- as well as in ductal 
lesions (Fig. 13), suggesting that Sox9 functions upstream of -and its expression 
is not affected by- Gata4 loss. As expected, in Kras* mice, Hnf1b was not 
expressed in Kras* PALes and it was only detected in PanINs. Similarly, Hnf1b 
was not detected in Kras*;Gata4-/- PALes but it was heterogeneously present in 
ductal lesions, even within a given duct (Fig. 13). 
Signalling molecules 
In order to shed light on the status of the Nf-kb and Jak/Stat3 signalling 
pathways in each type of lesion, we stained the pancreata of 1-year old mice for 
p65 and phospho-Stat3 (Fig. 13). In Kras* mice, PALes showed high p65 staining, 
unlike PanINs. Similarly, we observed up-regulation of p65 in Kras*;Gata4-/- 
PALes, but not in ductal lesions.  
Phospho-Stat3 staining followed a similar pattern since PALes in Kras* mice 
expressed high levels of phospho-Stat3, and also some PanINs, although at lower 
levels than PALes. In contrast, phospho-Stat3 was undetectable in PALes of 
Kras*;Gata4-/- mice, this being the most striking difference between genotypes 
for all markers tested. Similarly, phospho-Stat3 was undetectable in the ductal 
lesions present in Gata4-null pancreata. These results suggest that Gata4 is 
necessary for proper Kras*-induced signalling during metaplastic 
transformation, especially through Stat3. 
2.6. Gata4 participates in Kras*-induced inflammation 
In order to get insight into the mechanisms regulated by Gata4 in a Kras* context 
prior to acinar transformation and PanIN formation, we performed RNAseq to 
   RESULTS 
 87 
analyse the transcriptome of 8 week-old Kras* (n=3) and Kras*;Gata4-/- (n=3) 
pancreata, when metaplastic processes have not been widely initiated, and very 
few lesions can be detected. The RNAseq data obtained from Ptf1a-Cre+/KI and 
Gata4P/- mice were used as controls (Fig. 14).   
 
Figure 14. Kras*-induced inflammation requires functional Gata4. (A) RNA-seq data from 
pancreatic tissue of 8 week-old control, Kras* and Kras*;Gata4-/- (K*;G4-/-) mice was analysed to 
determine the consequences of Gata4 loss in a Kras* background. Gene Set Enrichment Analysis 
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(Fig. 14 cont.) (GSEA) was performed on the comparisons "Control vs Kras*" and " Kras*;Gata4-/- 
vs Kras*". We applied the KEGG library, which includes a variety of signatures that are 
representative for the majority of cellular processes in physiological and pathological conditions. 
Pathways that appeared to be differentially activated with FDR<0.25 were plotted. The values of 
the axis correspond to the Normalized Enrichment Score (NES). Different subgroups of pathways 
are indicated for further description. (B) Heat map showing FDR values of the two groups of 
pathways underscored in Fig. 14A. Left panel shows the pathways that are significantly enriched 
in Kras* when compared with both control and Kras*;Gata4-/-, which are mostly related to 
inflammation. Right panel shows the pathways that are significantly enriched in the comparison 
"Kras* vs Control", being these upregulated in Kras* condition, which include several pathways 
related to cancer (#). Name of pathways in subgroups 3, 4 and 5 are displayed in Table 3. 
 
Our first approach consisted of performing GSEA on the following comparisons: 
(I) control (Ptf1a-Cre+/KI) vs Kras* transcriptome, to unravel the biological 
processes and pathways induced upon Kras activation; (II) Kras* vs  Kras*; 
Gata4-/- transcriptome, to determine the pathways downregulated in the absence 
of Gata4 that might contribute to the reduced ADM and absence of PanINs. We 
applied the KEGG library and found that a similar set of pathways was 
significantly enriched in Kras* when compared to both control and Kras*;Gata4-/- 
pancreas (Fig. 14A). Several of these pathways were related to immune system 
activation and inflammatory processes (Fig. 14B), indicating that Kras* induces 
an early inflammatory response that is absent upon Gata4 deletion and that is 
not required for PDAC development.  
Kras* signals through the activation of MAPK and a constitutive activation of this 
pathway is linked to tumour formation in many tissues. In accordance, "MAPK 
signalling pathway" as well as other pathways related to carcinogenesis such as 
"Colorectal cancer", "Acute myeloid leukemia", "Pathways in cancer", "Basal cell 
carcinoma" and "Small cell lung cancer" were upregulated in Kras* compared to 
controls. Importantly, these pathways were also upregulated in Kras*;Gata4-/- 
pancreata, indicating that they are likely relevant to PDAC formation but they do 
not inevitably lead to PanINs (Fig. 14B). The list of the pathways enriched in 
other comparisons is displayed in Table 3. 
These results suggest that Gata4 controls, directly or indirectly, the Kras*-driven 
inflammatory response. In order to characterize this phenotype in more detail, 
we considered the expression of genes related to inflammation as well as cell-
specific markers using the RNAseq data (Fig. 15A). We observed that several 
chemoattractants (Ccl19, Ccl21a, Ccl5) and adhesion molecules (Icam1, Cd2, Itgal, 
Itgb7, Sell) were significantly upregulated in Kras* compared to control 
pancreata and also compared to Kras*;Gata4-/- pancreas. Accordingly, we 
observed a significant increase in total Cd45+ leukocytes. Analysis of specific 
leukocyte subpopulations revealed no significant differences in the neutrophil 
marker Mpo. Contrary, we observed a significant upregulation of Cd3e, Cd4, Cd8a, 
Foxp3 (T lymphocytes) and Cd19, Pax5, Cd22 (B lymphocytes) in Kras* pancreas 
compared to the other conditions. Interestingly, the expression of macrophage 
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markers (F4/80, Mac2, Csfr1, Clec10a) did not differ between control and Kras* 
pancreata, but levels significantly decreased in Kras*;Gata4-/- samples (Fig. 15A).  
These results suggest that Gata4 modulates the presence of resident 
macrophages in the pancreas, as this is the only immune subpopulation that 
significantly decreases in Gata4-null pancreata, independently of Kras status. 
[3] 
  Alanine aspartate and glutamate metabolism   Long term potentiation 
Alzheimer's disease 
 
Oxidative phosphorylation 
Aminoacyl tRNA biosynthesis 
 
Parknison's disease 
Amyotrophic lateral sclerosis (ALS) 
 
Peroxisome 
Arginine and proline metabolism 
 
Propanoate metabolism 
Butanoate metabolism 
 
Proteasome 
Cardiac muscle contraction 
 
Protein export 
Cysteine and methionine metabolism 
 
Regulation of autophagy 
Fatty acid metabolism 
 
RNA polymerase 
Glutathione metabolism 
 
Selenoamino acid metabolism 
Glycolysis gluconeogenesis 
 
Spliceosome 
Histidine metabolism 
 
Valine leucine and isoleucine degradation 
Huntington's disease  Vasopressin regulated water reabsorption 
   [4] 
 
[5] 
Arachidonic acid metabolism 
 
Ribosome  
Ether lipid metabolism 
 
Systemic lupus erythematosus 
Galactose metabolism 
  Glycerolipid metabolism 
 
 
Lysosome 
 
 
PPAR signaling pathway 
  Prion diseases 
  Table 3. KEGG pathways in Figure 14A. [3] Pathways significant only in the comparison Kras* 
vs Control, upregulated in Control. [4] Pathways  significant only in the comparison Kras* vs 
Kras*;Gata4-/-, upregulated in Kras*. [5] Pathways significant in both comparisons, enriched in 
Kras* (vs Kras*Gata4-/-) and in Control (vs Kras*). 
 
The RNAseq data showed that the Kras*-induced inflammatory response is 
blunted in the absence of Gata4. In order to unravel which pro-inflammatory 
factors are expressed by Kras* acinar cells in a Gata4-dependent manner, we 
analysed isolated acini (Fig. 15B). First, we examined the presence of 
contaminating T lymphocytes as a quality control for acinar explant purity by 
assessing expression of CD3 and found very low levels of expression with no 
significant differences between the two conditions. Then, we assessed the 
expression of genes that may induce an inflammatory response, whose 
expression was significantly downregulated in the RNAseq data in Kras*;Gata4-/- 
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compared to Kras* pancreata, including Ccl5, Ccl19, Icam1, Cxcl12, Cxcr4 and 
Reg3b.  
 
Figure 15. Gata4 regulates the acinar-specific expression of some inflammation-related 
factors (A) RNA-seq results showing expression of genes coding for chemoattractants, adhesion 
molecules, and markers for all leukocytes (Cd45, coded by Ptprc), and specific leukocyte types 
(macrophages, neutrophils, T and B lymphocytes). In general, expression of all markers is higher 
in Kras* than in both control and Kras*;Gata4P-/-  mice. P>0.05 (ns); P<0.05 (*); P<0.01 (**); 
P<0.001 (***). For the following markers, the gene coding for the specified protein is: Adgre1 
(F4/80); Lgals3 (Mac2). (B) Lef panel: Gene expression of inflammation-related genes in freshly 
isolated acini cultured for 24h culture, including T lymphocyte markers (Cd3e) for negative 
control, chemoattractants (Ccl5, Ccl19), adhesion molecules (Icam1), the pro-inflammatory 
Cxcl12-Cxcr4 axis, and the gene coding for pancreatitis-associated protein (Reg3b). All tested 
genes are expressed at significantly lower levels in Kras*;Gata4P-/- than in Kras* pancreas based 
on the results of the RNA-seq analysis (left panel). However, only Cxcl12, Cxcr4, and Reg3b are 
significantly decreased in Kras*;Gata4P-/- isolated acini (right panel). 
 
 
In isolated Kras*;Gata4-/- acini, expression of Ccl5, Ccl19 and Icam1 was not 
different from Kras* acini, indicating that differences in the levels of these 
chemoattractants in the RNAseq data is not due to an epithelial cell-autonomous 
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defect, but likely due to improper activation of immune subpopulations, instead. 
In contrast, Cxcl12, Cxcr4 and Reg3b (also termed Pancreatitis Associated 
Protein) transcripts were significantly downregulated in Kras*;Gata4-/- isolated 
acini, suggesting that Gata4 controls their expression, directly or indirectly, at 
the epithelial cell level (Fig. 15B). Importantly, these genes have been described 
to be expressed during inflammatory processes in the pancreas. These results 
show that changes in gene expression in the RNAseq data are not only due to 
deregulated transcription in Gata4-null acinar cells, but also in other cell types     
-most likely leukocyte subpopulations-, whose gene expression is also affected 
by the altered signalling coming from Gata4-/- acini. 
2.7. Infiltration of Kras*-induced epithelial lesions by macrophages and T 
lymphocytes requires Gata4 
In order to validate the RNAseq results showing a decrease in inflammatory cells 
in 8-week-old Kras*;Gata4-/- pancreata, we stained for F4/80, Mpo, Cd3, and 
Pax5 to assess the presence of macrophages, neutrophils, T lymphocytes and B 
lymphocytes, respectively. We did not observe differences in overall infiltrating 
cells in acinar parenchyma, but we noticed a differential presence of leukocytes 
surrounding histological abnormalities (lesions). We therefore analysed early 
lesions, including PALes and ductal metaplasias, from 4 different Kras*  (14 
lesions) and 4 Kras*;Gata4-/- (16 lesions) pancreata (Fig. 16).   
We observed that macrophages are present in all Kras*-induced lesions (14/14), 
both PALes and ductal lesions. Accordingly, other reports have described 
macrophages to be the most abundant leukocyte subpopulation in Kras*-induced 
lesions (Liou & Storz, 2015). In contrast, lower presence of macrophages could 
be observed in PALes and ductal lesions in Kras*;Gata4-/- pancreas (P=0.028). T 
lymphocytes were present in nearly all PALes and ductal lesions in Kras* 
(12/14), but we observed fewer Kras*;Gata4P-/- lesions with T lymphocyte 
infiltration (10/16), which also presented lower T cell abundance (P<0.001). 
Neutrophils could only be observed in nearly half (6/14) of the ductal lesions 
that were analysed and in none of the PALes; by contrast, only one Kras*;Gata4-/- 
lesion subjected to analysis showed presence of neutrophils (P=0.229). Finally, B 
lymphocytes were absent in Kras* mice, and only one Kras*;Gata4-/- lesion 
presented positive staining (P=0.341) (Fig. 16A). Altogether, these data suggest 
that Gata4 plays a role in recruiting macrophages and T lymphocytes to lesions 
in Kras* pancreata, and its lack results in decrease infiltration of these 
leukocytes. 
We also examined the presence of macrophages, T lymphocytes, B lymphocytes 
and neutrophils in the mesenteric lymph nodes that surround the pancreas and 
found that macrophages were nearly absent in Kras*;Gata4P-/- compared to Kras* 
mice (P<0.0001) (Fig. 16B). For the other leukocyte subpopulations we did not 
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observe major differences. Altogether, these data suggest that lack of Gata4 
impairs macrophage mobilization.  
 
Figure 16. Infiltration of Kras*-induced lesions by macrophages and T lymphocytes is 
modulated by Gata4. (A) Representative images of IHC and quantification of infiltrating 
leukocyte populations in the pancreas of 8 week-old Kras* and Kras*;Gata4P-/- (K*;G4-/-) mice, 
including lesions of both acinar and ductal morphology. Quantification is based on number of 
cells within the lesion: 1-5 cells (+), 6-15 cells (++), >15 cells (+++). Presence of macrophages 
was quantified according to staining intensity: mild (+), moderate (++), and strong (+++). P<0.05 
(*); P<0.01 (**); P<0.001 (***). (B) Right panel: Representative images of mesenteric lymph 
nodes stained for the macrophage marker F4/80 in Kras* and Kras*;Gata4P-/- mice. Left panel: 
Percentage of F4/80+ lymph nodes in each genotype (P<0.0001).  
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2.8. Gata4-null primary acinar preparations are defective in macrophage 
activation 
Considering these results, we hypothesized that factors secreted by acinar cells 
activate macrophage recruitment, which, in turn, leads to infiltration of T 
lymphocyte in the pancreas. To test this notion, we established suspension 
cultures of primary acinar cells from control, Gata4P-/-, Kras* and Kras*;Gata4P-/- 
mice for 48h in low-serum medium. Conditioned medium was added to 
RAW264.7 macrophages for 24h and the expression of markers of macrophage 
activation, such as Ccl5, Cxcl10 and Cxcl11, was analysed (Fig. 17). We found that 
macrophages treated with medium conditioned by Gata4-null acini expressed 
slightly lower levels of Ccl5 (P=0.183) and significantly lower levels of Cxcl10 
(P=0.009) and Cxcl11 (P=0.016) compared to medium from control (Ptf1a-
Cre+/KI) acini. 
 
Figure 17. Impaired macrophage 
activation by conditioned medium 
from Gata4-/- acinar preparations. 
Conditioned medium (48h) from 
isolated acinar cells cultured in low-
serum medium was added to RAW 
264.7 macrophages for 24h. 
Expression of inflammation activating 
genes was assessed by RT-qPCR. 
P>0.05 (ns); P<0.05 (*); P<0.01 (**); 
P<0.001 (***). 
When macrophages were treated with medium conditioned by Kras* acini, the 
expression of Ccl5, Cxcl10 and Cxcl11 was increased respect to Ptf1a-Cre 
controls. Importantly, macrophage treatment with medium conditioned by 
Kras*;Gata4P-/- cells resulted in even lower expression of Ccl5 (P=0.078), Cxcl10 
(P=0.002) and Cxcl11 (P=0.028) compared to macrophages treated with medium 
conditioned by Kras* acini. We also assessed the ability of the different 
conditioned media to induce T lymphocyte migration through transwells. 
Preliminary data showed that conditioned medium from Gata4-null acini does 
not differentially promote T lymphocyte migration compared to control medium 
(data not shown), suggesting that the lack of inflammatory response in a Gata4-
null context is due to impaired macrophage activation and not due to reduced T 
lymphocyte recruitment directly from acinar cells. 
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2.9. Reg3b is downregulated in Gata4-/- pancreata and contributes to 
macrophage activation  
As commented previously, visual inspection of the RNAseq data (Table 1) had 
highlighted Reg3b -and other Reg family members– as some of the most strongly 
downregulated genes in Gata4-/- pancreata (Fig. 18A). Interestingly, Reg3b 
expression is massively induced during pancreatitis (Keim et al. 1984). 
Therefore, we analysed whether loss of Gata4 affected its upregulation. Reg3b 
expression was dramatically upregulated at 24h during caerulein-induced acute 
pancreatitis in control mice (Ptf1a-Cre+/KI). By contrast, Reg3b levels in Gata4-/- 
pancreata were slightly upregulated, but at much lesser extent compared to 
controls  (P<0.001) (Fig. 18B).  
A role of Reg3b in neoplastic transformation in the pancreas has been proposed 
(Loncle et al., 2015). Therefore, we examined Reg3b expression in 1-year-old 
Kras* mice by IHC. We observed strong expression of Reg3b in acinar cells 
surrounding areas of metaplasia in the pancreas of Kras* mice but not in 
Kras*;Gata4P-/- pancreata, not even in areas presenting advanced lesions (Fig. 
18C).  
It has been reported that Reg3b is necessary to mobilize resident tissue 
macrophages in an infarcted heart to induce regeneration (Lörchner et al., 2015). 
Since Gata4P-/- mice are defective in both pancreatic Reg3b expression and 
macrophage activation, we hypothesized that Reg3b might be required to 
activate resident macrophages in the pancreas. To address this hypothesis, we 
tested the effect of recombinant Reg3b and Reg3b blocking antibodies on the 
activity of conditioned medium from Kras* isolated acini using RAW264.7 
macrophages as a readout (Fig. 18D). Similar to what we had previously 
observed, expression of Mmp9 and Cxcl16 was lower in macrophages treated 
with medium conditioned by Gata4-null cells. Induction of these genes was 
decreased when anti-Reg3b was added in Kras* medium and, conversely, their 
expression was increased when recombinant Reg3b was added to Kras*;Gata4-/- 
medium. The differences observed were not statistically significant but the 
findings suggest a role for Reg3b in macrophage activation.  
Gata4 has been proposed to directly regulate Reg3b expression in intestinal cells 
(Lepage et al., 2015). To assess whether Gata4 directly also controls Reg3b 
expression in normal pancreas, we examined the presence of peaks in the Reg3b 
genomic locus identified through a Gata4 ChIP-seq experiment generated in our 
laboratory (data not shown). We did not find a peak at the promoter of Reg3b, 
but we found a Gata4 binding signal in a region in-between all Reg family 
members, 13kB downstream of the Reg3b TSS (Fig. 17D). It has been described 
that Reg genes are part of a chromatin loop and that their expression is 
coordinated; therefore, we hypothesized that the signal observed in the ChIP-seq 
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data might be part of an enhancer regulating all Regs expression. We performed 
ChIP-qPCR to validate the ChIP-Seq data and found a clear enrichment compared 
to control IgG (P<0.01) (Fig. 18E). These results suggest that Gata4 regulates 
Reg3b directly in the pancreas.  
In order to determine whether the Reg3b production defect might be 
responsible for the failure of Gata4-/- acinar cells to undergo ADM in vitro, we 
analysed the ability of Reg3b-/- acinar cells to form cystic structures: Reg3b-/- 
acinar cells displayed an intermediate phenotype, with a moderately reduced 
ability to undergo ADM, compared to the Gata4-/- cells, suggesting that the defect 
of Gata4-null cells is not only due to low Reg3b secretion (Fig. 18F).  
 
 
Figure18. Reg3b expression is regulated by Gata4 and contributes to macrophage 
activation (A) RNA-seq results of expression of Reg family members in the pancreas of 8 week-
old control and Gata4P-/- mice. (B) Reg3b expression is markedly upregulated upon induction of 
an acute pancreatitis in control mice but not in Gata4P-/- mice. P<0.05 (*); P<0.01 (**); P<0.001 
(***). (C) Representative IHC images of Reg3b expression in the pancreas of 8 week-old Kras* 
and Kras*;Gata4P-/- mice. (D) Expression of Mmp9 and Cxcl16 in RAW 264.7 cells treated with 
medium conditioned by (from left to right): I. Kras* acini; II. Kras* acini +α-Reg3b blocking 
antibody; III. Kras*;Gata4-/- acini; IV. Kras*;Gata4-/- acini +recombinant (r)Reg3b. (E) ChIP-qPCR 
with anti-Gata4 antibodies to assess binding to a putative enhancer region of Reg3b. (F) Cyst 
formation by matrigel-embedded acinar cells from wild type and Reg3b-/- mice. 
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3. ROLE OF GATA4 IN PDAC PROGRESSION AND SURVIVAL 
Recent work performed in our laboratory has highlighted the role of Gata6 as a 
tumour suppressor during pancreatic carcinogenesis. Loss of Gata6 in mouse 
pancreas accelerates Kras*-driven carcinogenesis (Martinelli et al., 2015), and 
low levels of GATA6 in human PDAC cell lines is associated with enhanced 
tumour dissemination. In addition, patients with basal-like GATA6-low tumours 
have a shorter survival (Martinelli et al., 2016). All these data led us to 
investigate the role of Gata4 in an aggressive model of pancreatic carcinogenesis, 
and GATA4 expression in human samples and how it relates to patient survival. 
3.1. Trp53 inactivation accelerates tumour progression in Kras*;Gata4P-/- 
mice  
Multiple genetic events cooperate to promote PDAC development/progression 
through a variety of molecular mechanisms. Trp53 is a major gene involved in 
PDAC progression (Hingorani et al., 2005) and we aimed to determine the 
consequences of inactivating Trp53 in Kras* and Kras*;Gata4P-/- mice. We first 
analysed Kras*;Trp53-/-;Gata4-/- and control (Kras*;Trp53-/-;Gata4+/+) 6 week-old 
mice (Fig. 19A). Histological analyses revealed that Kras* mice presented a low 
incidence of low-grade PanINs (1/7 cases); in agreement with previous results, 
no PanINs could be observed in Kras*;Gata4P-/- mice. Although low number of 
AFL and high-grade PanIN could be observed in both genotypes, the presence of 
these lesions in a Gata4-null context indicated that Gata4 does not impair their 
development. Similarly, both mouse strains developed aggressive PDAC with 
high penetrance, again indicating that Gata4 is not necessary for PDAC 
development, which are favoured in a P53-null background. We did not observe 
significant differences in tumour grade, percentage of remodelled area and 
lipomatosis between genotypes.  
Next, we allowed mice age until they had to be sacrificed due to humane 
endpoint, at which point we analysed the pancreas. We found a low and similar 
incidence of low-grade PanINs and high-grade PanINs in both mouse strains. 
Similarly, the rate of areas affected by ADM, the number of AFL, and the 
occurrence and grade of PDAC were similar. We found a higher prevalence of 
cystic structures in Kras*;Trp53-/- pancreata, that were absent in Kras*;Trp53-/-; 
Gata4-/- counterparts, but the small number of mice analysed precluded 
statistical analysis (Fig. 19B). Finally, we analysed mouse survival; Kras*;Trp53-/-
;Gata4-/- mice died significantly earlier than controls (P<0.0001) (Fig. 19C). 
Similar results were obtained when using Kras*;Trp53+/-;Gata4-/- mice 
(P=0.0018). Altogether, these results indicate that, Gata4 and P53 cooperate in 
driving Kras*-initiated PDAC progression and support the role of Gata4 as a bona 
fide tumour suppressor gene. 
RESULTS 
 
 98 
 
Figure 19. Gata4 inactivation in Kras*;Trp53-/- mice accelerates tumour progression. (A) 
Experimental design: histology of Kras*;Trp53-/-; Gata4P-/- mice (in which recombination is 
mediated by Ptf1a-Cre at E10.5) was analysed at 6 weeks of age, before reaching the humane 
endpoint. Presence of low-grade (LG) PanIN, AFL, high-grade (HG) PanIN, PDAC and its grading, 
tissue remodelling and lipomatosis was analysed. (B) Experimental design: histology of 
Kras*;Trp53-/-;Gata4P-/- mice was analysed when reaching the humane endpoint (HEP). Presence 
of low-grade PanIN, cystic structures, ADM, AFL, high-grade PanIN, PDAC and its grading was 
analysed. (C) Left panel: Survival curve of Kras*; Trp53-/-;Gata4P-/- (n=10) and control mice 
(n=28), showing a poorer survival in the absence of Gata4 (P<0.0001). Right panel: Survival 
curve of Kras*;Trp53+/-;Gata4P-/- (n=11) and control mice (n=11), again showing a poorer 
survival in the absence of Gata4 (P<0.0018) 
 
 
3.2. GATA4-low PDAC displays basal-like phenotype and associates with 
poor patient survival 
 
To assess the implications of the studies conducted in mice in relationship to the 
molecular pathogenesis of human PDAC, we analysed GATA4 expression in 
normal and neoplastic pancreas using several, complementary, experimental 
strategies.  
 
In normal human pancreas, GATA4 is expressed with a cell-specific pattern 
similar to that observed in the mouse pancreas: it is detected in acinar cells but 
not in ductal or endocrine cells (Fig. 20A). We analysed a TMA series of 23 
evaluable cases and, interestingly, the majority of low-grade and high-grade 
PanINs showed detectable levels of GATA4 (out of 27 low-grade PanINs, 1 
showed negative, 2 weak, 6 moderate and 18 strong staining intensity; and out of 
2 high-grade PanINs, 1 showed moderate and 1 strong intensity). Contrary, 
expression in tumour cells was much lower (out of 20 PDAC cases, 12 showed 
negative, and 8 weak staining) (Fig. 20B,C). The differences in staining intensity 
between PanINs and PDAC was highly significant (P<0.001), but not between  
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Figure 20. Gata4 loss associates with high-grade lesions, basal-like phenotype, and poor 
survival in patients with PDAC. (A) Representative image of the expression of GATA4 in 
normal human pancreas showing expression in acinar cells but not in ductal or endocrine cells. 
(B) Histoscore for IHC analysis of GATA4 expression in the pancreas of patients with PDAC in a 
series of 23 evaluable cases (left panel), and in 1-year-old Kras* mice (N=17) (right panel). (C) 
Representative images of the expression of GATA4 in low-grade PanIN, high-grade PanIN, and 
PDAC. (D) Kaplan-Meier plot of survival of patients with high and low GATA4-expressing 
tumours. Dataset from Bailey et al. 2016. (E) Kaplan-Meier plot of survival of patients according 
to the expression of GATA4 and GATA6. Dataset from Bailey et al. (F) GATA4 expression          
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(Fig. 20 cont.) according to PDAC subtypes as defined by Bailey et al. (G) GSEA analysis 
comparing tumours expressing high vs. low GATA4 mRNA levels (first vs. last quartile). Libraries 
from Gene Ontology (GO) were used to run the analysis. Significance threshold was set at 
FDR<0.0.5.  
low- and high-grade PanINs (P=0.826). Similar Gata4 expression pattern was 
observed in neoplastic lesions of Kras* mice (Fig. 20B). 
 
We took advantage of the transcriptomic data of 456 cases of PDAC published by 
the Australian ICGC Consortium (P. Bailey et al., 2016) and analysed GATA4 
expression. We stratified all cases by considering the median expression of 
GATA4 across all cases. We defined tumours with GATA4 expression higher than 
the median as "GATA4-high" and those with GATA4 expression lower than the 
median as "GATA4-low". Survival analyses showed that patients with GATA4-low 
tumours had a shorter survival than GATA4-high cases, although the differences 
were not significant (Fig. 20D). We then surmised that GATA4 and GATA6 might 
have partially redundant roles in PDAC. A re-analysis of the survival data 
considering the subgroup of tumours that were GATA6-low/GATA4-low showed 
a highly significant association with poor outcome in this patient group 
(P=0.005) (Fig. 20E). 
 
Our laboratory and others have shown that GATA6 is expressed at lower levels 
in the quasi-mesenchymal or basal-like PDAC subtypes (P. Bailey et al., 2016; 
Martinelli et al., 2016). Interestingly, in the Australian ICGC consortium series 
GATA4 levels were also significantly lower in the squamous subtype (basal-like) 
than in the other groups (Fig. 20F). These findings are in accordance with 
reports that PDAC with a basal-squamous phenotype have worse outcome 
(Bailey et al., 2016; Martinelli et al., 2016; Moffitt et al., 2015).  
 
To get insight into the molecular mechanisms that might participate in this 
association with survival, we stratified all cases according to GATA4 levels and 
defined tumours in the top quartile of expression as "GATA4-high" and those in 
the bottom quartile as "GATA4-low". We performed GSEA applying Gene 
Ontology (GO) libraries and found that the main pathway enriched in "GATA4-
high" was "Digestion", a signature that includes a number of digestive enzymes 
(Fig. 20G). These results suggest that tumours expressing high Gata4 are more 
differentiated. Contrary, results from GSEA in "GATA4-low" samples revealed an 
enrichment in pathways related to enhanced proliferation such as "Cell cycle 
process", "Tissue development" or "Mitosis" (Fig. 20G). 
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Gata factors play a critical role during early embryo development and during 
organogenesis. Inactivation of Gata4 or Gata6 at the initiation of pancreatic 
development does not impede pancreas formation. However, concomitant 
inactivation of both genes results in pancreas agenesis (Carrasco et al., 2012; 
Xuan et al., 2012). Therefore, one Gata member (4 or 6) can compensate the lack 
of the other to allow pancreas formation, indicating that Gata4 and Gata6 share 
partially redundant functions during pancreas organogenesis.  
Recently, we have reported that Gata6 is crucial for the maintenance of acinar 
cells in the adult pancreas, as its deletion at e9.5 results in exocrine atrophy, 
adipocyte transdifferentiation and ADM. These results indicate that Gata6 has 
specific functions in the adult pancreas that cannot be compensated by Gata4. In 
addition, we have proposed that Gata6 can act as an important tumour 
suppressor gene in the pancreas as its deletion in a mutant Kras-induced model 
of carcinogenesis increases the incidence of PanIN and PDAC (Martinelli et al., 
2015). In addition, human PDAC cell lines with low GATA6 expression levels  
display high invasion in vitro and enhanced dissemination in vivo, and patients 
with GATA6-low expressing PDAC present poorer survival (Martinelli et al., 
2016). Given the prominent role that Gata6 plays in pancreas physiology and 
pathology, and the importance of both Gata4 and Gata6 during pancreas 
organogenesis, we asked whether Gata4 also plays a critical role in pancreas 
homeostasis and pathogenesis. Here, I will discuss our results showing that 
Gata4 has specific functions in the adult pancreas and that it plays a tumour 
suppressor role in mouse models of PDAC. 
1. Gata4 is dispensable for proper exocrine pancreas homeostasis or acinar 
differentiation 
In order to study the role of Gata4 in adult pancreas homeostasis we generated 
mice lacking Gata4 in the pancreas, as we previously did to study Gata6. We 
performed a detailed characterization of Gata4-/- pancreata both at the 
histological and RNA expression level. Unlike Gata6, which is expressed in all 
exocrine and endocrine cells, Gata4 is only expressed in acinar cells. This result 
was in accordance with other reports (Decker et al., 2006; Ketola et al., 2004; 
Nemer & Nemer, 2003; Ritz-Laser et al., 2005). Although we did not observe any 
Gata4+ endocrine cells, we cannot rule out that Gata4 plays a role in this 
compartment and that expression levels are under detection capacity of the 
technique used. Actually, some reports have attributed Gata4 a role in regulating 
glucagon expression (Ritz-Laser et al., 2005) and we have observed that Gata4P-/- 
mice show some alterations in glucose regulation consisting of lower glycaemia 
both in basal fasting conditions and upon glucose administration. We 
investigated possible causes by analysing expression levels of transcription 
factors that regulate endocrine function and expression of hormones controlling 
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glycaemia, but we could not detect any significant difference. Since Gata4P-/- mice 
did not have liver or weight problems (data not shown), and the objective of the 
work was to evaluate the role of Gata4 in exocrine physiology and pathogenesis, 
we did not investigate this phenotype further and focused on the role of Gata4 in 
the exocrine pancreas. 
The exocrine pancreas of Gata4P-/- mice did not show any major histological 
alterations except for a mild increase in the number of adipocytes and a slightly 
more basophilic cytoplasm in acinar cells, indicating lower enzyme content. 
These results were in contrast with those found in Gata6-/- pancreas. In addition, 
proliferation, apoptosis, DNA damage and polarity were not affected in Gata4-
null pancreata, unlike in the Gata6-null pancreata. Yet, there were subtle 
alterations suggesting perturbation of normal differentiation programmes such 
as the upregulation of Krt19 and a mild downregulation of some digestive 
enzymes. Thus, although initial studies showing Gata4 expression in the exocrine 
pancreas attributed it a role in this tissue, our results suggest that it might not be 
the case under physiological conditions. We therefore conclude that, unlike 
Gata6 or Ptf1a, which are necessary for the expression of the acinar 
transcriptome, Gata4 is not a critical driver of acinar gene expression. Indeed, 
lack of Gata4 results in mRNA upregulation of transcription factors that 
orchestrate proper acinar differentiation, such as Ptf1a, Gata6 or Nr5a2, 
suggesting that overexpression of these TF compensates the loss of Gata4.  
2. Gata4 as a possible regulator of epithelial-hematopoietic cell crosstalk 
Despite the lack of a damaging phenotype in the exocrine pancreas, the RNAseq 
data highlighted alterations in two pathways in the absence of Gata4: 
"Hematopoietic cell lineage" and "PPAR signalling". Hematopoietic cells can be 
grossly classified as being involved in the "innate" or "adaptive" immune 
response. Further analysis of the RNAseq data revealed that in Gata4-/- pancreas 
there is a significant downregulation of pathways controlling innate, but not 
adaptive, immunity (Fig. D1A). 
Innate immune cells (Fig. D1B) have been classically viewed as the responsible of 
eliciting an inflammatory response. Initially, cells of the innate immunity were 
described to trigger inflammation by recognizing foreign microbial and viral 
structures, (pathogen-associated molecular patterns, PAMPs). Studies in the last 
years have also attributed them the ability to induce inflammation upon 
recognition of normal cellular constituents released during injury and cell death 
(damage-associated molecular patterns, DAMPs) (Fig. D1C). Both PAMPs and 
DAMPs are recognized by pattern-recognition receptors (PRRs), which induce 
innate immune cells to upregulate co-stimulatory molecules as well as numerous 
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inflammatory chemokines and cytokines that attract and prime other leukocytes 
for activation, thus triggering inflammation (Shalapour & Karin, 2015).  
 
Figure D1. Leukocytes in damage and steady state of the pancreas. (A) GSEA results showing 
decreased regulation of pathways related to innate (but not adaptive) immunity in Gata4-/- 
pancreas compared to control. (B) Schematic representation of innate and adaptive immune 
cells. Hematopoietic Stem Cells (HSC) give rise to the Common Myeloid and Lymphoid 
Progenitors (CMP and LMP, respectively). The CMP gives rise to neutrophils (and other 
granulocytes) and to monocytes, which can differentiate into macrophages and a subset of 
dendritic cells (DCs). Together with other leukocytes (i.e. NK cells), they comprise the innate 
immunity cells. The LMP gives rise to B and T lymphocytes, as well as a subset of DCs, 
constituting the adaptive immunity. DCs are antigen-presenting cells highly specialized in 
triggering an adaptive immune response, and therefore they are considered the link between 
innate and adaptive immunity. Adapted from Rieger & Schroeder, 2012. (C) Basic representation 
of sterile (pathogen-free) inflammation. Upon injury, damaged cells release DAMPs that activate 
resident macrophages to induce inflammation and recruit neutrophils and monocytes that 
differentiate mainly into macrophages. Both of them remove dead cells, and then macrophages 
secrete anti-inflammatory cytokines that resolve inflammation and factors that promote tissue 
regeneration. Although not represented for simplification, the inflammatory process also 
requires a number of additional leukocytes that orchestrate the response, specially T 
lymphocytes. (D) RNAseq data showing expression of markers for leukocytes (Ptprc, coding for 
Cd45, P=0.006); myeloid cells (Cd11b), including macrophages (Adgre1, Mrc1, Clec10a, coding for 
F4/80, Cd206 and Cd301, respectively); DCs (Zbtb46, P=0.04); B lymphocytes (Cd19, Pax5); and T 
lymphocytes (Cd3d, Cd4, Cd8); in control (Gata4+) and Gata4-null (-) pancreata. Distribution of 
islet and exocrine leukocytes described in Calderon et al., 2015 is also shown. 
 
Innate immune cells not only sense the damage and induce inflammation, but 
also remove dead cells and promote tissue regeneration. Neutrophils and 
macrophages are responsible for phagocytosis and clearance of cellular debris. 
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While the first are specialized in degrading completely the phagocytised particle, 
the latter are able to present phagocytised antigens to regulate inflammation 
towards resolution and promote tissue recovery (Fadok et al., 1998; Gea-Sorlí & 
Closa, 2010; Ortega-Gómez et al., 2013) (Fig. D1C). 
It has been shown that leukocyte subpopulations display distinct distribution 
within the pancreas in basal conditions. Thus, macrophages predominate in the 
islets of Langerhans (>98%), while the exocrine pancreas contains a mixture of 
myeloid cells (mainly macrophages), DCs, and B and T lymphocytes (Fig. D1D) 
(Calderon et al., 2015). This study shows how macrophage depletion and 
replacement by donor stem cells results in a precise reconstitution of cellular 
profiles. Thus, maturation of each macrophage subpopulation depends on 
specific factors, as mice lacking functional Csf1              (Macrophage-Colony 
Stimulating Factor, M-CSF) showed a profound decrease in "islet" but not 
"exocrine" macrophages. Altogether, these results indicate the existence of an 
active epithelial-hematopoieti communication in the pancreas even in the 
absence of injury.  
Another study showed that mice lacking Major Histocompatibility Complex class 
II (MHC-II) expression developed a selective, progressive and fatal loss of 
exocrine, but not endocrine, pancreatic cells. Histological analyses revealed a 
progressive lymphocytic cell infiltration as the cause of the damage (Vallance et 
al. 1998). Interestingly, MHC-II is expressed by APCs to avuid autoimmune 
diseases, among other functions (Unanue et al., 2016). Consequently, a defect in 
this pathway might be deleterious for tissues with high self-antigen presenting 
activity. Since the pancreas is loaded with huge amounts of proteases (a 
potential weapon of mass destruction if released uncontrolledly), we speculate 
that a high self-antigen presentation rate would allow a rapid detection of any 
alteration and an effective repair by the immune system. This putative high rate 
of self-antigen presentation in the pancreas would explain the variety of 
leukocytes populating the exocrine, but not the endocrine, pancreas (Calderon et 
al., 2015); and again highlights the importance of tissue-specific communications 
between the epithelium and the immune system.   
A role of Gata4 in epithelial-hematopoietic crosstalk is also suggested by a 
significant downregulation of Ptprc (Cd45) in Gata4-/- pancreas compared to 
control. Markers of myeloid cells and DCs are also consistently downregulated; 
while lymphoid markers are barely detected, except for the B cell marker CD19, 
which regulates B cell responses to self-antigens (Fearon & Carroll, 2000), and is 
also downregulated in Gata4-/- pancreata (Fig. D1D). 
The other significantly downregulated pahtway in Gata4-/- pancreas was "PPAR 
signalling" (Fig. 3B). PPAR signalling has been shown to be necessary to maintain 
an M2 (anti-inflammatory) phenotype in resident macrophages in other tissues 
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(Kang et al., 2008; Odegaard et al., 2007), a feature that is also observed in 
pancreatic exocrine macrophages (Calderon et al., 2015). Since markers of M2 
macrophages also appear downregulated in our RNAseq data in the absence of 
Gata4 (not shown), low PPAR signalling in Gata4-/- pancreata might be indicative 
of a defect in macrophage polarization. Nevertheless, the decrease in PPAR 
signalling could also be related to lipid metabolism, as Gata4-/- pancreata show a 
slight increase in lipomatosis in basal conditions.  
Among all leukocyte markers we checked in our RNAseq data (Fig. 15A), 
macrophages were the only ones decreased in Gata4-null pancreas 
independently of Kras status (WT or mutant); while markers of other 
subpopulations were similarly expressed in all conditions except in Kras* -where 
they increase-, evidencing pancreas immune cell infiltration upon oncogenic 
signalling. In a Kras* background, the decrease of all immune cell markers in a 
Gata4-null context is also indicative of a role for Gata4 in regulating innate 
immune cells. 
Last, but not least, an unbiased genome-wide study identified GATA factors as 
the main regulators of epithelial innate immune responses in C. elegans. In 
addition, the authors proposed that this function is conserved in humans, as 
GATA6 was found to have a protective function in lung epithelial cells exposed to 
P. aeruginosa (Shapira et al., 2006). 
Altogether, these notions suggest that Gata4 regulates a crosstalk between 
epithelial and hematopoietic ells in the exocrine pancreas by inducing 
expression of genes necessary for proper homeostasis of resident immune cells. 
This idea allows interpreting some of the results presented in this work, and may 
be useful for further research on the field.  
3. Gata4 phosphorylation during acinar stress is indicative of an enhanced 
transcriptional activity  
The role of Gata4 during heart development, cardiomyocyte differentiation and 
stress responsiveness has been a matter of intense research (Borok & 
Papaioannou, 2016; Garg et al., 2003; Han et al., 2012; Holtzinger & Evans, 2005; 
Hu et al., 2011; Katanasaka et al., 2016; Kuo et al., 1997; Li et al., 2012; Liang et 
al., 2001; Mehta et al., 2015; Molkentin et al., 1997; Oka et al., 2006; Pu et al., 
2004; Van Berlo et al., 2011; Watt et al., 2004; Yu et al., 2016; Zhao et al., 2008; 
Zhou et al., 2012), providing insight into the regulation of its activity (Table D1). 
Gata4 post-translational modifications have been shown to enhance its 
transcriptional activity in response to hypertrophic stimuli. Specifically, 
phosphorylation of serine 105 mediated by Mek1-Erk1/2 kinases (Liang et al., 
2001) is one of the most common Gata4 post-translational modifications, and is 
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necessary for stress-induced cardiac hypertrophy in vivo (van Berlo et al., 2011). 
 
Modification Residue Function Mechanism Enzyme 
Acetylation 
K312/319/ 
321/323 
Transcriptional 
activation 
Increased DNA binding 
and transcriptional 
activity 
p300 
Phosphorylation 
S105 
Transcriptional 
activation 
Increased DNA binding 
ERK1/2, 
p38 
S160 
Transcriptional 
activation 
Increased interaction 
with co-activators 
CDK4 
Unknown 
Transcriptional 
inhibition, nuclear 
export of Gata4 
Increased interaction 
with Crm1 
GSK3-β 
S261 
Transcriptional 
activation 
Increased acetylation 
by p300 
ERK1/2, 
RSK2, PKA 
S419/420 
Transcriptional 
activation 
Increased DNA binding 
activity 
PKC 
Methylation K299 
Transcriptional 
activation 
Decreased interaction 
with p300 
EZH2 
SUMOylation K366 
Transcriptional 
activation 
Facilitation of nuclear 
localization 
SUMO-1, 
PIAS1 
Table D1. Post-translational modifications that modulate Gata4 transcriptional activity. Adapted 
from Katanasaka, et al., 2016 
We hypothesized that stress conditions might also induce Gata4 phosphorylation 
in the pancreas. Phopho-S105 was up-regulated in acinar cells in multiple 
experimental settings that trigger MAPK (Mek1-Erk1/2) activation, including 
acinar cell isolation and culture (Pinho et al., 2011), pancreatitis (Halbrook et al., 
2017), and mutant Kras-induced PanIN development (Collins et al., 2014). It is 
conceivable that pS105-Gata4 activates a distinct set of genes that are not 
expressed under physiological conditions that allow acinar cells to deal with 
stress/damage. For instance, Reg3b plays a role in pancreatitis as a mitogenic 
and anti-apoptotic factor to enhance tissue regeneration after damage (Gironella 
et al., 2013; Simon et al., 2003), and we have found that its induction during 
pancreatitis is directly regulated by Gata4. 
Since Gata4 is activated upon damage and its loss does not greatly affect exocrine 
pancreas homeostasis, it is possible that the major Gata4 function is related to 
pathological situations. To test this hypothesis, we induced a mild cerulein-
induced pancreatitis in Gata4-null mice. Some damage indicators (oedema, acute 
inflammation, acinar vacuolization) were consistently increased in the absence 
of Gata4, suggesting that Gata4 participates in the regenerative processes. 
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However, Gata4 was not absolutely required for leukocyte homing or for 
complete tissue recovery, indicating that other factors and signalling pathways 
compensated for its absence.  
In a model of induced intracellular activation of trypsinogen, this event is 
sufficient to cause massive cell death, which generates DAMPs that trigger 
inflammation (Gaiser et al., 2011), a process that is also observed in cerulein-
induced pancreatitis, yet to a lesser extent (Hofbauer et al., 1998). As previously 
commented, the contents of dead cells released to the interstitium are sensed by 
innate immune cells as damage signals, triggering inflammation (Piccinini & 
Midwood, 2010). Then, it is possible that pancreatitis in control and Gata4P-/- 
mice develops in a similar manner as it is likely triggered by DAMPs in both 
genotypes, independently of Gata4.  
4. Gata4 is required for PanIN but not for PDAC development 
Mutant Kras activation in the pancreas also induced Gata4 phosphorylation, as 
expected from the fact that Kras* activates Erk1/2 (Liang et al., 2001). Therefore, 
we hypothesized that Gata4 might be relevant to mediate Kras* oncogenic 
signalling. To test this idea, we studied Kras*-induced pancreatic tumourigenesis 
in a model where Gata4 deletion occurs concomitantly to Kras* activation early 
during pancreas organogenesis. In the absence of Gata4 there was a dramatic 
decrease in metaplastic ductal lesions, both tubular complexes (TCs) and PanINs, 
and in some cases the ductal-reprogrammed area was completely absent. 
Nevertheless, PDAC developed at a frequency similar to that of Kras* mice. In the 
light of these results, we propose that: 
1) Kras* signals through Gata4 to initiate ADM resulting in TCs and PanIN 
formation, possibly through phosphorylation by Erk1/2, which induces the 
activation of Gata4 target genes leading to phenotypic changes. 
2) Gata4 is not required for cells to acquire a ductal-like phenotype, defined by 
expression of Krt19 and occurrence of a glandular lumen. Although PanIN and 
PDAC are both ductal structures, their architectural differences rely not only in 
cell-autonomous features (mutations), but also in non cell-autonomous (micro-
environment). For instance, in the Kras* model, PanIN-associated macrophages 
present a pro-inflammatory M1 phenotype, while in later stages of 
carcinogenesis they switch to an anti-inflammatory M2 phenotype, which drives 
pancreatic fibrogenesis and supports tumourigenesis (Liou et al., 2017). 
Preliminary observations suggest that Gata4-null and Gata4+/+ PDAC stroma 
contain similar leukocyte subpopulations (data not shown). Thus, leukocytes in 
Gata4-/- PDAC might be contributing to the ductal phenotype through secretion 
of specific cytokines (i.e. IL17).  
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3) PDAC can arise in the absence of PanIN. This is a notable contribution of this 
work, as it allows dissecting the mechanisms leading to PanIN and PDAC. Co-
occurrence of both lesions in nearly all carcinogenesis models used to date 
preculded studying them as separate events. Only one model has also shown 
PanIN-less PDAC, yet it is based on expression of Kras* and mutant Trp53 by 
ductal cells (Bailey et al., 2015). As growing evidence suggest that PanINs arise 
mainly from acinar cells, this model might not be directly relevant for the study 
of PanIN-PDAC relationship. 
The classical model of tumour progression states that PDAC arises from PanIN 
through the accumulation of mutations and increase of atypia, yet this idea does 
not fit in our model. Recently, atypical flat lesions (AFL) have been postulated to 
be PDAC precursors as well (Aichler et al., 2012), a fact that questions the 
canonical progression model. Although histopathological analysis revealed that 
classical AFL were nearly absent in Kras*;Gata4-/- pancreas, other lesions 
resembling AFL were observed (AFL-like lesions), suggesting the existence of a 
wide array of morphologically distinct, but related, PDAC precursor lesions. One 
histological difference between these lesions relates to the stromal response, 
which is abundant in AFL  (Fig. D2A) and scarce in AFL-like lesions (Fig. D2B).  
 
 
Figure D2. AFL-like 
lesions. (A) Classical 
atypical flat lesion 
(AFL), showing a dense 
stromal response 
(extracted from Aichler 
et al., 2012). (B) 
Representative 
microphotographs of 
AFL-like lesions from  
Kras*; Gata4P-/- pancre-
ata showing a less 
fibrotic and highly 
cellular stroma. (C) 
Expression of the PSC 
marker Desmin (Des) 
showing an increase in 
Kras* compared to 
control and Kras*; 
Gata4-/- pancreas. 
P>0.05 (ns); P<0.05 
(*); P<0.01 (**); 
P<0.001 (***). 
 
PSCs, which are responsible for extracellular matrix deposition, have been 
shown to differentiate from monocytes during pancreatic regeneration (Ino et 
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al., 2014).  On the basis of our hypothesis proposing a role of Gata4 regulating 
cells of the innate immunity, loss of Gata4 might result in reduced monocyte 
infiltration and PSC differentiation, and reduced stromal response. Our RNAseq 
data shows a significant increase of the PSC marker Desmin compared to both 
control and Kras*;Gata4P-/- pancreas (Fig. D2C), indicating that Kras*-induced 
inflammation is accompanied by increased presence (and probably activation) of 
PSCs, which is halted in the absence of Gata4.  
It has been reported that the transcription factor Sox9 is also necessary for 
PanIN development from acinar cells -and not centroacinar or ductal cells (Kopp 
et al., 2012)-, which is in accordance to our results. The authors claimed that 
Sox9-dependent expression of genes necessary for ductal reprogramming during 
PanIN formation are the principal mechanism for PDAC initiation, as their 
analysis of 1 year-old Sox9P-/- mice did not reveal PanINs or PDAC. However, 
Gata4 and Sox9 likely orchestrate different pathways, as Sox9 is required to 
establish a ductal phenotype whereas our data suggest that Gata4 is necessary 
for Kras*-induced ADM and PanIN formation, but not for acquiring a ductal 
phenotype itself.  This notion is evidenced by the different experiments 
presented in this thesis showing that Gata4-/- acinar cells can actually acquire a 
ductal phenotype (pancreatitis in Gata4P-/- mice [Fig. 6B]; IL17 treatment in vitro 
and in vivo, [Fig. 11, 12]; and PDAC formation, [Fig. 7, 9]). 
The incidence of PanIN/PDAC discussed above is based on experiments in which 
Gata4 deletion and Kras* activation takes place during embryo development. 
Gata4 has been reported to play a role in pancreas specification and its deletion 
during organogenesis might have deleterious effects in the adult tissue. 
Therefore, we deleted Gata4 and activated Kras* selectively in adult acinar cells 
using the Ptf1aCreERT2/+ strain by inducing recombination at 8 weeks of age, when 
Ptf1a is only expressed in acinar cells (Pan et al., 2013). PDAC arising in this 
context unequivocally originated from acinar cells, as shown by the detection of 
YFP from the Rosa26YFP/YFP allele. Importantly, the frequency of tumours 
observed in Kras*Gata4P-/- mice was not significantly different compared to 
Kras* mice, indicating that, in adult mice, chronic pancreatitis can promote 
pancreatic carcinogenesis independently of Gata4. Moreover, these experiments 
support other studies showing an acinar origin of PDAC. 
These results also support a non-linear progression model where PDAC does not 
necessarily arise from low-grade PanIN. This hypothetical alternative model, 
which has been already postulated (Real et al., 2008), implicates that mutant 
Kras drives low-grade PanIN in parallel to PDAC, but that these two pathways 
are not necessarily linked at the cellular level and do not represent sequential 
events.  
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5. IL17 induces ADM in vitro, but not PanIN in vivo, in Gata4-/- acinar cells 
In order to determine whether Gata4-/- acinar cells can undergo ADM in vitro, we 
established 3D cultures and treated them with cytokines that were induced in 
Kras* pancreas (compared to control in RNAseq data), as well as other cytokines 
known to induce ADM. EGF and IL17 were the only factors that consistently 
induced ADM in Gata4+/+ acini. Both of them also enhanced ADM in Gata4-/- acini, 
but IL17 was most active in this assay. Importantly, EFG-treated Gata4-/- cells 
lost viability unlike EGF-treated Gata4+/+ cysts, suggesting a crucial role of Gata4 
in Egfr signal transduction, possibly through the Ras-Erk pathway. Contrarily, 
IL17 signalling induces ADM in a manner independent from Gata4 (Fig. D3). Yet, 
further work is needed to substantiate this hypothesis. 
 
Figure D3. ADM induced by EGF, 
but not IL17, requires Gata4. 3D 
cultures of KrasWT acinar cells were 
analysed at late time points (day 7). 
While EGF-treated Gata4+/+ cells still 
present a cystic structure, Gata4-/- 
cells undergo collapse. In contrast, 
IL17 promotes ADM until late time 
points in both genotypes, suggesting 
that EGF and IL17 activate different 
pathways to induce ADM.  
 
 
 
 
 
 
In vivo, IL17 has been shown to induce PanIN development in Kras* mice (Loncle 
et al., 2015; Mcallister et al., 2014). We have reproduced these results showing a 
higher prevalence of PanINs in adeno-IL17-injected than in adeno-GFP-injected 
Kras* mice. Contrarily, Kras*;Gata4P-/- mice receiving adeno-IL17 showed a sharp 
increase in lipomatosis and mucin-negative metaplasia, but not PanINs.  
Altogether, these results suggest that: 
1. Gata4 is downstream of the Egfr-Kras-Erk pathway and mediates a cell-
autonomous response that leads to ADM in a Gata4+/+ context (cysts in vitro, 
PanINs in vivo), and to cyst collapse in Gata4-/- (failure in maintaining a cystic 
phenotype in vitro, lack of PanIN in vivo). These results are in accordance with 
the fact that both EGF and Kras* signal through the MEK-ERK1/2 pathway, which 
phosphorylates Gata4, thus modulating its transcriptional activity. 
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2. Gata4 is required for acquiring a PanIN phenotype. We have shown that IL17 
promotes abnormal metaplasia instead of PanINs in a Gata4-null context. IL17 is 
a pro-inflammatory cytokine that promotes both immune cell responses (Jin & 
Dong, 2013; Jovanovic et al., 1998) and tumour growth, enhancing cell survival 
(L. Wang et al., 2009), and inhibiting apoptosis (Nam et al., 2008). Although the 
specific mechanisms through which IL17 induces metaplasia in Gata4-/- pancreas 
need to be further elucidated, we demonstrate that Gata4 is necessary for 
developing a PanIN phenotype. 
3. IL17 promotes ADM through mechanisms different from EGF, the former 
acting through Gata4-independent pathways and the latter through cell-
autonomous mechanisms involving Erk-Gata4 axis. Indeed, IL17 has been 
reported to signal through the Stat3 pathway to induce ADM (Loncle et al., 2015; 
Mcallister et al., 2014). Interestingly, we observed no phospho-Stat3 activation in 
Gata4-/- PALes (Fig. 13), while we could observe phospho-Stat3 positive acinar 
cells upon IL17 treatment in vivo (not shown). These observations suggest that 
ADM can result from different stimuli (EGF or IL17 treatment) through 
activation of different mechanisms (Kras-Erk-Gata4 and phospho-Stat3, 
respectively).  
6. A possible mechanism by which Gata4 regulates PanIN differentiation 
A significant increase in lipomatosis is observed in Kras*;Gata4-/- pancreata. 
Similar results have been observed in mouse models where acinar cells acquire 
an incomplete differentiation due to deletion of transcription factors controlling 
pancreatic organogenesis. Specifically, lineage tracing experiments have shown 
that inactivation of c-Myc or Gata6 during embryonic development results in 
replacement of immature acinar cells by adipocytes (Bonal et al., 2009; 
Martinelli et al., 2012), in part through transdifferentiation. Similarly, E2F 
transcription factors (E2F1/E2F2), which are ubiquitous key regulators of cell 
growth control, are necessary to maintain differentiation in pancreatic cells, and 
their deletion causes pancreas atrophy and replacement by ductal structures and 
adipose tissue (Iglesias et al., 2004). These studies suggest that incomplete 
acinar cell differentiation can favour transdifferentiation into adipocytes. Since 
Gata4 is required for PanIN development, its absence might promote adypocyte 
transdifferentiation in PanIN-to-be cells. The sharp increase of lipomatosis and 
the lack of PanINs in Kras*;Gata4P-/- mice infected with adeno-IL17 supports this 
idea. 
We think that Gata4-dependent PanIN development is related to the 
requirement of both Gata4 and Shh to regulate a gastric phenotype, which 
characterize PanINs. The evidences supporting this idea are listed below: 
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1. Hedgehog proteins (Shh, Ihh) play a critical role in early patterning of the 
primitive gut, from which the pancreas and the stomach develop. Both stomach 
specification and adult gastric gland differentiation depend on the Hedgehog 
pathway (Van den Brink, 2007; Van den Brink et al., 2001). Similarly, Gata4 plays 
a crucial role in gastric differentiation: by E18.5, Gata4-/- cells fail to support 
terminal differentiation of the gastric lineages. Importantly, lack of similar 
phenotypes in mice deficient for Gata5 or Gata6 indicate a unique role for Gata4 
in regulating differentiation of definitive endoderm to the stomach's glandular 
epithelium (Jacobsen et al., 2002). 
2. PanINs are structures with a characteristic morphology and gene expression 
that is not typically observed in the normal pancreas. As described previously, 
PanINs express mucins and other proteins that are not expressed by either 
ductal or acinar cells. In order to determine the expression profile of PanINs, a 
study analysed the gene expression profile of microdissected PanINs compared 
to pancreatic ductal cells. It was found that PanINs activate expression of foregut 
markers, especially genes that are expressed during gastric differentiation. In 
addition, it was proposed that this expression switch was mediated through 
activation of Hedgehog pathway (Prasad et al., 2005), which is needed not only 
for PanIN development, but also for progression to pancreatic cancer (Thayer et 
al., 2003).  
3. The role of both Shh and Gata4 in gastric differentiation and PanIN formation 
suggests an interplay between the two factors during stomach and PanIN 
development. Interestingly, Gata4 and Gata6 bind to a Shh enhancer and regulate 
its expression during pancreas organogenesis (Xuan & Sussel, 2016). We 
therefore hypothesize that Gata4 regulates Shh expression to induce PanIN 
transdifferentiation. Preliminary results show that control and Gata4-/- 
pancreata express low levels of Gli1 and Gli2 (effectors of Shh signalling), while 
their expression increase in Kras* but remains low in Kras*;Gata4-/- pancreas; 
and a similar expression pattern is observed for Shh (Fig. D4A).  
In addition, IHC analysis of Gli1 shows higher expression in PanINs compared to 
PALes (Fig. D4B). Altogether, these results suggest that Gata4 contributes to Shh 
regulation during PanIN formation. Yet, we have also observed Gli1 expression in 
tumours independently of Gata4 (Fig. D4B), supporting the idea that Shh is 
necessary for PDAC development cancer (Thayer et al., 2003), and that is 
expressed in a Gata4-independent manner at late stages of carcinogenesis. 
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Figure D4. Gata4 regulates Hedgehog signalling. (A) mRNA expression showing an 
upregulation of Gli1, Gli2 and Shh in Kras* pancreata, which is blunted in Kras*;Gata4-/-. P<0.05 
(*); P<0.01 (**); P<0.001 (***); nd (not detected). (B) Gli1 expression in PanIN, PALe and PDAC. 
7. Gata4 mediates Kras-induced inflammation 
The results from the RNAseq experiment show that Kras* induces expression of 
mediators that attract leukocytes and promote inflammation, and that this 
response is blunted in Gata4-null pancreata. Generally, tissue resident 
macrophages are the main responsible of initiating an inflammatory response 
(Davies et al., 2013), and likely play a role in Kras*-induced inflammation. 
Accordingly, macrophages are the major leukocyte subpopulation present in 
ADM and PanINs (Clark et al., 2007) and, importantly, it has been shown that in 
response to Kras*, acinar cells express Icam1 that activates macrophages to elicit 
an inflammatory response (Liou et al., 2015).  
We hypothesized that Gata4 regulates expression of genes necessary to stimulate 
macrophages upon Kras activation. To explore this notion, we isolated acinar 
cells and showed that multiple factors involved in macrophage activation are 
downregulated in Gata4-null acini, including Reg3b (Lörchner et al., 2015) and 
the Cxr4-Ccl12 axis (Lee et al. 2003), which is also known to be important during 
pancreatic cancer progression (Wu et al., 2013) through the activation of Sonic 
Hedgehog pathway (Singh et al., 2012).  
Although the specific acinar-secreted factors that activate macrophages need to 
be further characterized, our data show that medium conditioned by Gata4-/- 
acini is less effective in inducing cytokine expression by cultured macrophages. 
Although Reg3b is involved in macrophage activation, other known (i.e. Cxcl12) 
and unknown factors regulated by Gata4 are likely playing a role as well. The 
analysis of the secretome of Kras* and Kras*;Gata4-/- acinar cells will allow 
dissecting the factors that are differentially expressed and may play a role in 
macrophage activation. 
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8. PanINs constitute a tumour suppression barrier induced by 
inflammation and oncogenic stress. 
A role of inflammation in PanIN development has been described at the 
molecular and cellular levels. At the molecular level, cytokines such as IL17, TNF-
α and Ccl5 are known to induce PanIN development (Liou et al., 2013; Mcallister 
et al., 2014). At the cellular level, macrophages play a pivotal role in secreting 
cytokines and expressing metalloproteases that allow PanIN formation and 
extracellular matrix remodelling (Liou et al., 2013), and, as already described, 
acinar cells express Icam1 upon Kras* activation that attracts macrophages to 
promote PanIN development (Liou et al., 2015).  
PanIN-1 are known to be senescent structures (Caldwell et al., 2012; Collado et 
al., 2005). The senescence program locks the cells into a cell-cycle arrest that 
prevents the spread of damage to the next cell generation and precludes 
potential malignant transformation. A plethora of stresses can provoke cellular 
senescence, including telomeric dysfunction resulting from repeated cell division 
(replicative senescence), mitochondrial deterioration, oxidative stress, severe 
DNA damage and chromatin disruption (genotoxic stress), as well as the 
expression of certain oncogenes (oncogene-induced senescence) (Copp et al., 
2010). However, the senescent phenotype is not limited to an arrest of cell 
proliferation. In fact, senescent cells are metabolically active and undergo 
profound changes in protein expression and secretion, ultimately acquiring a 
Senescence-Associated Secretory Phenotype (SASP). SASP comprises 
interleukins, inflammatory cytokines, and growth factors that affect surrounding 
cells, reinforcing senescence, activating immune surveillance and promoting cell 
survival (Acosta et al., 2013).  
Considering that PanINs are Kras*-induced senescent structures, they likely 
contribute to stop oncogenic transformation. In a KrasWT context, damage-
induced inflammation promotes dedifferentiation of acinar cells, both being 
required for pancreas regeneration (Fig. D5A). However, when inflammation is 
not resolved due to continuous Kras signalling, cells cannot undergo acinar re-
differentiation (Morris et al., 2010) and, since inflammation is not resolved, 
epithelial cells continue receiving pro-survival signals. Since dedifferentiated 
cells have more potential to become tumourigenic (Friedmann-Morvinski et al., 
2012; Hermann et al., 2014; Kumar et al., 2012; Martinelli et al., 2015; Ziegler et 
al., 2013), the continuous proliferative and pro-survival stimuli might trigger the 
induction of protective mechanisms such as senescence, thus leading to PanIN 
development (Fig. D5B). Therefore, PanINs may be considered as a protective 
mechanism -in which dedifferentiated cells susceptible of oncogenic 
transformation undergo senescence- and not as direct PDAC precursors.  
The tumour-limiting effect of PanINs during oncogenic transformation has been 
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proposed in a number of studies. For instance, the study of Toll-like Receptors 
(TLRs), which bind DAMPs to trigger inflammation, has highlighted the 
importance of developing a proper inflammatory response in order to induce 
PanIN and limit carcinogenesis. Binding of DAMPs to TLRs results in an 
inflammatory response through Myd88 signalling pathway. Concretely, TLR9 
stimulation induces PSCs to become fibrogenic and secrete chemokines that 
promote inflammation, epithelial cell proliferation and PanIN development 
(Zambirinis et al., 2015); and similar results have been found for TLR7 (Ochi et 
al., 2012a) and for TLR4 (Ochi, Nguyen, et al., 2012b). Puzzlingly, inhibition of 
the TLR signalling transducer Myd88 results in exacerbated pancreatic 
inflammation and enhanced malignant progression due to a defect in DCs 
function (Ochi et al., 2012b). 
Figure D5. PanINs are tumour suppression barriers. (A) In KrasWT context, tissue damage 
(pancreatitis) induces DAMP-mediated inflammation and activates Kras to promote cell survival. 
These signals induce acinar cell dedifferentiation and ADM. When damage is resolved, inhibition 
of Kras signalling is necessary for promoting acinar re-differentiation and tissue regeneration.  
(B) Mutant Kras induces Gata4-dependent expression of genes that activate macrophages to 
trigger inflammation, and promotes cell survival and proliferation, which altogether results in 
acinar dedifferentiation and ADM. In this case, mutant Kras does not allow acinar re-
differentiation. Permanent proliferative signals from active Kras* and inflammatory cytokines 
increase oncogenic stress and activate Gata4 to induce PanIN formation, therefore limiting the 
tumourigenic process.  
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TLR-mediated inflammation may be interpreted as a response to infection or 
tissue injury (the actual activators of TLRs). In such situations, TLR-expressing 
cells, which are trained to be the guardians of a tissue with high damaging 
potential, receive signals to avoid a catastrophe: the uncontrolledly release of 
digestive enzymes. To do so, they orchestrate an inflammatory response in order 
to promote tissue regeneration; they isolate acini to protect them from enzymes 
released into the interstitium (fibrogenic response); and they induce cells 
suffering from oncogenic stress to undergo a senescent program (PanIN 
development). In this context, it is conceivable that loss of the regulator Myd88 
disrupts the mechanisms controlling inflammation, fibrogenesis and PanIN 
formation, resulting in enhanced tumourigenesis. 
Another example of the tumour-limiting effect of PanINs and their surrounding 
microenvironment has been highlighted by the study of the fibrogenic response. 
Although to a lesser extent compared to PDAC, PanINs also develop a stromal 
response that results in deposit of extracellular matrix surrounding the lesion, a 
process mediated by activated PSCs that interplay with pro-inflammatory 
macrophages and DCs (Shi et al., 2014). Initially, fibrosis was considered as a 
barrier for drug delivery (Olive et al., 2009) and, therefore, its depletion was a 
promising strategy to improve patient outcome. However, it has been recently 
shown that the fibrogenic response has anti-tumoural effects as they limit cancer 
cells potential to be invasive (Özdemir et al., 2015; Rhim et al., 2014).  
In line with these studies, our work also suggests a tumour-suppressing effect of 
PanINs. In the experiments where we show that PDAC develops in the absence of 
PanINs (Kras*;Gata4P-/- mice) (Fig. 7B, 8B, 19A, 19B), we have consistently 
observed that these tumours present higher grading than the ones formed in 
Kras* mice. In addition, we have provided with data showing that mice bearing 
Gata4-null tumours present poorer survival in a Trp53-/- background. Altogether, 
these results suggest that PanIN can limit tumour progression. 
9. How does PDAC develop in Kras*;Gata4-/- pancreas 
Given that PDAC can develop in the absence of PanINs, we aimed to investigate 
the putative precursor that may progress to frank malignancy. A detailed 
analysis of Kras*;Gata4-/- pancreata identified acinar cell clusters characterized 
by paleness, reduced eosinophilia, and a variable degree of hyperplasia, with or 
without enlarged lumina (ductal and acinar lesions, respectively), as the only 
abnormalities present in the pancreatic parenchyma. We designated these 
lesions “PALes” for “Pale Acinar Lesions”, and we hypothesize that PALes are 
clusters of acinar cells initiating a Kras*-induced metaplastic process, which 
would progress into ADM/PanIN in a Gata4+/+ context but not in a Gata4-/- 
genetic background (Fig. D6A). Indeed, other studies have inadvertedly reported 
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the presence of acinar PALes in Kras*;Gata4+/+ mice (Fig. D6B) (Guerra et al., 
2011, supplementary data). 
 
Figure D6. Hypothetical model of Gata4-/- PDAC development from AFL-like PAle lesions. 
(A) Representative images showing the different morphologies of small PALes, which are found 
in Kras*;Gata4-/- mice of all ages (left), and advanced PALes found only in Kras*;Gata4-/- mice 
older than 40w (right). (B) Proposed model of pancreatic carcinogenesis in Kras* and               
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(Fig. D6 cont.) Kras*;Gata4P-/- mice. Oncogenic signalling derived from permanent Kras 
activation of pancreatitis activates tumour-suppressor mechanisms such as Gata4-mediated 
PanIN development. Accumulation of oncogenic stress results in a genomic catastrophe that 
inactivates tumour suppressors and result in development of PDAC precursors: classical AFL 
(cAFL) in Kras* mice and AFL-like lesions in Kras*;Gata4P-/-. Although there is a long latency time 
before the genomic catastrophe occurs, AFL and AFL-like lesions rapidly progress to PDAC, which 
display a highly cellular or a fibrotic stroma in Gata4-/- and Gata4+/+ PDAC, respectively. 
Arrowheads indicate infiltration foci, indicative of malignancy.  
PALes characterized throughout this study could be frequently identified in mice 
of all ages, but advanced PALes (larger than PALes with increased atypia, but 
without reaching a PDAC status; earlier referred as AFL-like lesions) were much 
more scarce (Fig. D9A). A thorough quantification of these lesions is currently 
being performed, but a preliminary analysis shows that the incidence of 
advanced PALes resembles much more the incidence of tumours than that of 
early PALes. These results suggest that many PALes do not progress, but once 
they do, they rapidly develop into PDAC.  
As commented earlier, we suggest that advanced PALes are AFLs that look 
different from the ones originally described (Aichler et al., 2012), as they present 
a low-fiber and highly cellular stroma, probably due to the lack of PSCs activation 
in a Gata4-null context. Indeed, a preliminary analysis of the PDAC stroma in the 
presence or absence of Gata4 reveals higher fibrogenic response in the first case 
and higher cellular content in the second (represented in Fig. 9B). Considering 
that the stromal response limits pancreatic tumourigenesis, these results may 
account for the recurrent observation that Gata4-/- PDACs are of higher tumour 
grade and yield a poorer survival in a p53-null context. If that was the case, the 
work presented here would strengthen the recent hypothesis pointing to AFL as 
true PDAC precursors (Aichler et al., 2012), while low-grade PanINs would 
represent mainly dead-end lesions activating a senescence program (Fig. 9B) 
(Caldwell et al., 2012, Guerra et al., 2011, Collado et al., 2005). These findings 
would be in agreement with the high frequency of low-grade PanIN in the 
normal population, which do not progress to PDAC (Matsuda et al., 2017). In this 
regard, it is noteworthy that PALE-like lesions have recently been identified in 
human pancreata (Hruban R, personal communication). 
The proposed hypothesis is in agreement with a recent study showing that PDAC 
usually carries complex genomic rearrangements that are likely to be the cause 
of malignancy (Notta et al., 2016). This study proposes that PDAC does not 
necessarily develop through a particular sequence of genetic alterations (KRAS 
followed by CDKN2A, then TP53 and SMAD4) and that the evolutionary trajectory 
of pancreatic cancer progression is not gradual and can be attributted to a single 
genomic rearrangement event that inactivate en bloc the tumour suppressors 
CDKN2A, TP53 and SMAD4. These notions are consistent with the observation 
that 80% of pancreatic cancer patients present with advanced disease at 
diagnosis. The reasons for the occurrence of such catastrophic mitotic 
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phenomena are far from being understood, but their contribution to frank 
malignancy has been postulated (Rode et al., 2016). 
10. GATA4 in human tumours  
Our exploratory analysis of the role of GATA4 in human tumours has unveiled 
that GATA4 expression is absent from normal ducts but it is detectable in PanINs 
and in a fraction of patient’s PDAC. 
Given our previous findings of loss of GATA6 expression in basal-like tumours, 
we analysed GATA4 expression in the context of the molecular taxonomy of 
PDAC (P. Bailey et al., 2016; Collisson et al., 2011; Moffitt et al., 2015; Noll et al., 
2016). GATA4 expression was also lower in tumours with a basal-like/squamous 
phenotype and low GATA4 expression is related to poorer survival. Interestingly, 
the combined analysis of GATA4 and GATA6 expression showed that patients 
with tumours having a low expression of both genes had the lowest survival, 
suggesting partially non-overlapping function for the two genes. Tumours 
expressing high-GATA4 also showed higher activity of the pathway "digestion", 
which includes several digestive enzymes, and therefore is indicative of cell 
differentiation. Contrarily, tumours expressing low GATA4 display higher 
activity of the pathways involved in cell cycle progression and mitosis. 
Altogether, these results suggest that GATA4 also plays a tumour suppressive 
role in human carcinogenesis, and that detection of GATA proteins in PDAC 
biopsies could be informative of patient survival. 
11. Final remarks 
Our work provides evidence that Gata4 is an important regulator of Kras*-
induced inflammation and metaplasia. Unlike Gata6, Gata4 is not required to 
maintain acinar function, yet we suggest that Gata4 regulates an epithelial-
hematopoitic signalling in the pancreas in the steady state. This regulation is not 
evident in basal conditions, but it becomes overt in a Kras* context, where the 
oncogene fails to induce inflammation and ADM/PanIN in the absence of Gata4. 
We propose that upon Kras* activation, Gata4 regulates the expression of factors 
that stimulate macrophages to elicit an inflammatory response, as well as it 
allows epithelial cells suffering from oncogenic stress to undergo PanIN 
transdifferentiation, whose senescent state limits carcinogenesis. Accordingly, 
Gata4-null PDAC presents higher grading and poorer survival in a Trp53-/- 
background. Overall, our results show that Gata4 has unique functions in the 
pancreas that are fundamental for developing a proper response to Kras*-
induced oncogenic stress.  
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1. Gata4 is dispensable for pancreas development after E10.5 and, unlike Gata6, 
it is not required for the maintenance of acinar homeostasis in the adult.  
2. Gata4P-/- mice develop tumours when mutant Kras expression is activated 
either in pancreatic progenitors or in adult acinar cells. However, they do not 
develop PanIN or acino-ductal metaplasia. 
3. Gata4-null acinar cells can undergo metaplasia upon IL17 treatment in vitro, 
but fail to form PanINs upon IL17 administration in vivo, indicating that Gata4 is 
necessary for PanIN development. 
4. Gata4 is required for the inflammatory response induced by mutant Kras in 
the pancreas. 
5. Gata4 regulates the expression of soluble factors, including Reg3b, which 
activate macrophages to enhance a further inflammatory response. 
6. In mice, Gata4 behaves as a tumour suppressor gene when its inactivation is 
combined with that of Trp53 and the activation of mutant Kras. 
7. GATA4 is lost in a subset of human PDAC, especially in the squamous subtype. 
Patients with tumours showing low levels of expression of GATA4 and GATA 
have the poorest survival.  
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1. Gata4 es prescindible para el desarrollo del páncreas posteriormente a E10.5 
y, contrariamente a Gata6, no se requiere para el mantenimiento de la 
homeostasis acinar en el adulto.  
2. Los ratones Gata4P-/- desarrollan tumoures cuando la expresión de Kras 
mutante se activa tanto en progenitores pancreáticos como en células acinares 
adultas. Aun así, no desarrollan PanINs ni metaplasia acino-ductal. 
3. Las células acinares deficientes en Gata4 pueden desarrollar metaplasia ante el 
tratamiento con IL17 in vitro, pero no son capaces de formar PanINs ante la 
administración de IL17 in vivo, indicando que Gata4 es necesario para el 
desarrollo de PanINs.  
4. Gata4 se require durante la respuesta inflamatoria inducida por Kras mutante 
en el páncreas. 
5. Gata4 regula la expresión de factores solubles, incluyendo Reg3b, que activan 
a macrófagos para aumentar una posterior respuesta inflamatoria. 
6. En ratones, Gata4 se comporta como un gen supresor de tumoures cuando su 
inactivación se combina con la de Trp53 y la activación de Kras mutante. 
7. La expresión de GATA4 se pierde en un grupo de PDAC en humanos, 
especialmente en el subtipo escamoso. Los pacientes con tumoures que 
presentan niveles bajos de expresión de GATA4 y GATA6 tienen el peor 
pronóstico. 
 
 
 
 
 
 
 
 
 
 
   BIBLIOGRAPHY 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
   BIBLIOGRAPHY 
 135 
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Morton, J. P., Athineos, D., … 
Gil, J. (2013). A complex secretory program orchestrated by the 
inflammasome controls paracrine senescence. Nat Cell Biol, 15(8), 978–990. 
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., … 
DePinho, R. A. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to 
produce metastatic pancreatic ductal adenocarcinoma. Genes dev, 17(24), 
3112–3126.  
Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., & Edlund, H. (1998). beta-Cell-
specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-
cell phenotype and maturity onset diabetes. Genes dev, 12, 1763–1768. 
Aichler, M., Seiler, C., Tost, M., Siveke, J., Mazur, P. K., Da Silva-Buttkus, P., … 
Esposito, I. (2012). Origin of pancreatic ductal adenocarcinoma from 
atypical flat lesions: a comparative study in transgenic mice and human 
tissues. J Pathol, 226(5), 723–734. 
Akinci, E., Banga, A., Greder, L. V, Dutton, J. R., & Slack, J. M. (2012). 
Reprogramming of pancreatic exocrine cells towards a beta (β) cell 
character using Pdx1, Ngn3 and MafA. Biochem J, 442(3), 539–550. 
Amaral, A. F., Porta, M., Silverman, D. T., Milne, R. L., Kogevinas, M., Rothman, N., 
… Malats, N. (2013). Pancreatic cancer risk and levels of trace elements. Gut, 
61(11), 1583–88.  
Amundadottir, L., Kraft, P., Stolzenberg-solomon, R. Z., Fuchs, C. S., Petersen, G. 
M., Arslan, A. A., … Hoover, R. N. (2009). Genome-wide association study 
identifies variants in the ABO locus associated with susceptibility to 
pancreatic cancer. Nat Genet, 41(9), 986–90.  
Andreotti, G., & Silverman, D. T. (2012). Occupational Risk Factors and Pancreatic 
Cancer: A Review of Recent Findings. Mol Carcinog, 51(1), 98–108.  
Apte, M. V, & Wilson, J. S. (2003). Stellate Cell Activation in Alcoholic Pancreatitis. 
Pancreas, 27(4), 316–320. 
Ardito, C. M., Grüner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, 
N., Mazur, P. K., … Siveke, J. T. (2012). EGF Receptor Is Required for KRAS-
Induced Pancreatic Tumorigenesis. Cancer Cell, 22(3), 304–317.  
Baeyens, L., Bonné, S., Bos, T., Rooman, I., Peleman, C., Lahoutte, T., … Bouwens, L. 
(2009). Notch Signaling as Gatekeeper of Rat Acinar-to-β-Cell Conversion in 
Vitro. Gastroenterology, 136(5), 1750–1760.  
Bailey, J. M., Alsina, J., Rasheed, Z. A., Mcallister, F. M., Fu, Y. Y., Plentz, R., … Leach, 
S. D. (2014). DCLK1 Marks a Morphologically Distinct Subpopulation of Cells 
With Stem Cell Properties in Preinvasive Pancreatic Cancer. 
Gastroenterology, 146(1), 245–256.  
Bailey, J. M., Hendley, A. M., Lafaro, K. J., Pruski, M. A., Jones, N. C., Alsina, J., … 
Iacobuzio-donahue, C. A. (2015). p53 mutations cooperate with oncogenic 
Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene, 
35(32), 4282-8. 
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A., Gingras, M., … Andrew, V. 
(2016). Genomic analyses identify molecular subtypes of pancreatic cancer. 
Nature, 531(7592), 47–52.  
Balagué, C., Gambús, G., Carrato, C., Porchet, N., Aubert, J.-P., Kim, Y. S., & Real, F. 
(1994). Altered Expression of MUC2, MUC4, and MUC5 Mucin Genes in 
Pancreas Tissues and Cancer Cell Lines. Gastroenterology, 106(4), 1054–
1061.  
BILIOGRAPHY 
 136 
Bao, Y., Prescott, J., Yuan, C., Zhang, M., Kraft, P., Babic, A., … Wolpin, B. M. (2017). 
Leucocyte telomere length, genetic variants at the TERT gene region and 
risk of pancreatic cancer. Gut, 66(6), 1116–22.  
Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V, Hezel, A. F., … 
Depinho, R. A. (2006). Both p16(Ink4a) and the p19(Arf)-p53 pathway 
constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl 
Acad Sci U S A, 103(15), 5947–52.  
Bardeesy, N., & Depinho, R. A. (2002). Pancreatic cancer biology and genetics. 
Nat Rev Cancer, 2(12), 897–909.  
Bartsch, D. K., Gress, T. M., & Langer, P. (2012). Familial pancreatic cancer-
current knowledge. Nat Rev Gastroenterol Hepatol, 9(8), 445–453.  
Becker, A. E., Hernandez, Y. G., Frucht, H., & Lucas, A. L. (2014). Pancreatic ductal 
adenocarcinoma: Risk factors, screening, and early detection. World J 
Gastroenterol, 20(32), 11182–11198.  
Benitez, C. M., Goodyer, W. R., & Kim, S. K. (2012). Deconstructing Pancreas 
Developmental Biology. Cold Spring Harb Perspect Biol, 4(6), pii: a012401. 
Beres, T. M., Masui, T., Swift, G. H., Shi, L., Henke, R. M., & Macdonald, R. J. (2006). 
PTF1 Is an Organ-Specific and Notch-Independent Basic Helix-Loop-Helix 
Complex Containing the Mammalian Suppressor of Hairless (RBP-J) or Its 
Paralogue, RBP-L. Mol Cell Biol, 26(1), 117–130.  
Biankin, A. V, Waddell, N., Kassahn, K. S., Gingras, M., Muthuswamy, L. B., Johns, A. 
L., … Al., E. (2012). Pancreatic cancer genomes reveal aberrations in axon 
guidance pathway genes. Nature, 491(7424), 399–405.  
Bockman, D. E., Boydston, W. R., & Anderson, M. C. (1982). Origin of Tubular 
Complexes in Human Chronic Pancreatitis. Am J Surg, 144(2), 243–9. 
Bockman, D. E., Guo, J., Büchler, P., Müller, M. W., Bergmann, F., & Friess, H. 
(2003). Origin and Development of the Precursor Lesions in Experimental 
Pancreatic Cancer in Rats. Lab Invest, 83(6), 853–859.  
Bonal, C., Thorel, F., Ait-Lounis, A., Reith, W., Trumpp, A., & Herrera, P. (2009). 
Pancreatic Inactivation of c-Myc Decreases Acinar Mass and 
Transdifferentiates Acinar Cells Into Adipocytes in Mice. Gastroenterology, 
136(1), 309–319.  
Bonnefond, A., Sand, O., Guerin, B., Durand, E., De Graeve, F., Huyvaert, M., … 
Froguel, P. (2012). GATA6 inactivating mutations are associated with heart 
defects and, inconsistently, with pancreatic agenesis and diabetes. 
Diabetologia, 55(10), 2845–7.  
Borok, M. J., & Papaioannou, V. E. (2016). Unique functions of Gata4 in mouse 
liver induction and heart development. Dev Biol, 410(2), 213–22. 
Bosetti, C., Lucenteforte, E., Silverman, D., Petersen, G., Bracci, P., Ji, B., … La 
Vecchia, C. (2012). Cigarette smoking and pancreatic cancer: an analysis 
from the International Pancreatic Cancer Case-Control Consortium (Panc4). 
Ann Oncol, 23(7), 280–84.  
Bouwens, L. (1998). Cytokeratins and Cell Differentiation in the Pancreas. J 
Pathol, 184(3), 234–239. 
Brembeck, F. H., Schreiber, F. S., Deramaudt, T. B., Craig, L., Rhoades, B., Swain, G., 
… Rustgi, A. K. (2003). The Mutant K-ras Oncogene Causes Pancreatic 
Periductal Lymphocytic Infiltration and Gastric Mucous Neck Cell 
Hyperplasia in Transgenic Mice. Cancer Res, 63(9), 2005–2009. 
Buchholz, M., Braun, M., Heidenblut, A., Kestler, H. A., Klöppel, G., Schmiegel, W., 
   BIBLIOGRAPHY 
 137 
… Gress, T. M. (2005). Transcriptome analysis of microdissected pancreatic 
intraepithelial neoplastic lesions. Oncogene, 24(44), 6626–36.  
Calderon, B., Carrero, J. A., Ferris, S. T., Sojka, D. K., Moore, L., Epelman, S., … 
Unanue, E. R. (2015). The pancreas anatomy conditions the origin and 
properties of resident macrophages. J Exp Med, 212(10), 1497–1512.  
Caldwell, M. E., DeNicola, G. M., Martins, C. P., Jacobetz, M. a, Maitra,  a, Hruban, R. 
H., & Tuveson, D. a. (2012). Cellular features of senescence during the 
evolution of human and murine ductal pancreatic cancer. Oncogene, 31(12), 
1599-1608. 
Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., … Kern, S. 
E. (2003). BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10): Mutations in 
Distinct Subsets of Pancreatic Cancer. Am J Pathol, 163(4), 1255–1260. 
Carrasco, M., Delgado, I., Soria, B., Martín, F., & Rojas, A. (2012). GATA4 and 
GATA6 control mouse pancreas organogenesis. J Clin Invest, 122(10), 3504–
3515.  
Carrière, C., Seeley, E. S., Goetze, T., Longnecker, D. S., & Korc, M. (2007). The 
Nestin progenitor lineage is the compartment of origin for pancreatic 
intraepithelial neoplasia. Proc Natl Acad Sci USA, 104(11), 4437–42. 
Carrière, C., Young, A. L., Gunn, J. R., Longnecker, D. S., & Korc, M. (2009). Acute 
pancreatitis markedly accelerates pancreatic cancer progression in mice 
expressing oncogenic Kras. Biochem Biophys Res Commun, 382(3), 561–565.  
Carrière, C., Young, A. L., Gunn, J. R., Longnecker, D. S., & Korc, M. (2011). Acute 
Pancreatitis Accelerates Initiation and Progression to Pancreatic Cancer in 
Mice Expressing Oncogenic Kras in the Nestin Cell Lineage, PLoS One, 6(11), 
e27725.  
Case, R. M. (1978). Synthesis, Intracellular Transport and Discharge of 
Exportable Proteins in the Pancreatic Acinar Cell and Other Cells. Biol Rev, 
53, 211–354. 
Chao, C. S., McKnight, K. D., Cox, K. L., Chang, A. L., Kim, S. K., & Feldman, B. J. 
(2015). Novel GATA6 Mutations in Patients with Pancreatic Agenesis and 
Congenital Heart Malformations. PLoS One, 10(2), e0118449.  
Cheng, J. Q., Ruggerit, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watsont, D. K., & 
Testa, J. R. (1996). Amplification of AKT2 in human pancreatic cancer cells 
and inhibition of AKT2 expression and tumorigenicity by antisense RNA. 
Proc Natl Acad Sci U S A, 93(8), 3636–3641. 
Childs, E., Mocci, E., Campa, D., Bracci, P., Gallinger, S., Goggins, M., … Klein, A. 
(2015). Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated 
with susceptibility to pancreatic cancer. Nat Genet, 47(8), 911–6.  
Chirgwin, J. M., Przybyla, A. E., Macdonald, R. J., & Rutter, W. J. (1979). Isolation of 
Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease. 
Biochemistry, 18(24), 5294–99. 
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. 
H. (2007). Dynamics of the immune reaction to pancreatic cancer from 
inception to invasion. Cancer Res, 67(19), 9518–9527.  
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., … 
Serrano, M. (2005). Senescence in premalignant tumours. Nature, 
436(7051), 642.  
Collins, M. A., Yan, W., Sebolt-leopold, J. S., & Pasca, M. (2014). Mapk Signaling is 
Required for Dedifferentiation of Acinar Cells and Development of 
BILIOGRAPHY 
 138 
Pancreatic Intraepithelial Neoplasia in Mice. Gastroenterology, 146(3), 822-
834. 
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., … Gray, J. 
W. (2011). Subtypes of pancreatic ductal adenocarcinoma and their 
differing responses to therapy. Nat Med, 17(4), 500–504.  
Consortium, B. C. L. (1999). Cancer risks in BRCA2 mutation carriers. J Natl 
Cancer Inst, 91(15), 1310–6. 
Copp, J., Desprez, P., Krtolica, A., & Campisi, J. (2010). The Senescence-Associated 
Secretory Phenotype: The Dark Side of Tumor Suppression. Annu Rev Pathol, 
5, 99–118. 
D’Amato, E., Giacopelli, F., Giannattasio, A., Annunzio, G., Bocciardi, R., Musso, M., 
… Ravazzolo, R. (2010). Genetic investigation in an Italian child with an 
unusual association of atrial septal defect, attributable to a new familial 
GATA4 gene mutation, and neonatal diabetes due to pancreatic agenesis. 
Diabet Med, 27(10), 1195-200. 
Dabeva, M. D., Hurston, E., & Shafritz, D. A. (1995). Transcription Factor and 
Liver-Specific mRNA Expression in Facultative Epithelial Progenitor Cells of 
Liver and Pancreas. Am J Pathol, 147(6), 1633–48. 
Dalva, M., El, K., Steine, S. J., Johansson, B. B., Ringdal, M., Torsvik, J., … Molven, A. 
(2017). Copy number variants and VNTR length polymorphisms of the 
carboxyl-ester lipase (CEL) gene as risk factors in pancreatic cancer. 
Pancreatology, 17(1), 83–88.  
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., … Futreal, P. A. 
(2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 
949–54. 
Davies, L. C., Jenkins, S. J., Allen, J. E., & Taylor, P. R. (2013). Tissue-resident 
macrophages. Nat Immunol, 14(10), 986–995.  
De Franco, E., Shaw-smith, C., Flanagan, S. E., Shepherd, M. H., Consortium, I. N., 
Hattersley, A. T., & Ellard, S. (2013). GATA6 Mutations Cause a Broad 
Phenotypic Spectrum of Diabetes From Pancreatic Agenesis to Adult-Onset 
Diabetes Without Exocrine Insufficiency. Diabetes, 62(3), 993–7.  
De La O, J., Emerson, L. L., Goodman, J. L., Froebe, S. C., Illum, B. E., Curtis, A. B., & 
Murtaugh, L. C. (2008). Notch and Kras reprogram pancreatic acinar cells to 
ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A, 105(48), 18907–12. 
Decker, K., Goldman, D. C., L. Grasch, C., & Sussel, L. (2006). Gata6 is an important 
regulator of mouse pancreas development. Dev Biolo, 298(2), 415–429.  
Desai, B. M., Oliver-Krasinski, J., De Leon, D. D., Farzad, C., Hong, N., Leach, S. D., & 
Stoffers, D. A. (2007). Preexisting pancreatic acinar cells contribute to acinar 
cell, but not islet β cell, regeneration. J Clin Invest, 117(4), 971–977.  
Diersch, S., Wirth, M., Schneeweis, C., Jörs, S., Geisler, F., Siveke, J., … Schneider, G. 
(2016). KrasG12D induces EGFR-MYC cross signaling in murine primary 
pancreatic ductal epithelial cells. Oncogene, 35(29),  
Direnzo, D., Hess, D. A., Damsz, B., Hallett, J. E., Marshall, B., Goswami, C., … 
Konieczny, S. F. (2012). Induced Mist1 Expression Promotes Remodeling of 
Mouse Pancreatic Acinar Cells. Gastroenterology, 143(2), 469–480.  
Distler, M., Aust, D., Weitz, J., Pilarsky, C., & Grützmann, R. (2014). Precursor 
Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN. Biomed Res 
Int, 474905. 
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery Jr, C. A., 
   BIBLIOGRAPHY 
 139 
Butel, J. S., & Bradley, A. (1992). Mice deficient for p53 are developmentally 
normal but susceptible to spontaneous tumours. Nature, 356(6366), 215-21. 
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004). Adult pancreatic b-cells 
are formed by self-duplication rather than stem-cell differentiation. Nature, 
429(6987), 41–6. 
Duell, E. J. (2012). Epidemiology and Potential Mechanisms of Tobacco Smoking 
and Heavy Alcohol Consumption in Pancreatic Cancer. Mol Carcinog, 51(1), 
40–52. 
Egawa, N., Lin, Y., Tabata, T., Kuruma, S., Hara, S., Kubota, K., & Kamisawa, T. 
(2013). ABO blood type, long-standing diabetes, and the risk of pancreatic 
cancer. World J Gastroenterol, 19(16), 2537–42.  
Eifes, S., Chudasama, K. K., Molnes, J., Wagner, K., Hoang, T., Schierloh, U., … 
Beaufort, C. De. (2013). A novel GATA6 mutation in a child with congenital 
heart malformation and neonatal diabetes. Clin Case Rep, 1(2), 86–90.  
El-serag, H., Engels, E. A., Landgren, O., Chiao, E., Henderson, L., Amaratunge, H. 
C., & Giordano, T. P. (2010). Risk of Hepatobiliary and Pancreatic Cancers 
Following Hepatitis C Virus Infection: A Population-based Study of U.S. 
Veterans. Hepatology, 49(1), 116–123.  
Esposito, I., Seiler, C., Bergmann, F., Friess, H., & Schirmacher, P. (2007). 
Hypothetical Progression Model of Pancreatic Cancer With Origin in the 
Centroacinar-Acinar Compartment, Pancreas, 35(3), 212–217. 
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. 
M. (1998). Macrophages That Have Ingested Apoptotic Cells In Vitro Inhibit 
Proinflammatory Cytokine Production Through Autocrine/Paracrine 
Mechanisms Involving TGF-b, PGE2, and PAF. J Clin Invest, 101(4), 890–8. 
Farquhar, M. G., & Palade, G. E. (1998). The Golgi apparatus: 100 years of 
progress and controversy. Trends Cell Biol, 8(1), 2–10. 
Fearon, D. T., & Carroll, M. C. (2000). Regulation of B lymphocyte responses to 
foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol, 
18, 393–422. 
Fendrich, V., Esni, F., Garay, M. V. R., Feldmann, G., Habbe, N., Jensen, J. N., … 
Maitra, A. (2008). Hedgehog Signaling Is Required for Effective 
Regeneration of Exocrine Pancreas. Gastroenterology, 135(2), 621–631.  
Fernández-del Castillo, C. (2008). Mucinous Cystic Neoplasms. J Gastrointest 
Surg, 12(3), 411–3.  
Flandez, M., Cendrowski, J., Cañamero, M., Salas, A., del Pozo, N., Schoonjans, K., & 
Real, F. X. (2014). Nr5a2 heterozygosity sensitises to, and cooperates with, 
inflammation in KRas(G12V)-driven pancreatic tumourigenesis. Gut, 63(4), 
647–55.  
Friedmann-Morvinski, D., Bushong, E. A., Ke, E., Soda, Y., Marumoto, T., Singer, O., 
… Verma, I. M. (2012). Dedifferentiation of Neurons and Astrocytes by 
Oncogenes Can Induce Gliomas in Mice. Science, 338, 1080–5. 
Fu, B., Luo, M., Lakkur, S., Lucito, R., & Iacobuzio-Donahue, C. A. (2008). Frequent 
genomic copy number gain and overexpression of GATA-6 in pancreatic 
carcinoma. Cancer Biol Ther, 7(10), 1593–1601.  
Gaiser, S., Daniluk, J., Liu, Y., Tsou, L., Chu, J., Lee, W., … Ji, B. (2011). Intracellular 
activation of trypsinogen in transgenic mice induces acute but not chronic 
pancreatitis. Gut, 60(10), 1379–88.  
Garg, V., Kathiriya, I. S., Barnes, R., Schluterman, M. K., King, I. N., Butler, C. A., … 
BILIOGRAPHY 
 140 
Srivastava, D. (2003). GATA4 mutations cause human congenital heart 
defects and reveal an interaction with TBX5. Nature, 424(6947), 443–7.  
Gasslandek, T., Ihse, I., & Smeds, S. (1992). The Importance of the Centroacinar 
Region in Cerulein-Induced Mouse Pancreatic Growth. Scand J Gastroenterol, 
27(7), 564-70. 
Gea-Sorlí, S., & Closa, D. (2010). Role of macrophages in the progression of acute 
pancreatitis. World J Gastrointest Pharmacol Ther, 1(5), 107–111. 
Genkinger, J. M., Spiegelman, D., Anderson, K. E., Bergkvist, L., Bernstein, L., Van 
Den Brandt, P. A., … Smith-Warner, S. A. (2009). Alcohol intake and 
pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer 
Epidemiol Biomarkers Prev, 18(3), 765–776. 
George, K. M., Leonard, M. W., Roth, M. E., Lieuw, K. H., Kioussis, D., Grosveld, F., & 
Engel, J. D. (1994). Embryonic expression and cloning of the murine GATA-3 
gene. Development, 120(9), 2673–2686. 
Giardiello, F. M., Welsh, S. B., Hamilton, S. R., Offerhaus, G. J. A., Gittelsohn, A. M., 
Booker, S. V, … Luk, G. D. (1987). Increased risk of cancer in the Peutz-
Jeghers syndrome. N Engl J Med, 316(24), 1511–4. 
Giardiello, F., Offerhaus, G., Lee, D., Krush, A., Tersmette, A., Booker, S., … 
Hamilton, S. (1993). Increased risk of thyroid and pancreatic carcinoma in 
familial adenomatous polyposis. Gut, 34(10), 1394–1396. 
Gironella, M., Calvo, C., Fernéz, A., Closa, D., Iovanna, J. L., Rosello-Catafau, J., & 
Folch-Puy, E. (2013). Reg3b deficiency impairs pancreatic tumor growth by 
skewing macrophage polarization. Cancer Res, 73(18), 5682–5694.  
Gittes, G. K. (2009). Developmental biology of the pancreas: A comprehensive 
review. Dev Biolo, 326(1), 4–35.  
Goggins, M., Hruban, R. H., & Kern, S. E. (2000). BRCA2 Is Inactivated Late in the 
Development of Pancreatic Intraepithelial Neoplasia. Am J Pathol, 156(5), 
1767–1771. 
Gomez-rubio, P., Zock, J., Rava, M., Marquez, M., Sharp, L., Hidalgo, M., … 
Investigators, P. S. (2015). Reduced risk of pancreatic cancer associated 
with asthma and nasal allergies. Gut, 0, 1–9.  
Gong, M., Simaite, D., Kühnen, P., Heldmann, M., Spagnoli, F., Blankenstein, O., … 
Raile, K. (2013). Two Novel GATA6 Mutations Cause Childhood-Onset 
Diabetes Mellitus, Pancreas Malformation and Congenital Heart Disease. 
Horm Res Paediatr, 79(4), 250–256.  
Gong, Y., Zhou, Q., Zhou, Y., Lin, Q., Zeng, B., Chen, R., & Li, Z. (2012). Gastrectomy 
and risk of pancreatic cancer: systematic review and meta-analysis of 
observational studies. Cancer Causes Control, 23(8), 1279–88.  
Gorelick, F. S., & Thrower, E. (2009). The Acinar Cell and Early Pancreatitis 
Responses. Clin Gastroenterol Hepatol, 7(11), 1–12.  
Graña O; Rubio-Camarillo M; Fdez-Riverola F; Pisano DG; Glez-Peña D. (2016). 
 Nextpresso: next generation sequencing expression analysis pipeline. 
 Current Bioinformatics. Accepted for Publication. ISSN: (Online) 2212-
 392X - (Print) 1574-8936. 
Grapin-botton, A. (2005). Ductal cells of the pancreas, Int J Biochem Cell Biol , 
37(3), 504–510. 
Grützmann, R., Post, S., Saeger, H. D., & Niedergethmann, M. (2011). Intraductal 
Papillary Mucinous Neoplasia (IPMN) of the pancreas. Dtsch Arztebl Int, 
108(46), 788–795. 
   BIBLIOGRAPHY 
 141 
Gu, G., Dubauskaite, J., & Melton, D. A. (2002). Direct evidence for the pancreatic 
lineage: NGN3+ cells are islet progenitors and are distinct from duct 
progenitors. Development, 129(10), 2447–2457. 
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., 
Cañamero, M., … Barbacid, M. (2011). Pancreatitis-induced inflammation 
contributes to pancreatic cancer by inhibiting oncogene-induced 
senescence. Cancer Cell, 19(6), 728–739.  
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., … 
Barbacid, M. (2003). Tumor induction by an endogenous K-ras oncogene is 
highly dependent on cellular context. Cancer Cell 4(2), 111–120. 
Guerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-
Gallego, L., … Barbacid, M. (2007). Chronic Pancreatitis Is Essential for 
Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in 
Adult Mice. Cancer Cell, 11(3), 291–302.  
Gukovskaya, A. S., Vaquero, E., Zaninovic, V., Gorelick, F. S., Lusis, A. J., Brennan, 
M. L., … Pandol, S. J. (2002). Neutrophils and NADPH Oxidase Mediate 
Intrapancreatic Trypsin Activation in Murine Experimental Acute 
Pancreatitis. Gastroenterology, 122(4), 974–984.  
Habbe, N., Shi, G., Meguid, R. A., Fendrich, V., Esni, F., Chen, H., … Maitra, A. 
(2008). Spontaneous induction of murine pancreatic intraepithelial 
neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. 
Proc Natl Acad Sci U S A, 105(48), 18913–18918.  
Habtezion, A. (2015). Inflammation in acute and chronic pancreatitis. Curr Opin 
Gastroenterol, 31(5), 395-9.  
Halangk, W., Lerch, M. M., Brandt-Nedelev, B., Roth, W., Ruthenbuerger, M., 
Reinheckel, T., … Deussing, J. (2000). Role of cathepsin B in intracellular 
trypsinogen activation and the onset of acute pancreatitis. J Clin Invest, 
106(6), 773–781. 
Halbrook, C. J., Wen, H., Ruggeri, J. M., Takeuchi, K. K., Zhang, Y., Pasca di 
Magliano, M., & Crawford, H. C. (2017). Mitogen-activated Protein Kinase 
Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for 
Organ Regeneration in Pancreatitis. Cell Mol Gastroenterol Hepatol, 3(1), 99–
118.  
Hall, P., & Lemoine, N. (1992). Rapid Acinar to Ductal Transdifferentiation In 
Cultured Human Exocrine Pancreas. J Pathol, 166(2), 97–103. 
Han, M., Yang, Z., Sayed, D., He, M., Gao, S., Lin, L., … Abdellatif, M. (2012). GATA4 
expression is primarily regulated via a miR-26b-dependent post-
transcriptional mechanism during cardiac hypertrophy. Cardiovascular 
Research, 93(4), 645–654. 
Hassan, M. M., Li, D., El-Deeb, A. S., Wolff, R. A., Bondy, M. L., Davila, M., & 
Abbruzzese, J. L. (2008). Association Between Hepatitis B Virus and 
Pancreatic Cancer. J Clin Oncol, 26(28), 4557–62.  
Hayashi, K. Y., Tamaki, H., Handa, K., Takahashi, T., Kakita, A., & Yamashina, S. 
(2003). Differentiation and proliferation of endocrine cells in the 
regeneratinc rat pancreas after 90% pancreatectomy. Arch Histol Cytol, 
66(2),163-74 
He, C., Cheng, H., & Zhou, R. (2007). GATA family of transcription factors of 
vertebrates: phylogenetics and chromosomal synteny. J Biosci, 32(7), 1273–
80. 
BILIOGRAPHY 
 142 
Hermann, P. C., Sancho, P., Cañamero, M., Martinelli, P., Madriles, F., Michl, P., … 
Heeschen, C. (2014). Nicotine Promotes Initiation and Progression of KRAS-
Induced Pancreatic Cancer via Gata6-Dependent Dedifferentiation of Acinar 
Cells in Mice. Gastroenterology, 147(5), 1119–33.  
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & Depinho, R. A. 
(2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes 
Dev, 20(10), 1218–49.  
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., 
… Tuveson, D. A. (2003). Preinvasive and invasive ductal pancreatic cancer 
and its early detection in the mouse. Cancer Cell, 4(6), 437–450.  
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. 
H., … Tuveson, D. A. (2005). Trp53R172H and KrasG12D cooperate to 
promote chromosomal instability and widely metastatic pancreatic ductal 
adenocarcinoma in mice. Cancer Cell, 7(5), 469–483.  
Hofbauer, B., Saluja, A. K., Lerch, M. M., Bhagat, L., Bhatia, M., Lee, H. S., … Steer, M. 
L. (1998). Intra-acinar cell activation of trypsinogen during caerulein-
induced pancreatitis in rats. Am J Physiol, 275(2 Pt 1), G352-62. 
Holmstrom, S. R., Deering, T., Swift, G. H., Poelwijk, F. J., Mangelsdorf, D. J., 
Kliewer, S. A., & Macdonald, R. J. (2011). LRH-1 and PTF1-L coregulate an 
exocrine pancreas-specific transcriptional network for digestive function. 
Genes Dev, 25(16), 1674–79.  
Holtzinger, A., & Evans, T. (2005). Gata4 regulates the formation of multiple 
organs. Development, 132(17), 4005–4014.  
Hong, S. M., Park, J. Y., Hruban, R. H., & Goggins, M. (2011). Molecular signatures 
of pancreatic cancer. Arch Pathol Lab Med, 135(6), 716–27. 
Hruban, R. H., Adsay, N., Albores-Saavedra, J., Compton, C., Garrett, E., Goodman, 
S., … Offerhaus, G. (2001). Pancreatic intraepithelial neoplasia- a new 
nomenclature and classification system for pancreatic duct lesions. Am J 
Surg Pathol, 25(5), 579–86. 
Hruban, R. H., Canto, M., Goggins, M., Schulick, R., & Klein, A. P. (2010). Update on 
Familial Pancreatic Cancer. Adv Surg, 44, 293–311. 
Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000). Progression model for 
pancreatic cancer. Clinical Cancer Res, 6(8), 2969–2972. 
Hruban, R. H., Maitra, A., & Goggins, M. (2008). Update on Pancreatic 
Intraepithelial Neoplasia. Int J Clin Exp Pathol, 1(4), 306–16. 
Huang, H., Liu, Y., Daniluk, J., Gaiser, S., Chu, J., Wang, H., … Ji, B. (2013). Activation 
of Nuclear Factor-κB in Acinar Cells Increases the Severity of Pancreatitis in 
Mice. Gastroenterology, 144(1), 202–210.  
Huang, L., Wu, C., Yu, D., Wang, C., Che, X., Miao, X., … Lin, D. (2013). Identification 
of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic 
pancreatic cancer. Carcinogenesis, 34(5), 1001–5.  
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., 
Woodward, M. (2005). Type-II diabetes and pancreatic cancer: a meta-
analysis of 36 studies. Br J Cancer, 92(11), 2076–83.  
Iglesias, A., Murga, M., Laresgoiti, U., Skoudy, A., Bernales, I., Fullaondo, A., … 
Zubiaga, A. M. (2004). Diabetes and exocrine pancreatic insufficiency in 
E2F1/E2F2 double-mutant mice. J Clin Invest, 113(10), 1398–1407. 
http://doi.org/10.1172/JCI200418879.1398 
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Fujitani, Y., Fujitani, S., … Moses, H. 
   BIBLIOGRAPHY 
 143 
L. (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by 
pancreas-specific blockade of transforming growth factor-β signaling in 
cooperation with active Kras expression. Genes Dev, 20(22), 3147–60.  
Infante, J. R., Somer, B. G., Oh, J., Li, C., Scheulen, M. E., Kasubhai, S. M., … Liu, Y. 
(2014). A randomised, double-blind, placebo-controlled trial of trametinib, 
an oral MEK inhibitor, in combination with gemcitabine for patients with 
untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer, 50(12), 
2072–81.  
Ino, K., Masuya, M., Tawara, I., Miyata, E., Oda, K., Nakamori, Y., … Katayama, N. 
(2014). Monocytes Infiltrate the Pancreas via the MCP-1/CCR2 Pathway and 
Differentiate into Stellate Cells. PLoS One, 9(1), e84889. 
Iodice, S., Maisonneuve, P., Botteri, E., Teresa, M., & Lowenfels, A. B. (2010). ABO 
blood group and cancer. Eur J Cancer, 46(18), 3345–50.  
Jacobsen, C. M., Narita, N., Bielinska, M., Syder, A. J., Gordon, J. I., & Wilson, D. B. 
(2002). Genetic Mosaic Analysis Reveals That GATA-4 Is Required for 
Proper Differentiation of Mouse Gastric Epithelium. Dev Biol, 241(1), 34–46.  
Jarosz, M., Sekuła, W., & Rychlik, E. (2012). Influence of Diet and Tobacco 
Smoking on Pancreatic Cancer Incidence in Poland in 1960–2008. 
Gastroenterol Res Pract. http://doi.org/10.1155/2012/682156. 
Jenne, D. E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jescke, R., … Zimmer, M. 
(1998). Peutz-Jeghers syndrome is caused by mutations in a novel serine 
threonine kinase. Nat Genet, 18(1), 38–43. 
Jonckheere, N., Skrypek, N., & Van Seuningen, I. (2010). Mucins and Pancreatic 
Cancer. Cancers, 2(4), 1794–1812.  
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., … Kinzler, 
K. W. (2008). Core Signaling Pathways in Human Pancreatic Cancers 
Revealed by Global Genomic Analyses. Science, 321(5897), 1801–1806.  
Jovanovic, D. V, Battista, J. A. Di, Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & JP, 
P. (1998). IL-17 stimulates the production and expression of 
proinflammatory cytokines, IL-β and TNF-α, by Human Macrophages. J 
Immunol, 160(7), 3513–21. 
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016). Pancreatic cancer. The 
Lancet, 388(10039), 73–85.  
Kanda, M., Matthaei, H., Wu, J., Hong, S. M., Yu, J., Borges, M., … Goggins, M. (2012). 
Presence of somatic mutations in most early-stage pancreatic intraepithelial 
neoplasia. Gastroenterology, 142(4), 730-733.  
Kang, C., Xu, Q., Martin, T. D., Li, M. Z., Demaria, M., Aron, L., … Elledge, S. J. (2015). 
The DNA damage response induces inflammation and senescence by 
inhibiting autophagy of GATA4. Science 349(6255), aaa5612.  
Kastrinos, F., Mukherjee, B., Tayob, N., Wang, F., Sparr, J., Raymond, V. M., … 
Syngal, S. (2009). The Risk of Pancreatic Cancer in Families with Lynch 
Syndrome. JAMA, 302(16), 1790–5.  
Katanasaka, Y., Suzuki, H., Sunagawa, Y., Hasegawa, K., & Morimoto, T. (2016). 
Regulation of Cardiac Transcription Factor GATA4 by Post-Translational 
Modification in Cardiomyocyte Hypertrophy and Heart Failure. Int Heart J, 
57(6), 672–675. 
Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R. J., & Wright, C. V. E. 
(2002). The role of the transcriptional regulator Ptf1a in converting 
intestinal to pancreatic progenitors. Nat Genet, 32(1), 128–134.  
BILIOGRAPHY 
 144 
Keim, V., Rohr, G., Stöckert, H., & Haberich, F. (1984). An additional secretory 
protein in the rat pancreas. Digestion, 29(4), 242–9. 
Ketola, I., Otonkoski, T., Pulkkinen, M. A., Niemi, H., Palgi, J., Jacobsen, C. M., … 
Heikinheimo, M. (2004). Transcription factor GATA-6 is expressed in the 
endocrine and GATA-4 in the exocrine pancreas. Mol Cell Endocrinol, 226(1–
2), 51–57.  
Kim, W. Y., & Sharpless, N. E. (2006). The Regulation of INK4/ARF in Cancer and 
Aging. Cell, 127(2), 265–275.  
Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, 
G. J. A., … Hruban, R. H. (2004). Prospective Risk of Pancreatic Cancer in 
Familial Pancreatic Cancer Kindreds. Cancer Res, 64(7), 2634–38. 
Klöppel, G., Solcia, E., Longnecker, D., Capella, C., & Sobin, L. (1996). Histological 
Typing of Tumours of the Exocrine Pancreas. 
Ko, L. J., & Engel, J. D. (1993). DNA-Binding Specificities of the GATA 
Transcription Factor Family, Mol Cell Biol, 13(7), 4011–22. 
Kong, B., Bruns, P., Behler, N. A., Chang, L., Schlitter, A. M., Cao, J., … Michalski, C. 
W. (2016). Dynamic landscape of pancreatic carcinogenesis reveals early 
molecular networks of malignancy. Gut, doi: 10.1136/gutjnl-2015-310913.  
Kopp, J. L., Von Figura, G., Mayes, E., Liu, F.-F., Dubois, C. L., Morris IV, J. P., … 
Sander, M. (2012). Identification of Sox9-dependent acinar-to-ductal 
reprogramming as the principal mechanism for initiation of pancreatic 
ductal adenocarcinoma. Cancer Cell, 22(6), 737–50.  
Koutsourakis, M., Langeveld,  a, Patient, R., Beddington, R., & Grosveld, F. (1999). 
The transcription factor GATA6 is essential for early extraembryonic 
development. Development, 126(9), 723–32.  
Krapp, A., Knöfler, M., Frutiger, S., Hughes, G. J., Hagenbüchle, O., & Wellauer, P. K. 
(1996). The p48 DNA-binding subunit of transcription factor PTF1 is a new 
exocrine pancreas-specific basic helix-loop-helix protein. EMBO J, 15(16), 
4317–4329. 
Krapp, A., Knöfler, M., Ledermann, B., Bürki, K., Berney, C., Zoerkler, N., … 
Wellauer, P. K. (1998). The bHLH protein PTF1-p48 is essential for the 
formation of the exocrine and the correct spatial organization of the 
endocrine pancreas. Genes Dev, 12(23), 3752–3763. 
Kumar, S. M., Liu, S., Lu, H., Zhang, H., Zhang, P. J., Gimotty, P. A., … Xu, X. (2012). 
Acquired cancer stem cell phenotypes through Oct4-mediated 
dedifferentiation. Oncogene, 31, 4898–911. 
Kuo, C. T., Morrisey, E. E., Anandappa, R., Sigrist, K., Lu, M. M., Parmacek, M. S., … 
Leiden, J. M. (1997). GATA4 transcription factor is required for ventral 
morphogenesis and heart tube formation. Genes Dev, 11(8), 1048–1060.  
Kwei, K. A., Bashyam, M. D., Kao, J., Ratheesh, R., Reddy, E. C., Kim, Y. H., … Pollack, 
J. R. (2008). Genomic profiling identifies GATA6 as a candidate oncogene 
amplified in pancreatobiliary cancer. PLoS Genet, 4(5), e1000081. 
Lango Allen, H., Flanagan, S. E., Shaw-Smith, C., De Franco, E., Akerman, I., 
Caswell, R., … Ellard, S. (2012). GATA6 haploinsufficiency causes pancreatic 
agenesis in humans. Nat Genet, 44(1), 20–2.  
Larsson, S. C., Orsini, N., & Wolk, A. (2007). Body mass index and pancreatic 
cancer risk: A meta-analysis of prospective studies. Int J Cancer, 120(9), 
1993–8.  
Larsson, S. C., & Wolk, A. (2012). Red and processed meat consumption and risk 
   BIBLIOGRAPHY 
 145 
of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer, 
106(3), 603–7.  
Lavemiere, A. C., MacNeill, C., Mueller, C., Poelmann, R. E., Burch, J. B. E., & Evans, 
T. (1994). GATA-4/5/6, a Subfamily of Three Transcription Factors 
Transcribed in Developing Heart and Gut. J Biol Chem, 269(37), 23177–
23184. 
Lechene de la Porte, P., Iovanna, J., Odaira, C., Choux, R., Sarles, H., & Berger, Z. 
(1991). Involvement of tubular complexes in pancreatic regeneration after 
acute necrohemorrhagic pancreatitis. Pancreas, 6(3), 298–306. 
Lemper, M., Leuckx, G., Heremans, Y., German, M., Heimberg, H., Bouwens, L., & 
Baeyens, L. (2014). Reprogramming of human pancreatic exocrine cells to β 
-like cells. Cell Death Differ, 22(7), 1117–1130.  
Lentjes, M. H. F. M., Niessen, H. E. C., Akiyama, Y., Bruïne, A. P. D. E., Melotte, V., & 
Engeland, M. V. A. N. (2016). The emerging role of GATA transcription 
factors in development and disease, Expert Rev Mol Med, 18, 1–15.  
Lepage, D., Bruneau, J., Brouillard, G., Jones, C., Lussier, C. R., Rémillard, A., … 
Boudreau, F. (2015). Identification of GATA-4 as a novel transcriptional 
regulatory component of regenerating islet-derived family members. 
Biochim Biophys Acta, 1849(12), 1411–1422.  
Lerch, M. M., Halangk, W., & Krüger, B. (2000). The role of Cysteine proteases in 
intracellular pancreatic Serine protease activation. Adv Exp Med Biol, 477, 
403–11. 
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-john, S., & Treiber, M. (2011). 
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of 
Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer. 
Cancer Cell, 19(4), 456–469.  
Li, J., Zhou, R., Zhang, J., & Li, Z. (2014). Calcium signaling of pancreatic acinar 
cells in the pathogenesis of pancreatitis. World J Gastroenterol, 20(43), 
16146–16152.  
Li, T., Liu, Z., Hu, X., Ma, K., & Zhou, C. (2012). Involvement of ERK-RSK cascade in 
phenylephrine-induced phosphorylation of GATA4. Biochim Biophys Acta, 
1823(2), 582–592.  
Li, W., Nakanishi, M., Zumsteg, A., Shear, M., Wright, C., Melton, D. A., & Zhou, Q. 
(2014). In vivo reprogramming of pancreatic acinar cells to three islet 
endocrine subtypes. eLife, 3, 1–20.  
Liang, Q., Wiese, R. J., Bueno, O. F., Dai, Y., Markham, B. E., & Molkentin, J. D. 
(2001). The Transcription Factor GATA4 Is Activated by Extracellular 
Signal-Regulated Kinase 1- and 2-Mediated Phosphorylation of Serine 105 
in Cardiomyocytes. Mol Cell Biol, 21(21), 7460–69.  
Lieu, H., Christa, L., Smith, A. J. H., Bayne, R., Hunt, S. P., & Br, C. (2006). Reg2 
Inactivation Increases Sensitivity to Fas Hepatotoxicity and Delays Liver 
Regeneration Post-hepatectomy in Mice. Hepatology, 44(6):1452-64. 
Lilleväli, K., Matilainen, T., Karis, A., & Salminen, M. (2004). Partially Overlapping 
Expression of Gata2 and Gata3 During Inner Ear Development. Dev Dyn, 
231(4), 775–781.  
Lin, G., Zeng, Z., Wang, X., Wu, Z., Wang, J., Wang, C., … Quan, H. (2012). 
Cholecystectomy and risk of pancreatic cancer: a meta-analysis of 
observational studies. Cancer Causes Control, 21(1), 59–67.  
Liou, G., Bastea, L., Fleming, A., Zhang, L., Bardeesy, N., Storz, P., … Dawson, D. W. 
BILIOGRAPHY 
 146 
(2017). The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions 
Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis. Cell 
Rep, 19(7), 1322–33. 
Liou, G., Döppler, H., Necela, B., Krishna, M., Crawford, H. C., Raimondo, M., & 
Storz, P. (2013). Macrophage-secreted cytokines drive pancreatic acinar-to-
ductal metaplasia through NF- kb and MMPs, 202(3), 563–577.  
Liou, G., & Storz, P. (2015). Inflammatory macrophages in pancreatic acinar cell 
metaplasia and initiation of pancreatic cancer, 2(3), 247–251. 
Liou, G. Y., Döppler, H., Necela, B., Edenfield, B., Zhang, L., Dawson, D. W., & Storz, 
P. (2015). Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar 
cells causes attraction of macrophages to expedite the formation of 
precancerous lesions. Cancer Discovery, 5(1), 52–63.  
Loncle, C., Bonjoch, L., Folch-puy, E., Lopez-millan, M. B., Lac, S., Chuluyan, E., … 
Lomberk, G. (2015). IL17 Functions through the Novel REG3b-JAK2–STAT3 
Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis 
to Pancreatic Cancer, Cancer Res, 75(22), 4852–4863.  
Lörchner, H., Pöling, J., Gajawada, P., Hou, Y., Polyakova, V., Kostin, S., … Braun, T. 
(2015). Myocardial healing requires Reg3β-dependent accumulation of 
macrophages in the ischemic heart. Nat Med, 21(4), 1–21.  
Lüttges, J., Galehdari, H., Bröcker, V., Schwarte-Waldhoff, I., Henne-Bruns, D., 
Klöppel, G., … Hahn, S. A. (2001). Allelic Loss Is Often the First Hit in the 
Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic 
Carcinogenesis. Am J Pathol, 158(5), 1677–1683. 
Lynch, H. T., Deters, C. A., Snyder, C. L., Lynch, J. F., Villeneuve, P., Silberstein, J., … 
Brand, R. E. (2005). BRCA1 and pancreatic cancer: pedigree findings and 
their causal relationships. Cancer Genet Cytogenet, 158(2), 119–25.  
Lynch, H. T., Fusaro, R. M., Lynch, J. F., & Brand, R. (2008). Pancreatic cancer and 
the FAMMM syndrome. Fam Cancer, 7(1), 103–12.  
Ma, Q., Teter, B., Ubeda, O. J., Morihara, T., Dhoot, D., Nyby, M. D., … Cole, G. M. 
(2008). Overexpression of Interleukin-1β in the Murine Pancreas Results in 
Chronic Pancreatitis, 135(4):1277-87  
MacDonald, R. J., Swift, G. H., & Real, F. X. (2010). Transcriptional control of 
acinar development and homeostasis. Progress in Molecular Biology and 
Translational Science (Vol. 97). Elsevier Inc.  
Magenheim, J., Klein, A. M., Stanger, B. Z., Ashery-Padan, R., Sosa-Pineda, B., Gu, G., 
& Dor, Y. (2011). Ngn3 + endocrine progenitor cells control the fate and 
morphogenesis of pancreatic ductal epithelium. Dev Biol, 359(1), 26–36.  
Maisonneuve, P., BC, M., & Lowenfels, A. B. (2007). Risk of pancreatic cancer in 
patients with cystic fibrosis. Gut, 56(9), 1327–8.  
Maitra, A., Fukushima, N., Takaori, K., & Hruban, R. H. (2005). Precursors to 
Invasive Pancreatic Cancer. Adv Anat Pathol, 12(2), 81–91. 
Maitra, A., & Hruban, R. H. (2008). Pancreatic cancer. Annu Rev Pathol, 3, 157–88.  
Malumbres, M., & Barbacid, M. (2003). RAS oncogenes: the first 30 years. Nature 
Rev Cancer, 3(6), 459–65. 
Martinelli, P., Cañamero, M., Pozo, N., Madriles, F., Zapata, A., & Real, F. X. (2012). 
Gata6 is required for complete acinar differentiation and maintenance of the 
exocrine pancreas in adult mice. Gut, 62(10), 1–8.  
Martinelli, P., Madriles, F., Cañamero, M., Pau, E. C. S., Pozo, N., Guerra, C., & Real, 
F. X. (2015). The acinar regulator Gata6 suppresses Kras G12V -driven 
   BIBLIOGRAPHY 
 147 
pancreatic tumorigenesis in mice, Gut, 0, 1–11.  
Martinelli, P., Pau, E. C. S., Cox, T., Jr, B. S., Dusetti, N., Greenhalf, W., … Real, F. X. 
(2016). GATA6 regulates EMT and tumour dissemination, and is a marker of 
response to adjuvant chemotherapy in pancreatic cancer. Gut, doi: 
10.1136/gutjnl-2015-311256 1–12.  
Massagué, J. (2008). TGFβ in Cancer. Cell, 134(2), 215–230.  
Masui, T., Long, Q., Beres, T. M., Magnuson, M. A., & Macdonald, R. J. (2007). Early 
pancreatic development requires the vertebrate Suppressor of Hairless ( 
RBPJ ) in the PTF1 bHLH complex. Genes Dev, 21(20), 2629–2643.  
Masui, T., Swift, G. H., Deering, T. Y. E., Shen, C., Coats, W. S., Long, Q., … 
Macdonald, R. J. (2010). TRACT Replacement of Rbpj With Rbpjl in the PTF1 
Complex Controls the Final Maturation of Pancreatic Acinar Cells. YGAST, 
139(1), 270–280. http://doi.org/10.1053/j.gastro.2010.04.003 
Masui, T., Swift, G. H., Hale, M. A., Meredith, D. M., Johnson, J. E., & Macdonald, R. J. 
(2008). Transcriptional Autoregulation Controls Pancreatic Ptf1a 
Expression during Development and Adulthood. Mol Cell Biol, 28(17), 5458–
5468.  
Matsubayashi, H., Takaori, K., Morizane, C., Maguchi, H., Mizuma, M., Furuse, J., … 
Shimosegawa, T. (2017). Familial pancreatic cancer: concept, management 
and issues. World J Gastroenterol, 23(6), 935–948.  
Matsuda, Y., Furukawa, T., Yachida, S., Nishimura, M., Seki, A., Nonaka, K., … Mino-
Kenudson, M. (2017). The Prevalence and Clinicopathological 
Characteristics of High-Grade Pancreatic Intraepithelial Neoplasia. Pancreas, 
46(5), 658–664.  
Matsuda, Y., Ishiwata, T., Izumiyama-Shimomura, N., Hamayasu, H., Fujiwara, M., 
Tomita, K., … Arai, T. (2015). Gradual Telomere Shortening and Increasing 
Chromosomal Instability among PanIN Grades and Normal Ductal Epithelia 
with and without Cancer in the Pancreas. PLoS One, 10(2), 1–13.  
Mcallister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., … Leach, S. D. 
(2014). Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 
Signaling Axis in Preinvasive Pancreatic Neoplasia. Cancer Cell, 25(5), 621–
637.  
Means, A. L., Meszoely, I. M., Suzuki, K., Miyamoto, Y., Rustgi, A. K., Coffey, R. J., … 
Leach, S. D. (2005). Pancreatic epithelial plasticity mediated by acinar cell 
transdifferentiation and generation of nestin-positive intermediates. 
Development, 132(16), 3767–76.  
Means, A. L., Ray, K. C., Singh, A. B., Washington, M. K., Whitehead, R. H., Harris, R. 
C., … Leach, S. D. (2003). Overexpression of Heparin-Binding EGF-Like 
Growth Factor in Mouse Pancreas Results in Fibrosis and Epithelial 
Metaplasia. Gastroenterology, 124(4), 1020–1036.  
Mehta, G., Kumarasamy, S., Wu, J., Walsh, A., Liu, L., Williams, K., … de la Serna, I. 
L. (2015). MITF interacts with the SWI/SNF subunit, BRG1, to promote 
GATA4 expression in cardiac hypertrophy. J Mol Cell Cardiol, 88, 101–110. 
Meredith, D. M., Borromeo, M. D., Deering, T. G., Casey, B. H., Savage, T. K., Mayer, 
P. R., … Johnson, E. (2013). Program Specificity for Ptf1a in Pancreas versus 
Neural Tube Development Correlates with Distinct Collaborating Cofactors 
and Chromatin Accessibility. Mol Cell Biol, 33(16), 3166–79.  
Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobuzio-Donahue, C. 
A., … Leach, S. D. (2003). Notch mediates TGFα-induced changes in epithelial 
BILIOGRAPHY 
 148 
differentiation during pancreatic tumorigenesis Yoshiharu. Cancer Cell, 3(6), 
565–576. 
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., 
… Yeh, J. J. (2015). Virtual microdissection identifies distinct tumor- and 
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet, 
47(10):1168-78. 
Molero, X., Vaquero, E. C., Flández, M., González, A. M., Ortiz, M. À., Cibrián-Uhalte, 
E., … Real, F. X. (2012). Gene expression dynamics after murine pancreatitis 
unveils novel roles for Hnf1a in acinar cell homeostasis. Gut, 61(8), 1187–
1196.  
Molkentin, J. D. (2000). The zinc finger-containing transcription factors GATA-4, -
5, and -6: Ubiquitously expressed regulators of tissue-specific gene 
expression. J Biol Chem, 275(50), 38949–38952.  
Molkentin, J. D., Lin, Q., Duncan, S. A., & Olson, E. N. (1997). Requirement of the 
transcription factor GATA4 for heart tube formation and ventral 
morphogenesis. Genes Dev, 11(8), 1061–1072.  
Morrell, D., Chase, C. L., & Swift, M. (1990). Cancers in 44 Families with Ataxia- 
Telangiectasia. Cancer Genet Cytogenet, 50(1), 119–123. 
Morris IV, J. P., Cano, D. A., Sekine, S., Wang, S. C., & Hebrok, M. (2010). b-catenin 
blocks Kras-dependent reprogramming of acini into pancreatic cancer 
precursor lesions in mice. J Clin Invest, 120(2), 508–520.  
Morrisey, E. E., Ip, H. S., Tang, Z., & Parmacek, M. S. (1997). GATA-4 Activates 
Transcription Via Two Novel Domains That Are Conserved within the GATA-
4/5/6 Subfamily. J Biol Chem, 272(13), 8515–8524. 
Moskaluk, C. A., Hruban, R. H., & Kern, S. E. (1997). p16 and K-ras Gene Mutations 
in the Intraductal Precursors of Human Pancreatic Adenocarcinoma. Cancer 
Res, 57(11), 2140–2144. 
Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, 
R., … Kern, S. E. (2002). Evaluation of Candidate Genes MAP2K4, MADH4, 
ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 
Mutations in 17%. Cancer Res, 62(13), 3789–93. 
Murphy, S. J., Hart, S. N., Halling, G. C., Johnson, S. H., Smadbeck, J. B., Drucker, T., 
… Vasmatzis, G. (2016). Integrated Genomic Analysis of Pancreatic Ductal 
Adenocarcinomas Reveals Genomic Rearrangement Events as Significant 
Drivers of Disease, Cancer Res 76(3), 749-67. 
Nagasao, J., Yoshioka, K., Amasaki, H., & Mutoh, K. (2003). Centroacinar and 
intercalated duct cells as potential precursors of pancreatic endocrine cells 
in rats treated with streptozotocin, Ann Anat, 185(2), 211–6. 
Nagata, K., Horinouchi, M., Saitou, M., Higashi, M., Nomoto, M., Goto, M., & 
Yonezawa, S. (2007). Mucin expression profile in pancreatic cancer and the 
precursor lesions. J Hepatobiliary Pancreat Surg, 14(3), 243–54.  
Nam, J., Terabe, M., Kang, M., Chae, H., Voong, N., Yang, Y., … Wakefield, L. M. 
(2008). Transforming Growth Factor B Subverts the Immune System into 
Directly Promoting Tumor Growth through Interleukin-17. Cancer Res, 
68(10), 3915–24. 
Nardelli, J., Thiesson, D., Fujiwara, Y., Tsai, F., & Orkin, S. H. (1999). Expression 
and Genetic Interaction of Transcription Factors GATA-2 and GATA-3 during 
Development of the Mouse Central Nervous System. Dev Biol, 210(2), 305–
321. 
   BIBLIOGRAPHY 
 149 
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & 
Barbacid, M. (2012). EGF Receptor Signaling Is Essential for K- Ras 
Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell, 22(3), 
318–330.  
Nemer, G., & Nemer, M. (2003). Transcriptional activation of BMP-4 and 
regulation of mammalian organogenesis by GATA-4 and -6. Dev Biol, 254(1), 
131–148.  
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., … 
Werner, J. (2016). CYP3A5 mediates basal and acquired therapy resistance 
in different subtypes of pancreatic ductal adenocarcinoma, Nat Med, 22(3), 
278-87 
Notta, F., Chan-seng-yue, M., Lemire, M., Li, Y., Wilson, G. W., Connor, A. A., … 
Gallinger, S. (2016). A renewed model of pancreatic cancer evolution based 
on genomic rearrangement patterns. Nature, 0(0), 1–20.  
Notta, F., Hahn, S., & Real, F. X. The genetic roadmap of pancreatic cancer: still 
evolving. Manuscript in preparation. 
Ochi, A., Graffeo, C. S., Zambirinis, C. P., Rehman, A., Hackman, M., Fallon, N., … 
Miller, G. (2012a). Toll-like receptor 7 regulates pancreatic carcinogenesis 
in mice and humans. J Clin Invest, 122(11), 4118–29.  
Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., … 
Miller, G. (2012b). MyD88 inhibition amplifies dendritic cell capacity to 
promote pancreatic carcinogenesis via Th2 cells. The Journal of 
Experimental Medicine, 209(9), 1671–87. 
Odegaard, J. I., Ricardo-gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, 
V., Mukundan, L., … Chawla, A. (2007). Macrophage-specific PPARg controls 
alternative activation and improves insulin resistance. Nature, 447(7148), 
2–7. 
Offield, M. F., Jetton, T. L., Labosky, P. A., Ray, M., Stein, R. W., Magnuson, M. A., … 
Wright, C. V. E. (1996). PDX-1 is required for pancreatic outgrowth and 
differentiation of the rostral duodenum. Development, 122(3), 983–995. 
Ohlsson, H., Karlsson, K., & Edlund, T. (1993). IPF1, a homeodomain-containing 
transactivator of the insulin gene. EMBO J, 12(11), 4251–4259. 
Oka, T., Maillet, M., Watt, A. J., Schwartz, R. J., Aronow, B. J., Duncan, S. A., & 
Molkentin, J. D. (2006). Cardiac-specific deletion of gata4 reveals its 
requirement for hypertrophy, compensation, and myocyte viability. Circ Res, 
98(6), 837–845.  
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., Mcintyre, D., Honess, D., 
… Tuveson, D. A. (2009). Inhibition of Hedgehog Signaling a Mouse Model of 
Pancreatic Cancer. Science, 324(5933), 1457–61. 
Omichinski, J., Trainor, C., Gronenborn, A., Clore, G., & Felsenfeld, G. (1993). A 
small single-“finger ” peptide from the erythroid transcription factor GATA-
1 binds specifically to DNA as a zinc or iron complex. Proc Natl Acad Sci U S 
A, 90(5), 1676–1680. 
Ornitz, D. M., Hammer, R. E., Messing, A., Palmiter, R. D., & Brinster, R. L. (1987). 
Pancreatic Neoplasia Induced by SV40 T-Antigen Expression in Acinar Cells 
of Transgenic Mice. Science, 238(4824), 188–93. 
Ortega-Gómez, Al., Perretti, M., & Soehnlein, O. (2013). Resolution of 
inflammation: an integrated view. EMBO Mol Med, 5(5), 661–674.  
Özdemir, B. C., Pentcheva-Hoang, Tsvetelina Carstens, J., Zheng, X., Wu, C.-C., 
BILIOGRAPHY 
 150 
Simpson, T., Laklai, H., … Kalluri, R. (2015). Depletion of Carcinoma-
Associated Fibroblasts and Fibrosis Induces Immunosuppression and 
Accelerates Pancreas Cancer with Diminished Survival. Cancer Cell, 25(6), 
719–734.  
Pan, F. C., Bankaitis, E. D., Boyer, D., Xu, X., Van de Casteele, M., Magnuson, M. a, … 
Wright, C. V. E. (2013). Spatiotemporal patterns of multipotentiality in 
Ptf1a-expressing cells during pancreas organogenesis and injury-induced 
facultative restoration. Development, 140(4), 751–64.  
Pan, F. C., & Wright, C. (2011). Pancreas organogenesis: From bud to plexus to 
gland. Dev Dyn, 240(3), 530–565.  
Pehlivan, T., Pober, B. R., Brueckner, M., Garrett, S., Slaugh, R., Van Rheeden, R., … 
Hing, A. V. (1999). GATA4 Haploinsufficiency in Patients With Interstitial 
Deletion of Chromosome Region 8p23.1 and Congenital Heart Disease. Am J 
Med Genet, 83(3), 201–206. 
Pérez-Mancera, P. A., Guerra, C., Barbacid, M., & Tuveson, D. A. (2012). What we 
have learned about pancreatic cancer from mouse models. Gastroenterology, 
142(5), 1079–1092.  
Petersen, G. M., Amundadottir, L., Fuchs, C. S., Kraft, P., Stolzenberg-solomon, R. 
Z., Jacobs, K. B., … Chanock, S. J. (2010). A genome-wide association study 
identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 
1q32.1 and 5p15.33. Nat Genet, 42(3), 224–228.  
Petersen, O. H., & Tepikin, A. V. (2008). Polarized Calcium Signaling in Exocrine 
Gland Cells. Annu Rev Physiol, 70, 273–299.  
Piccinini, A. M., & Midwood, K. S. (2010). DAMPening Inflammation by 
Modulating TLR Signalling. Mediators Inflamm, doi: 10.1155/2010/672395. 
Pin, C. L., Rukstalis, J. M., Johnson, C., & Konieczny, S. F. (2001). The bHLH 
transcription factor Mist1 is required to maintain exocrine pancreas cell 
organization and acinar cell identity. J Cell Biol, 155(4), 519–530.  
Pinho, A. V. (2011). Pancreatic acinar cell plasticity: Senescence, epithelial-
mesenchymal transition and p53. Doctoral Thesis (UPF). 
Pinho, A. V, Rooman, I., Reichert, M., De Medts, N., Bouwens, L., Rustgi, A. K., & 
Real, F. X. (2011). Adult pancreatic acinar cells dedifferentiate to an 
embryonic progenitor phenotype with concomitant activation of a 
senescence programme that is present in chronic pancreatitis. Gut, 60(7), 
958–966.  
Prasad, N. B., Biankin, A. V, Fukushima, N., Maitra, A., Dhara, S., Elkahloun, A. G., … 
Leach, S. D. (2005). Gene Expression Profiles in Pancreatic Intraepithelial 
Neoplasia Reflect the Effects of Hedgehog Signaling on Pancreatic Ductal 
Epithelial Cells. Cancer Res, 65(5), 1619–26. 
Pu, W. T., Ishiwata, T., Juraszek, A. L., Ma, Q., & Izumo, S. (2004). GATA4 is a 
dosage-sensitive regulator of cardiac morphogenesis. Dev Biol, 275(1), 235–
244.  
Puri, S., & Hebrok, M. (2010). Cellular plasticity within the pancreas--lessons 
learned from development. Dev Cell, 18(3), 342–356.  
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012). 
Oncogenic Kras-Induced GM-CSF Production Promotes the Development of 
Pancreatic Neoplasia. Cancer Cell, 21(6), 836–847.  
Quaife, C. J., Pinkert, C. A., Omit, D. M., Palmiter, R. D., & Brinstert, R. L. (1987). 
Pancreatic Neoplasia Induced by ras Expression in Acinar Cells of 
   BIBLIOGRAPHY 
 151 
Transgenic Mice. Cell, 48(6), 1023–34. 
Raderer, M., Wrba, F., Kornek, G., Maca, T., Dy, K., Weinlaender, G., … Scheithauer, 
W. (1998). Association between Helicobacter pylori infection and pancreatic 
cancer. Oncology, 55(1), 16–9. 
Raimondi, S., Lowenfels, A. B., Morselli-labate, A. M., Maisonneuve, P., & Pezzilli, 
R. (2010). Pancreatic cancer in chronic pancreatitis; aetiology, incidence, 
and early detection. Best Pract Res Clin Gastroenterol, 24(3), 349–358.  
Real, F. (2003). A “Catastrophic Hypothesis” for Pancreas Cancer Progression. 
Gastroenterology, 124(7), 1958–64.  
Real, F. X., Uhalte, E. C., & Martinelli, P. (2008). Pancreatic Cancer Development 
and Progression: Remodeling the Model. Gastroenterology, 135(3), 724–728.  
Reddy, J. K., Rao, M. S., Qureshi, S. A., Reddy, M. K., Scarpelli, D. G., & Lalwani, N. D. 
(1984). Induction and Origin of Hepatocytes in Rat Pancreas. J Cell Biol, 
98(6), 2082–90. 
Reichert, M., Blume, K., Kleger, A., Hartmann, D., & Von Figura, G. (2016). 
Developmental Pathways Direct Pancreatic Cancer Initiation from Its 
Cellular Origin. Stem Cells Int, doi: 10.1155/2016/9298535  
Reichert, M., & Rustgi, A. K. (2011). Pancreatic ductal cells in development, 
regeneration, and neoplasia. J Clin Invest, 121(12), 4572–8.  
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., 
… Stanger, B. Z. (2014). Stromal elements act to restrain, rather than 
support, pancreatic ductal adenocarcinoma. Cancer Cell, 25(6), 735–747. 
Rieger, M. A., & Schroeder, T. (2012). Hematopoiesis. Cold Spring Harb Perspect 
Biol, 4(12), pii: a008250. 
Risch, H. A., Yu, H., Lu, L., & Kidd, M. S. (2010). AB0 Blood Group, Helicobacter 
pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. J 
Natl Cancer Inst, 102(7), 502–5.  
Ritz-Laser, B., Mamin, A., Brun, T., Avril, I., Schwitzgebel, V. M., & Philippe, J. 
(2005). The zinc finger-containing transcription factor Gata-4 is expressed 
in the developing endocrine pancreas and activates glucagon gene 
expression. Mol Endocrinol, 19(3), 759–70.  
Rode, A., Maass, K. K., Willmund, K. V., & Lichter, P. (2016). Chromothripsis in 
cancer cells: An update. Int J Cancer, 138(10), 2322–33. 
Rodríguez-Seguí, S., Akerman, I., & Ferrer, J. (2012). GATA believe it: New 
essential regulators of pancreas development. J Clin Invest, 122(10), 3469–
3471.  
Rorsman, P., & Braun, M. (2013). Regulation of insulin secretion in human 
pancreatic islets. Annu Rev Physiol, 75, 155–79.  
Rovira, M., Scott, S.-G., Liss, A. S., Jensen, J., Thayer, S. P., & Leach, S. D. (2010). 
Isolation and characterization of centroacinar/terminal ductal progenitor 
cells in adult mouse pancreas. Proc Natl Acad Sci U S A, 107, 75–80.  
Roy, S. K., Srivastava, R. K., & Shankar, S. (2010). Inhibition of PI3K/AKT and 
MAPK/ERK pathways causes activation of FOXO transcription factor, 
leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal, 
5(10), 1–13. 
Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L., & Lee, D. C. (1990). 
Overexpression of TGFα in Transgenic Mice: Induction of Epithelial 
Hyperplasia, Pancreatic Metaplasia, and Carcinoma of the Breast. Cell, 61(6), 
1121–35. 
BILIOGRAPHY 
 152 
Sawey, E. T., Johnson, J. A., & Crawford, H. C. (2007). Matrix metalloproteinase 7 
controls pancreatic acinar cell transdifferentiation by activating the Notch 
signaling pathway. Proc Natl Acad Sci U S A, 104(49), 19327–32. 
Schaffer, A. E., Freude, K. K., Nelson, S. B., & Sander, M. (2010). Ptf1a and Nkx6 
transcription factors function as antagonistic lineage determinants in 
multipotent pancreatic progenitors. Dev Cell, 18(6), 1022–1029.  
Schwarzenberger, P., Russa, V. La, Miller, A., Ye, P., Huang, W., Zieske, A., … Kolls, 
J. K. (1998). IL-17 Stimulates Granulopoiesis in Mice: Use of an Alternate, 
Novel Gene Therapy-Derived Method for In Vivo Evaluation of Cytokines. J 
Immunol, 161(11), 6383–9. 
Serrano, M., Lin, A. W., Mccurrach, M. E., Beach, D., & Lowe, S. W. (1997). 
Oncogenic ras Provokes Premature Cell Senescence Associated with 
Accumulation of p53 and p16INK4a. Cell, 88(5), 593–602. 
Shalapour, S., & Karin, M. (2015). Immunity, inflammation, and cancer: an eternal 
fight between good and evil. J Clin Invest, 125(9), 3347–55. 
Shapira, M., Hamlin, B. J., Rong, J., Chen, K., Ronen, M., & Tan, M. (2006). A 
conserved role for a GATA transcription factor in regulating epithelial innate 
immune responses. Proc Natl Acad Sci U S A, 103(38), 14086–91. 
Shaw-Smith, C., De Franco, E., Allen, H. L., Batlle, M., Flanagan, S. E., Borowiec, M., 
… Ellard, S. (2014). GATA4 mutations are a cause of neonatal and childhood-
onset diabetes. Diabetes, 63(8), 2888-94.  
Shay, J. W., & Wright, W. E. (2010). Telomeres and telomerase in normal and 
cancer stem cells. FEBS Lett, 584(17), 3819–3825.  
Shen, C.-N., Slack, J. M., & Tosh, D. (2000). Molecular basis of transdifferentiation 
of pancreas to liver. Nat Cell Biol, 2(12), 879–87. 
Shen, C., Horb, M. E., Slack, J. M., & Tosh, D. (2003). Transdifferentiation of 
pancreas to liver. Mechanisms of Development, 120(1), 107–116. 
Shi, C., Washington, M. K., Chaturvedi, R., Drosos, Y., Revetta, F. L., Weaver, C. J., … 
Means, A. L. (2014). Fibrogenesis in pancreatic cancer is a dynamic process 
regulated by macrophage–stellate cell interaction. Lab Invest, 94(4), 409–
421. 
Shimizu, R., & Yamamoto, M. (2016). GATA-related Hematological Disorders. 
Experimental Hematology, 44(8), 696–705. 
http://doi.org/10.1016/j.exphem.2016.05.010 
Siegel, P. M., & Massagué, J. (2003). Cytostatic and Apoptotic Actions of TGF-β in 
Homeostasis and Cancer. Nat Rev Cancer, 3(11), 807–21.  
Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics CA Cancer J Clin,  
67(1), 7–30.  
Simon, M., Pauloin, A., Normand, G., Lieu, H., Mouly, H., Pivert, G., … Christa, L. 
(2003). HIP/PAP stimulates liver regeneration after partial hepatectomy 
and combines mitogenic and anti-apoptotic functions through the PKA 
signaling pathway. FASEB J, 17(11), 1441–50.  
Singh, A. P., Arora, S., Bhardwaj, A., Srivastava, S. K., Kadakia, M. P., Wang, B., … 
Singh, S. (2012). CXCL12/CXCR4 protein signaling axis induces sonic 
hedgehog expression in pancreatic cancer cells via extracellular regulated 
kinase- and Akt kinase-mediated activation of nuclear factor κB: 
Implications for bidirectional tumor-stromal interactions. J Biol Chem, 
287(46), 39115–39124.  
Siveke, J. T., Lubeseder-Martellato, C., Lee, M., Mazur, P. K., Nakhai, H., Radtke, F., 
   BIBLIOGRAPHY 
 153 
& Schmid, R. M. (2008). Notch Signaling Is Required for Exocrine 
Regeneration After Acute Pancreatitis. Gastroenterology, 134(2), 544–555.  
Slack, J. M. W. (1995). Developmental Biology of the Pancreas. Development, 
121(6), 1569-80. 
Slack, J. M. W., & Tosh, D. (2001). Transdifferentiation and metaplasia — 
switching cell types. Curr Opin Genet Dev, 11(5), 581–6. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter 
strain, Nat Genet, 21(1), 70–71. 
Stanescu, D. E., Hughes, N., Patel, P., & De Leon, D. D. (2015). A novel mutation in 
GATA6 causes pancreatic agenesis. Pediatr Diabetes, 16(1), 67–70.  
Stanger, B. Z., & Hebrok, M. (2013). Control of Cell Identity in Pancreas 
Development and Regeneration. Gastroenterology, 144(6), 1170–79.  
Stevens, R., Roddam, A., & Beral, V. (2007). Pancreatic cancer in type I and young-
onset diabetes: systematic review and meta-analysis. Br J Cancer, 96(3), 
507–9.  
Stocks, T., Rapp, K., Bjørge, T., Manjer, J., Ulmer, H., Selmer, R., … Stattin, P. 
(2009). Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic 
Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts. 
PLoS Med, 6(12), e1000201.  
Stolzenberg-Solomon, R. Z., Graubard, B. I., Limburg, P., Taylor, P. R., Virtamo, J., & 
Albanes, D. (2005). Insulin, glucose, insulin resistance, and pancreatic 
cancer in male smokers. JAMA, 294(22), 2872–8. 
Storz, P. (2017). Acinar cell plasticity and development of pancreatic ductal 
adenocarcinoma. Nat Rev Gastroenterol Hepatol, 14(5), 296-304. 
Strobel, O., Dor, Y., Alsina, J., Stirman, A., Lauwers, G., Trainor, A., … Thayer, S. P. 
(2007). In Vivo Lineage Tracing Defines the Role of Acinar-to-ductal 
Transdifferentiation in Inflammatory Ductal Metaplasia. Gastroenterology, 
133(6), 1999–2009. 
Suzuki, E., Evans, T., Lowry, J., Truong, L., Bell, D. W., Testa, J. R., & Walsh, K. 
(1996). The human GATA-6 gene: structure, chromosomal location, and 
regulation of expression by tissue-specific and mitogen-responsive signals. 
Genomics, 38(3), 283–290. 
Suzuki, S., Nakao, A., Sarhat, A. R., Furuya, A., Matsuo, K., Tanahashi, Y., … Azuma, 
H. (2014). A Case of Pancreatic Agenesis and Congenital Heart Defects With 
a Novel GATA6 Nonsense Mutation: Evidence of Haploinsufficiency due to 
Nonsense-Mediated mRNA Decay. Am J Med Genet, 164(2), 476–479.  
Swift, G. H., Rose, S. D., & Macdonald, R. (1994). An Element of the Elastase I 
Enhancer Is an Overlapping Bipartite Binding Site Activated by a 
Heteromeric Factor. J Biol Chem, 269(17), 12809–12815. 
Swift, M., Reitnauer, P. J., Morrell, D., & Chase, C. L. (1987). Breast and other 
cancers in families with ataxia-telangiectasia. N Engl J Med 316(21), 1289–
94. 
Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., … Omata, 
M. (1996). Analysis of K-ras Gene Mutation in Hyperplastic Duct Cells of the 
Pancreas Without Pancreatic Disease. Gastroenterology, 110(1), 227–231. 
Tak, P. P., & Firestein, G. S. (2001). NF-κB: a key role in inflammatory diseases. J 
Clin Invest, 107(1), 7–11. 
Thayer, S. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., … 
Hebrok, M. (2003). Hedgehog is an early and late mediator of pancreatic 
BILIOGRAPHY 
 154 
cancer tumorigenesis, 1607(1998), 1603–1607. 
Tokoro, T., Tezel, E., Nagasaka, T., Kaneko, T., & Nakao, A. (2003). Differentiation 
of Acinar Cells into Acinoductular Cells in Regenerating Rat Pancreas. 
Pancreatology, 3(6), 487–496.  
Tramacere, I., Scotti, L., Jenab, M., Bagnardi, V., Bellocco, R., Rota, M., … La 
Vecchia, C. (2010). Alcohol drinking and pancreatic cancer risk: a meta-
analysis of the dose-risk relation. Int J Cancer, 126(6), 1474–86.  
Tsai, S.-F., Martin, D. I., Zon, L. I., D, D. A., Wong, G. G., & Orkin, S. H. (1989). 
Cloning of cDNA for the major DNA-binding protein of the erythroid lineage 
through expression in mammalian cells. Nature, 339(6224), 446–451. 
Unanue, E. R., Turk, V., & Neefjes, J. (2016). Variations in MHC Class II Antigen 
Processing and Presentation in Health and Disease. Annu Rev Immunol, 
20(34), 265–97. 
Van Berlo, J. H., Elrod, J. W., Aronow, B. J., Pu, W. T., & Molkentin, J. D. (2011). 
Serine 105 phosphorylation of transcription factor GATA4 is necessary for 
stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A, 
108(30), 12331–12336.  
Van den Brink, G. R. (2007). Hedgehog Signaling in Development and 
Homeostasis of the Gastrointestinal Tract. Physiol Rev, 87, 1343–1375.  
Van den Brink, G. R., Hardwick, J. C., Tytgat, G. N., Brink, M. A., Ten Kate, F. J., Van 
Deventer, S. J., & Peppelenbosch, M. P. (2001). Sonic Hedgehog Regulates 
Gastric Gland Morphogenesis in Man and Mouse. Gastroenterology, 121(2), 
317–328.  
Van Heek, N. T., Meeker, A. K., Kern, S. E., Yeo, C. J., Lillemoe, K. D., Cameron, J. L., 
… Maitra, A. (2002). Telomere Shortening Is Nearly Universal in Pancreatic 
Intraepithelial Neoplasia. Am J Pathol, 161(5), 1541–1547. 
Vasen, H., Gruis, N., Frants, R., Van der Velden, P., Hille, E., & Bergman, W. (2000). 
Risk of developing pancreatic cancer in families with familial atypical 
multiple mole melanoma associated with a specific 19 deletion of p16 (p16-
Leiden). Int J Cancer, 87(6), 809–11. 
Vila, M., Lloreta, J., & Real, F. X. (1994). Normal human pancreas cultures display 
functional ductal characteristics. Lab Investigation, 71(3), 423–31. 
Visvader, J. E., Crossley, M., Hill, J., Orkin, S. H., & Adams, J. M. (1995). The C-
Terminal Zinc Finger of GATA-1 or GATA-2 Is Sufficient To Induce 
Megakaryocytic Differentiation of an Early Myeloid Cell Line, Mol Cell Biol 
15(2), 634–641. 
Vogelstein, B., Fearon, E. R., Hamilton, S., Kern, S., Preisinger, A., Leppert, M., … 
Bos, J. (1988). Genetic alterations during colorectal tumour development. N 
Engl J Med, 319(9), 525–32. 
Von Figura, G., Morris Iv, J. P., Wright, C. V. E., & Hebrok, M. (2014). Nr5a2 
maintains acinar cell differentiation and constrains oncogenic Kras-
mediated pancreatic neoplastic initiation. Gut, 63, 656–664.  
Vonlaufen, A., Wilson, J. S., & Apte, M. V. (2008). Molecular mechanisms of 
pancreatitis: Current opinion. J Gastroenterol Hepatol, 23(9), 1339–1348.  
Vousden, K. H., & Lane, D. P. (2007). p53 in health and disease. Nat Rev Mol Cell 
Biol, 8(4), 275–283.  
Waddell, N., Pajic, M., Patch, A., Chang, D. K., Kassahn, K. S., Bailey, P., … 
Grimmond, S. M. (2015). Whole genomes redefine the mutational landscape 
of pancreatic cancer. Nature., 518(7540), 495–501.  
   BIBLIOGRAPHY 
 155 
Wagner, M., Lührs, H., Klöppel, G., Adler, G., & Schmid, R. M. (1998). Malignant 
Transformation of Duct-like Cells Originating From Acini in Transforming 
Growth Factor α Transgenic Mice. Gastroenterology, 115(5), 1254–1262. 
Wang, R. N., Kliippel, G., Bouwens, L., & Jette, C. (1995). Duct- to islet-cell 
differentiation and islet growth in the pancreas of duct-ligated adult rats. 
 Diabetologia, 38(12), 1405–1411. 
Watt, A. J., Battle, M. A., Li, J., & Duncan, S. A. (2004). GATA4 is essential for 
formation of the proepicardium and regulates cardiogenesis. Proc Natl Acad 
Sci U S A, 101(34), 12573–8.  
Watt, A. J., Zhao, R., Li, J., & Duncan, S. a. (2007). Development of the mammalian 
liver and ventral pancreas is dependent on GATA4. BMC Dev Biolo, 7, 37.  
Weiss, F., Simon, P., Bogdanova, N., Mayerle, J., Dworniczak, B., Horst, J., & Lerch, 
M. (2005). Complete cystic fibrosis transmembrane conductance regulator 
gene sequencing in patients with idiopatic chronic pancreatitis and controls. 
Gut, 54(10), 1456–60.  
Weissmueller, S., Manchado, E., Saborowski, M., Iv, J. P. M., Wagenblast, E., Davis, 
C. A., … Lowe, S. W. (2014). Mutant p53 Drives Pancreatic Cancer Metastasis 
through Cell-Autonomous PDGF Receptor b Signaling. Cell, 157(2), 382–394.  
Whitcomb, D. C. (2012). Genetics of Alcoholic and Non-Alcoholic Pancreatitis. 
Curr Opin Gastroenterol, 28(5), 1–8.  
Whitcomb, D. C., Gorry, M. C., Preston, R. A., Furey, W., Sossenheimer, M. J., Ulrich, 
C. D., … Ehrlich, G. D. (1996). Hereditary pancreatitis is caused by a mutation 
in the cationic trypsinogen gene. Nat Genet, 12(2), 141–5. 
Whitcomb, D. C., & Lowe, M. E. (2007). Human Pancreatic Digestive Enzymes. Dig 
Dis Sci, 52(1), 1–17.  
Wilentz, R. E., Iacobuzio-Donahue, C. A., Argani, P., Mccarthy, D. M., Parsons, J. L., 
Yeo, C. J., … Hruban, R. H. (2002). Loss of Expression of Dpc4 in Pancreatic 
Intraepithelial Neoplasia: Evidence That DPC4 Inactivation Occurs Late in 
Neoplastic Progression. Cancer Res, 60(7), 2002–2006. 
Willemer, S., & Adler, G. (1989). Histochemical and ultrastructural characteristics 
of tubular complexes in human acute pancreatitis. Dig Dis Sci, 34(1), 46–55. 
Witkiewicz, A. K., Mcmillan, E. A., Balaji, U., Baek, G., Lin, W., Mansour, J., … 
Knudsen, E. S. (2015). Whole-exome sequencing of pancreatic cancer 
defines genetic diversity and therapeutic targets. Nat Commun, 6(6744), 1–
11.  
Wolpin, B. M., Rizzato, C., Kraft, P., Kooperberg, C., Petersen, G. M., Wang, Z., … 
Amundadottir, L. T. (2014). Genome-wide association study identifies 
multiple susceptibility loci for pancreatic cancer. Nat Genet, 46(9), 994–
1000.  
Wu, P. F., Lu, Z. P., Cai, B. B., Tian, L., Zou, C., Jiang, K. R., & Miao, Y. (2013). Role of 
CXCL12/CXCR4 signaling axis in pancreatic cancer. Chin Med J, 126(17), 
3371–74.  
Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., & 
Kolesnick, R. (2003). Pharmacologic inactivation of kinase suppressor of 
ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med, 9(10), 1267–
1268.  
Xuan, S., Borok, M. J., Decker, K. J., Battle, M. A., Duncan, S. A., Hale, M. A., … Sussel, 
L. (2012). Pancreas-specific deletion of mouse Gata4 and Gata6 causes 
pancreatic agenesis. J Clin Invest, 122(10), 3516–3528.  
BILIOGRAPHY 
 156 
Xuan, S., & Sussel, L. (2016). GATA4 and GATA6 regulate pancreatic endoderm 
identity through inhibition of hedgehog signaling. Development, 143, 780–
786.  
Yau, D., De Franco, E., Flanagan, S. E., Ellard, S., Blumenkrantz, M., & Mitchell, J. J. 
(2017). Case report : maternal mosaicism resulting in inheritance of a novel 
GATA6 mutation causing pancreatic agenesis and neonatal diabetes 
mellitus. Diagn Pathol, 12(1), 1–7.  
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & Depinho, R. 
A. (2016). Genetics and biology of pancreatic ductal adenocarcinoma. Genes 
Dev, 30(4), 355–385.  
Yorifuji, T., Kawakita, R., Hosokawa, Y., Fujimaru, R., Yamaguchi, E., & Tamagawa, 
N. (2012). Dominantly inherited diabetes mellitus caused by GATA6 
haploinsuf fi ciency : variable intrafamilial presentation. J Med Genet, 49(10), 
642–3.  
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014). Revisiting STAT3 
signalling in cancer: new and unexpected biological functions. Nat Rev 
Cancer, 14(11), 736–746.  
Zambirinis, C. P., Levie, E., Nguy, S., Avanzi, A., Barilla, R., Xu, Y., … Miller, G. 
(2015). TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J 
Exp Med, 212(12), 2077–2094. 
Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., … Di 
Magliano, M. P. (2013). Interleukin-6 is required for pancreatic cancer 
progression by promoting MAPK signaling activation and oxidative stress 
resistance. Cancer Res, 73(20), 6359–6374.  
Zhao, R., Watt, A. J., Battle, M. A., Li, J., Bondow, B. J., & Duncan, S. A. (2008). Loss 
of both GATA4 and GATA6 blocks cardiac myocyte differentiation and 
results in acardia in mice. Dev Biol, 317(2), 614–619.  
Zhao, R., Watt, A. J., Li, J., Luebke-Wheeler, J., Morrisey, E. E., & Duncan, S. A. 
(2005). GATA6 Is Essential for Embryonic Development of the Liver but 
Dispensable for Early Heart Formation. Mol Cell Biol, 25(7), 2622–2631.  
Zhong, Y., Wang, Z., Fu, B., Pan, F., Yachida, S., Dhara, M., … Iacobuzio-Donahue, C. 
A. (2011). GATA6 Activates Wnt Signaling in Pancreatic Cancer by 
Negatively Regulating the Wnt Antagonist Dickkopf-1. PLoS ONE, 6(7), 
e22129.  
Zhou, P., He, A., & Pu, W. T. (2012). Regulation of GATA4 Transcriptional Activity 
in Cardiovascular Development and Disease. Current Topics in Dev Biol, 100, 
143–6. 
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., & Melton, D. A. (2008). In vivo 
reprogramming of adult pancreatic exocrine cells to b-cells. Nature, 
455(7213), 627–32.  
Zhou, Q., Law, A. C., Rajagopal, J., Anderson, W. J., Gray, P. A., & Melton, D. A. 
(2007). A Multipotent Progenitor Domain Guides Pancreatic Organogenesis. 
Dev Cell, 123(1), 103–14.  
Zhu, L., Tran, T., Rukstalis, J. M., Sun, P., Damsz, B., & Konieczny, S. F. (2004). 
Inhibition of Mist1 Homodimer Formation Induces Pancreatic Acinar-to-
Ductal Metaplasia. Mol Cell Biol, 24(7), 2673–2681.  
 Ziegler, P. K., Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Go, S. I., … 
Greten, F. R. (2013). Intestinal Tumorigenesis Initiated by Dedifferentiation 
and Acquisition of Stem-Cell-like Properties. Cell, 152(1–2), 25–38. 
